



Optimum

NO ES OPOSICIÓN

700
183
200

Derecho de la Competencia, Propiedad Industrial y Comercio Exterior

Señora Jefe,

DIVISIÓN DE NUEVAS CREACIONES

Superintendencia de Industria y Comercio

E. S. D.



Nº 06-051/21-00012-0000

Referencia : Expediente Nº 06 51721
Asunto : Remisión de información a la solicitud de patente de
Invención titulada "ENOXAPARINA PARA EL
TRATAMIENTO DEL CANCER"
Solicitante : AVENTIS PHARMA S.A.

Publicada en la Gaceta de la Propiedad Industrial
Nº 607 del 31 de agosto de 2009

Yo, **CIELO ANGELA PEÑA RODRIGUEZ**, abogada en ejercicio, identificada como aparece al pie de su firma, con tarjeta profesional No. **82701** del Consejo Superior de la Judicatura, en mi condición de apoderada de la sociedad **GYNOPHARM S.A.** conformada bajo las leyes de la República de Colombia y domiciliada en la ciudad de Barranquilla, Colombia, atentamente manifiesto que estando dentro del término de ley y por orden expresa de mi representada, presento remisión de información a la concesión del registro de la Patente de Invención titulada **"ENOXAPARINA PARA EL TRATAMIENTO DEL CANCER"**, cuyo titular es **AVENTIS PHARMA S.A.**, y pido a Usted declarar fundada esta remisión de información y en consecuencia negar el registro de la patente solicitada.

1. INTERÉS PARA ACTUAR

Conforme a lo dispuesto en el artículo 42 de la Decisión 486 de 2000 de la CAN, estando dentro del término estipulado por la ley, manifiesto el legítimo interés de nuestra representada para oponerse al registro de la patente de la referencia, atendiendo a que la solicitud pretendía no cumple con los requisitos dispuestos en la ley como se analizará más adelante y de ser concedida afectaría directamente la comercialización de algunos productos de mi representada, que contienen, en particular enoxaparina. Por lo tanto, solicito respetuosamente a ese Despacho se sirva tener en cuenta la presente remisión de información dentro del trámite administrativo que se surte en esta Superintendencia.

2. FUNDAMENTOS DE HECHOS

2.1. La solicitud objeto de la presente fue presentada el 30 de mayo de 2006 reivindicando prioridad bajo la solicitud EP20030293028 del 2003-12-04; y fue publicada en Colombia, en la Gaceta de la Propiedad Industrial N° 607 del 31 de agosto de 2009, cuya publicación internacional corresponde a la WO2005/053713 del 31/08/2009.

2.2. La solicitud colombiana 06 51721 objeto de la presente remisión de información, se refiere al uso de enoxaparina para tratar una enfermedad asociada a la modulación de la actividad de la heparanasa, excepto cuando dicha enfermedad es Liquen plano; en el que la actividad de la heparanasa contribuye a la patología y/o síntomas de la enfermedad, excepto cuando dicha enfermedad es una enfermedad autoinmune.

2.3. En primera instancia, se debe advertir que algunas reivindicaciones también se refieren a un uso y a un método de tratamiento y no sólo a la composición farmacológica o a un método de fabricación mediante la cual se obtenga un producto tangible y según la legislación, decisión 486 de la Comunidad Andina de Naciones, Artículo 14.- *"Los Países Miembros otorgarán patentes para las invenciones, sean de producto o de procedimiento (...) "*, los usos no están contemplados como patentables; y, Artículo 20.- *"No serán patentables (...) d) los métodos terapéuticos o quirúrgicos para el tratamiento humano o animal, así como los métodos de diagnóstico aplicados a los seres humanos o a animales"*. Solo serán patentables los productos o procedimientos. Por lo tanto a luz de la norma, dicha materia referente al uso y a un método de tratamiento no sería patentable.

2.4. Ahora bien, con base en el artículo 14 de la Decisión 486 de la CAN consagra lo siguiente: *"Los países miembros otorgarán patentes para las invenciones, sean de producto o procedimiento, en todos los campos de la tecnología, siempre que sean nuevas, tengan nivel inventivo y sean susceptibles de aplicación industrial"*. Así las cosas, las invenciones objeto de patente deben ser nuevas y tener nivel inventivo. Bien, pues antes de la fecha de prioridad de esta solicitud se encuentran los siguientes documentos que afecta la patentabilidad de la presente solicitud:

- D1: US2003195461 publicada el 16 de octubre de 2003.

2.5. Ahora bien, además que la presente bajo la Norma colombiana pretende un objeto que no es patentable, además se refiere a una materia que no es novedosa. Particularmente el documento D1, revela con anterioridad un método para la inhibición de la adherencia de célula de un tumor y una variedad de dolor e inflamación que incluye al menos a un agente de adherencia de célula de antitumor y múltiple dolor e inflamación agentes inhibitorios en la concentración diluida en

203-186/14
29/3

un portador fisiológico. Particularmente en el párrafo 0107, D1 revela que el activo inhibición de la adherencia de célula de un tumor es la enoxaparina. Así las cosas, como lo evidencia dicho documento D1, además que la presente no comprende aplicación industrial por referirse a un uso, la presente solicitud tampoco es novedosa pues lo revelado ya se encontraba en el estado de la técnica.

2.6. En consecuencia y de acuerdo a lo descrito anteriormente, se deriva que la solicitud colombiana 06 51721 no puede pretender un monopolio por patente toda vez que lo que pretende no cumple con los dos de los tres requisitos necesarios para su protección.

2.7. Que por consiguiente, respecto a la solicitud pretendida se tiene que:

2.7.1. **CARECE DE NOVEDAD:** Según la decisión 486 de la Comunidad Andina de Naciones, Artículo 16. *"Una invención se considerará nueva cuando no esté comprendida en el estado de la técnica. El estado de la técnica comprenderá todo lo que haya sido accesible al público por una descripción escrita u oral, utilización, comercialización o cualquier otro medio antes de la fecha de presentación de la solicitud de patente o, en su caso, de la prioridad reconocida."* A la fecha de prioridad, 4 de diciembre de 2003 ya era conocido, pues como se demostró, era parte del arte anterior con base en el documento D1, el uso de la enoxaparina como activo para la inhibición de la adherencia de célula de un tumor, sobre el cual busca protección en el capítulo reivindicatorio.

2.7.2. **CARENCIA DE APLICACIÓN INDUSTRIAL:** La Decisión 486 de la CAN consagra en su artículo 14 lo siguiente: *"Los países miembros otorgarán patentes para las invenciones, sean de producto o procedimiento, en todos los campos de la tecnología, siempre que sean nuevas, tengan nivel inventivo y sean susceptibles de aplicación industrial"*. La presente solicitud carece de aplicación Industrial ya que como se demostró anteriormente, algunas cláusulas reclaman el método terapéutico y estos no son aplicables industrialmente porque primero no se

obtiene un producto o proceso; y segundo no es reproducible o repetible a escala industrial. Por lo tanto, el objeto de la presente invención referido a los usos y métodos terapéuticos, no cumplen con el requisito de la aplicación industrial.

2.8. Dado lo anterior, es posible deducir que la solicitud y lo reivindicado no es objeto de patentabilidad pues es contrario a lo que dicta la Decisión 486 de la Comunidad Andina de Naciones, Artículo 14.- *"Los Países Miembros otorgarán patentes para las invenciones, sean de producto o de procedimiento, en todos los campos de la tecnología, siempre que sean nuevas, tengan nivel inventivo y sean susceptibles de aplicación industrial."* La solicitud pretendida no cumple con dos de los tres requisitos de patentabilidad.

2.9. Por todo lo anterior, atentamente solicito a usted que se sirva declarar fundada la presente remisión de información y en consecuencia negar el registro a la solicitud de patente titulada **"ENOXAPARINA PARA EL TRATAMIENTO DEL CANCER"**, cuyo titular es **AVENTIS PHARMA S.A.**, solicitud Colombiana que apareció publicada en la Gaceta de la Propiedad Industrial N° 607 del 31 de agosto de 2009.

3. PRUEBAS

De conformidad con lo dispuesto por las normas vigentes, solicito a usted tener como prueba en este asunto los siguientes:

- D1: US2003195461 publicada el 16 de octubre de 2003.

20/6
20/5
20/3

4. FUNDAMENTO DE DERECHO

Fundamento esta observación en las normas legales siguientes:

- 4.1. Numeral 1 del artículo 586 del Código de Comercio.
- 4.2. Artículo 42 de la Decisión 486 de la Comisión del Acuerdo de Cartagena.
- 4.3. En las demás normas concordantes.

5. ANEXOS

Para los efectos correspondientes anexo al presente escrito los siguientes documentos:


1. Poder para actuar en el presente.
2. Documento que acredita al representante legal de GYNOPHARM S.A.
3. Recibo de caja del respectivo pago de tasa.
4. Copias de los documentos:

- DI: US2003195461 publicada el 16 de octubre de 2003.

6. NOTIFICACIONES

Para efectos de notificaciones que por disposición del artículo 50 del Decreto 01 de 1984 debe hacer su Despacho, informo que mi representada y la suscrita recibiremos notificaciones en la Secretaría de su Despacho o en mis oficinas situadas en la Carrera 13 N° 119-95, Of. 104 de esta ciudad de Bogotá.

Señor Superintendente,



CIELO ANGELA PEÑA RODRIGUEZ
C.C. 51'940.252 de Bogotá
T.P.A. 82701 del C.S. de la J.



201-91
208

CERTIFICADO NACIONAL

CAMARA DE COMERCIO DE BARRANQUILLA

FECHA: 2009.10/29

HORA: 15:48:23

OPERACION: 02701.00923

PAGINA: 1

CERTIFICADO DE EXISTENCIA Y REPRESENTACION LEGAL, O DE INSCRIPCION DE DOCUMENTOS.

EL INSCRITO SECRETARIO DE LA CAMARA DE COMERCIO DE BARRANQUILLA, CON FUNDAMENTO EN LAS INSCRIPCIONES DEL REGISTRO MERCANTIL:

CERTIFICA

Que por Escritura Publica No. 7,551 del 17 de Dic/bre de 1997, otorgada en la Notaria Sa. de Barranquilla, inscrito(as) en esta Cámara de Comercio, el 18 de Diciembre de 1997 bajo el No. 72,965 del libro respectivo, fue constituida la sociedad-----
anónima denominada GYNOPHARM S.A. -----

CERTIFICA

que dicha sociedad ha sido reformada por las siguientes escrituras y/o documentos privados:

Numero	aaaa/mm/dd	Notaria	No. Insc o Reg	aaaa/mm/dd
42	1999/03/25	Notaria 3a. de Barranquilla	80,373	1999/04/13

CERTIFICA

que de acuerdo con la(s) escritura(s) arriba citada(s), la sociedad se rige por las siguientes disposiciones:

DENOMINACION O RAZON SOCIAL:

GYNOPHARM S.A.-----

DOMICILIO PRINCIPAL: Barranquilla.

NIT No: 802.058.273-4.

MATRICULA MERCANTIL: 145,470.

CERTIFICA

Dirección para notificaciones judiciales:

CR 40 C No 80 - 12 OF 517.

De la ciudad de Barranquilla.

CERTIFICA

DURACION: El término de duración de la sociedad se fijó hasta el 16 de Diciembre de 2027.

CERTIFICA

OBJETO SOCIAL: a) la fabricación de capsulas y otros productos similares a partir de materiales tales como gelatinas u otros de distinta naturaleza, que puedan ser utilizados como envases o recipientes de producción y sustancias químicas, farmacéuticas y cosméticas, para

*** CONTINUA ***

CERTIFICADO NACIONAL

CAMARA DE COMERCIO DE PARIANQUILLA

FECHA: 2009/10/29

HORA: 15:48:33

OPERACION: 02C041079221

PAGINA: 2

uso y consumo humano y veterinario. b) La investigacion, desarrollo y fabricacion de toda clase de productos y sustancias quimicas, farmaceuticas y cosmeticas para uso y consumo humano, animal y vegetal. c) La compra y venta de materias primas, insumos y productos intermedios necesarios para los procesos de fabricacion de sustancias quimicas, farmaceuticas y cosmeticas, asi como la comercializacion interna y externa de los productos terminados. d) La compra, venta, importacion, exportacion y distribucion de toda clase de elementos instrumentales y equipos, medicos, quirurgicos, odontologicos y hospitalarios para la salud humana y animal. e) Actuar como representante o agente de personas naturales y juridicas nacionales y extranjeras en la realizacion de operaciones o transacciones relacionadas con la industria farmaceutica y en especial con cualesquiera de las actividades descritas en los literales a), b), c) y d) antes transcritos. f) Prestar los servicios de asesoria y consultoria en las areas administrativa, de mercadeo, analisis clinico, asistencia tecnica, investigacion, costos y produccion exportaciones, importaciones, ventas, relacionadas con iguales o similares actividades a las que constituyen el objeto de GYNOPHANN S.A., asi como los de publicidad y promocion de productos quimicos, cosmeticos y farmaceuticos para uso humano, animal o industrial. g) Adquirir, operar, administrar y explotar, a cualquier titulo, empresas o establecimientos dedicados a la investigacion, desarrollo, fabricacion o comercializacion de productos quimicos, farmaceuticos, hospitalarios o cosmeticos. En desarrollo de su objeto principal, la sociedad podra tomar interes social como accionista, socio o fundador de empresas que tengan igual o similar objeto; comprar, vender, importar y exportar maquinarias, insumos y repuestos requeridos para el desarrollo de sus actividades; tomar dinero en prestamo, financiar y garantizar las operaciones comerciales que celebre con terceros relativas a su objeto; celebrar y ejecutar todo tipo de actos y contratos necesarios para desarrollar sus operaciones; girar, aceptar, otorgar y protestar todo tipo de titulos valores e instrumentos negociables; comprar, vender y constituir gravamenes sobre bienes muebles e inmuebles; designar representantes o apoderados en el pais y en el exterior y, en

*** CONTINUA ***



01

8 8 6 9 2 6 8 9 6

SECRET FICADO NACIONAL

CAMARA DE COMERCIO DE BARRANQUILLA

PECHA: 2009 10/29

HORA: 15:48:23

REFRAC: 02C041079223

PAGINA: 3

general, realizar cualquier acto o negocio que sea necesario o conveniente para el desarrollo de su objeto social y para la mejor protección de sus intereses corporativos o lo de sus socios.-----

$\epsilon^+ \quad \epsilon^- \quad \mu^+ \quad \tau^+ \quad l \quad | \quad e^- \quad A$

CAPITAL.

Mr. Anderson:

Valor Acción

Autore: **Guido**

\$*****4,000,000.00 *****4,000,000 *****1,000

Executive

*****2,672,646,000 *****2,672,646 *****1,000

Parvicio

*****2.672.646.193 *****2.672.646 *****1.000

C E R T I F I C A T E

ADMINISTRACION: Seran funciones de la junta directiva, entre otras: Autorizar cualquier acto o contrato cuya cuantia sea superior al equivalente en pesos Colombianos a cincuenta mil dolares de los Estados Unidos de America (US\$50.000.00), liquidados a la tasa de cambio representativa del mercado vigente el dia en que se surta la aprobacion y para enajenar o gravar bienes inmuebles y demas activos fijos de la sociedad, cualquiera que sea la cuantia de la transaccion. Las demas que le sean propias y no esten atribuidas a otro organo social y las que le correspondan en virtud de la ley. La sociedad tendra un Gerente General, quien ejercera la administracion y representacion legal de la sociedad y tendra las siguientes atribuciones, entre otras: Ejercer la representacion legal de la sociedad en todos los actos y contratos que se requieran para el desarrollo del objeto social, de conformidad con lo previsto en las leyes y en los presentes estatutos. Aprobar y celebrar en nombre de la sociedad todo acto o contrato cuya cuantia sea igual o inferior al equivalente en pesos Colombianos a cincuenta mil dolares de los Estados Unidos de America (US\$50.000.00), liquidados a la tasa de cambio representativa del mercado vigente el dia en que se surta la aprobacion o celebracion de dicho acto. Para contratar, a cualquier titulo, bienes inmuebles de la sociedad o constituir gravamenes sobre los mismos, debera obtener la aprobacion de la junta directiva, cualquiera que sea la cuantia de la transaccion; o las demas funciones que le corres-

• • • C O N F I D E N T I A L • • •

CERTIFICADO NACIONAL

CAMARA DE COMERCIO DE BARRANQUILLA

FECHA: 2009-10/29

HORA: 15:48:23

OPERACION: 02C041079223

PAGINA: 4

ponderar como representante legal por disposición de la ley, de estos estatutos o de la junta directiva. El Gerente General tendrá un suplente, designado por la junta directiva, quien lo reemplazara con idénticas facultades en sus faltas temporales, absolutas o momentáneamente accidentales, sin que sea necesario para ello acreditar la ausencia del principal.-----

C E R T I F I C A

Que según Acta No. 15 del 18 de Febrero de 2008 correspondiente a la Asamblea de Accionistas en Bogotá, de la sociedad:

GYNOPHARM S.A.-----

cuya parte pertinente se inscribió en esta Cámara de Comercio, el 25 de Febrero de 2008 bajo el No. 137,919 del libro respectivo, fueron hechos los siguientes nombramientos:

CLASE: JUNTA DIRECTIVA

Principales

1. Llobet Paul Manuel	CC.*****14,670,196
2. Zanatta Reheman Leonardo Andres	CC.*****2,760,271
3. Munoz Marroquin Diego	CC.*****7,688,292
4. Montealegre Gonzalez Andres Leonardo	CC.*****9,950,262

Suplentes

1. Ajudelo Polaez Luis Hernando	CC.*****14,738,997
2. Araca Almanza Arleth Ayelina	CC.*****36,719,415
3. Penaranda Urbina Adriana Paola	CC.*****53,120,683
4. Iovar Vasquez Ruth	CC.*****52,175,756

C E R T I F I C A

Que según Acta No. 18 del 30 de Octubre de 2003 correspondiente a la Junta Directiva en Barranquilla, de la sociedad: **GYNOPHARM S.A.** cuya parte pertinente se inscribió en esta Cámara de Comercio, el 06 de Nov/bre de 2003 bajo el No. 107,783 del libro respectivo, fueron hechos los siguientes nombramientos:

Cargo/Nombre	Identificación
Gerente General.	
Palacios Aragon Luis Alberto	CE.*****319,788

C E R T I F I C A

Que según Acta No. 49 del 03 de Marzo de 2008 correspondiente a la

*** CONTINUA ***



01



* 2 6 9 7 4 8 9 7 *

209 4/20

CERTIFICADO NACIONAL

CAMARA DE COMERCIO DE BARRANQUILLA

FECHA: 2009.10/19

HORA: 15:48:23

SERIAL: 027041029223

PAGINA: 5

Junta Directiva en Barranquilla, de la sociedad: GYNOPHARM S.A. cuya parte pertinente se inscribió en esta Cámara de Comercio, el 11 de Mayo de 2009 bajo el No. 36,342 del libro respectivo, fueron hechos los siguientes nombramientos:

Cargo/Nombre	Identificación
Suplente del Gerente:	
Kellajeli Centurion Andres Fernando	CE.*****351,283

C E R T I F I C A

Que según Acta No. 19 del 30 de Abril de 2009 correspondiente a la Asamblea de Accionistas en Barranquilla, de la sociedad: GYNOPHARM S.A. cuya parte pertinente se inscribió en esta Cámara de Comercio, el 27 de Mayo de 2009 bajo el No. 149,314 del libro respectivo, fueron hechos los siguientes nombramientos:

Cargo/Nombre	Identificación
Revisor Fiscal:	
PENALOSA AUDITORES & ASOCIADOS S.A.	Ni.*****630,095,635

C E R T I F I C A

Que por Documento Privado del 11 de Mayo de 2009, otorgado en Poder por Penatosa Auditores & Asociados S.A. inscrito en esta Cámara de Comercio, el 27 de Mayo de 2009 bajo el No 149,315 del libro respectivo, fueron hechos los siguientes nombramientos:

Cargo/Nombre	Identificación
Designados: Revisor Fiscal Ppal	
Padilla Romero Ivan Paris	CC.*****80,025,798
Designados: Revisor Fiscal Suplente	
Gomez Asociado Clara Judith	CC.*****52,544,226

C E R T I F I C A

Que según Documento Privado de fecha 12 de Octubre del 2.000, inscrito en esta Cámara de Comercio el 23 de Noviembre del 2.000 bajo el No. 1.802 del libro respectivo, consta que el señor RUBEN MINSKI GONZALEZ C.C. No. 1.343.952, actuando como Presidente y representante legal de la sociedad GYNOPHARM S.A., otorga Poder Especial, Amplio y Suficiente a FARRI BENITEZ FIGUEROA GARCIA C.C. No. 32.731.070, para que en nombre y representación de la sociedad suscriba todas las declaraciones cambiarias a que esta obligada GYNOPHARM

*** CONTINUA ***

CERTIFICADO NACIONAL

CAMARA DE COMERCIO DE BARRANQUILLA

FECHA: 2009/10/29

HORA: 15:48:23

OPERACION: 02CC41029223

PAGINA: 6

S.A., en el giro normal de sus negocios y operaciones sociales.-----

C E R T I F I C A

Que segun Documento Privado de fecha 10 de Octubre del 2.000, Inscrito en esta Camara de Comercio el 12 de junio del 2.002, bajo el 2.164 del libro respectivo, consta que el señor JORGE CASTELLANOS MARTINEZ, identificado con C.C.No.19.460.049, actuando como representante legal de la sociedad GYNOPHARM S.A, otorga Poder Especial Amplio y Suficiente a KAREN FIGUEROA GARCIA, identificada con la cedula de ciudadanía No.32.732.070 de Barranquilla, mediante documento privado de octubre 10/2000, inscrito en la Camara de Comercio de Barranquilla bajo el No.1.872 del libro respectivo, para que en representacion de GYNOPHARM S.A, suscriba las declaraciones cambiarias a los que esta obligada GYNOPHARM S.A. en el giro ordinario de sus negocios y operaciones sociales.-----

C E R T I F I C A

Que por Escritura Pública No. 2,404 del 26 de Mayo de 2009, otorgada en la Notaria Ia. de Bogota cuya parte pertinente se inscribio en esta Camara de Comercio, el 02 de Julio de 2009 bajo el No. 3,948 del libro respectivo,-----
consta que el señor LUIS ALBERTO PALACIOS ARAGON con CE No.19788, en su calidad de Representante Legal de GYNOPHARM S.A., manifiesto que confiere poder general, amplio y suficiente a la Doctora -----
CAROLINA MARIA ROMERO CERON, identificada con cedula de ciudadanía numero 52.352.190, para que en nombre de la sociedad GYNOPHARM -----
S.A., promueva y defienda los intereses de la sociedad judicial y extrajudicialmente, en toda especie de gestiones y actuaciones ante las autoridades administrativas o jurisdiccionales en especial ----
para: a) Recibir notificaciones de cualesquiera tipo de actos -----
emanados de las autoridades administrativas o judiciales. b) -----
Presentar recursos por la via administrativa o judicial, renunciar a terminos, desistir, conciliar, transigir y modificar. c) Elevar peticiones y solicitar informacion a las autoridades -----
administrativas y jurisdiccionales. d) Presentar demandas ante las autoridades administrativas y judiciales.-----

C E R T I F I C A

*** CONTINUA ***



01



* 8 6 9 7 6 8 9 8 *

21012/21

CERTIFICADO NACIONAL

CAMARA DE COMERCIO DE BARRANQUILLA

FECHA: 2009-10-29

HORA: 15:48:24

PERMANENTE: 000011270027

PAGINA: 3

Que en esta Cámara de Comercio no aparecen inscripciones posteriores de documentos referentes a reforma, disolución, liquidación o nombramientos de representantes legales de la expresada sociedad.

CERTIFICADO


Que su última Renovación fue el: 31 de Marzo de 2009.


La información de la compañía de establecimiento se suministra en Certificados de Matrícula, la de contratos sujetos a registro, en Certificados Especiales.

CERTIFICA

que los actos de registro aquí certificados quedan en firme cinco días hábiles después de la correspondiente inscripción, siempre que, dentro de dicho término, no sean objeto de los recursos de reposición ante esta entidad, y/o de apelación para ante la Superintendencia de Industria y Comercio.

m. fajardo





211 212 8
212

PODER ESPECIAL

Yo, **LUIS PALACIOS ARAGÓN**, mayor de edad y vecino de la ciudad de Barranquilla (Colombia), identificado como aparece al pie de mi firma, quien en el presente documento actúa en calidad de Representante Legal de la sociedad **GYNOPHARM S.A.** sociedad legalmente constituida y domiciliada en la ciudad de Barranquilla (Colombia), por el presente documento otorgo a la doctora **CIELO ANGELA PEÑA RODRIGUEZ**, abogada en ejercicio, identificada como aparece al pie de su firma, con tarjeta profesional No. 82701 del C.S. de la J., poder especial, amplio y suficiente, para presentar ante ese Despacho una remisión de información a la solicitud de patente No. 06 051.721, titulada "ENOXAPARINA PARA EL TRATAMIENTO DEL CANCER", cuyo titular es **AVENTIS PHARMA S.A.**, publicada en la gaceta No. 607 del 31 de agosto de 2009.

Nuestro apoderado queda facultado, de manera expresa, para realizar todo tipo de actos necesarios para llevar a cabo el trámite de dicha remisión, incluyendo, sin limitación, preparar y presentar solicitudes, hacer declaraciones, pagar tasas, contribuciones e impuestos, recabar los títulos o certificados. Asimismo quedan autorizados para impugnar administrativa y judicialmente todo lo que fuere resuelto en el expediente a que se hace expresa referencia en el presente poder, con todas las facultades generales y específicas que fuera requerido para ella.

De la misma manera, además de las facultades que le confiere la naturaleza del presente mandato, se encuentran facultados para recibir, desistir, transigir, sustituir, y reasumir el presente poder, incoar acciones, interponer recursos y demás facultades conferidas por la ley.


27 NOV 2009

Dado y Firmado en Barranquilla (Colombia) a los ____ días del mes de ____ de 2009.

GYNOPHARM S.A.

Cédula de Extranjería No. 319788.
NIT: 802.008.7794
Representante Legal

Aceptos:


CIELO ANGELA PEÑA RODRIGUEZ
C.C. 51'940.252 de Bogotá
T.P.A. 82701 del C.S. de la J.

DILIGENCIA DE RECONOCIMIENTO

En la Ciudad de Bogotá D.C. a 27 de Noviembre de 2007
Compareció ante la Notaria Primera del Circuito de Bogotá

José Salazar Hagon
Quien se identificó con la Cédula de Ciudadanía

Número: 3197AB

Expedida en Bogotá

y Declaró que la firma y huella que aparecen en el presente documento son suyas y que la conformidad del mismo es cierta.

El declarante,

El Notario Primero




NOTARIA PRIMERA



DEL CIRCULO DE BOGOTÁ

003 659690





US 2003/0195461 A1

218
212(19) **United States**(12) **Patent Application Publication**
Demopoulos et al.(10) Pub. No.: **US 2003/0195461 A1**(43) Pub. Date: **Oct. 16, 2003**(54) **IRRIGATION SOLUTION AND METHODS
FOR INHIBITION OF TUMOR CELL
ADHESION, PAIN AND INFLAMMATION**(60) Provisional application No. 60/162,416, filed on Oct.
28, 1999.**Publication Classification**(75) Inventors: Gregory A. Demopoulos, Mercer Island,
WA (US); Pamela Pierce-Palmer, San
Francisco, CA (US); Jeffrey M. Herz,
Mill Creek, WA (US); Darrell L.
Timelink, Dallas, TX (US)(51) Int. Cl.⁷ A61K 31/00; A61M 31/00
(52) U.S. Cl. 604/89; 514/1Correspondence Address:
OMEROS MEDICAL SYSTEMS, INC.
1420 FIFTH AVENUE
SUITE 2675
SEATTLE, WA 98101 (US)(57) **ABSTRACT**

(73) Assignee: Omeros Corporation


(21) Appl. No.: 10/288,997

(22) Filed: Nov. 6, 2002

Related U.S. Application Data(63) Continuation of application No. 09/658,815, filed on
Sep. 11, 2000, now Pat. No. 6,492,332, which is a
continuation-in-part of application No. 09/072,913,
filed on May 4, 1998, now Pat. No. 6,261,279, which
is a continuation of application No. 08/670,699, filed
on Jun. 26, 1996, now Pat. No. 5,820,583, which is a
continuation-in-part of application No. PCT/US95/
16028, filed on Dec. 12, 1995, which is a continua-
tion-in-part of application No. 08/353,775, filed on
Dec. 12, 1994, now abandoned.


A method and solution for perioperatively inhibiting tumor cell adhesion and a variety of pain and inflammation processes at wounds from general surgical procedures including oral/dental procedures. The solution preferably includes at least one anti-tumor cell adhesion agent and multiple pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for preemptive inhibition of pain and while avoiding undesirable side effects associated with oral, intramuscular, subcutaneous or intravenous application of larger doses of the agents. One preferred solution to inhibit tumor cell adhesion, pain and inflammation includes at least one anti-tumor cell adhesion agent, a serotonin₂ antagonist, a serotonin₁ antagonist, a histamine antagonist, a serotonin agonist, a cyclooxygenase inhibitor, a neuropeptide antagonist, a neuropeptide antagonist, a perineceptor antagonist, an ATP-sensitive potassium channel opener, a calcium channel antagonist, a bradykinin antagonist, a bradykinin antagonist and a μ -opioid agonist.

Fig. 1 VASCULAR CELL MOLECULAR TARGETS & SIGNALING INFORMATION



2/2/03


Fig. 2 DETAILED SIGNALING PATHWAYS IN A VASCULAR SMOOTH MUSCLE CELL



2/2/14

Fig. 3


MOLECULAR SITES OF DRUG ACTION IN PREFERRED ARTHROSCOPIC SOLUTION



2/5

MOLECULAR SITES OF DRUG ACTION IN PREFERRED CARDIOVASCULAR & GENERAL VASCULAR SOLUTION -- 1/11

Fig. 4



2/16

Fig. 5





Fig. 6


MOLECULAR SITES OF DRUG ACTION IN PREFERRED UROLOGIC SOLUTION



2/2


MOLECULAR SITES OF DRUG ACTION IN PREFERRED GENERAL SURGICAL WOUND SOLUTION

Fig. 7



MECHANISM OF ACTION OF NO DONOR DRUGS ON A VASCULAR SMOOTH MUSCLE CELL

Fig. 8



2/2




Fig. 9




Fig. 10A




Fig. 10B




Fig. 11




Fig. 12




Fig. 13




Fig. 14




Fig. 15

IRRIGATION SOLUTION AND METHODS FOR INHIBITION OF TUMOR CELL ADHESION, PAIN AND INFLAMMATION

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] The present application is a continuation of copending U.S. application Ser. No. 09/658,815 filed Sep. 11, 2000, which is a continuation-in-part of U.S. application Ser. No. 09/072,913 filed May 4, 1998, which is a continuation of U.S. patent application Ser. No. 08/670,699 filed Jan. 26, 1996, (U.S. Pat. No. 5,820,583), which is a continuation-in-part of International Patent Application PCT/US95/16,028, filed Dec. 12, 1995, which designates the United States and which is a continuation-in-part of U.S. patent application Ser. No. 08/583,774, filed Dec. 12, 1994 (abandoned), and claims the benefit of U.S. Provisional Application Serial No. 60/162,416 filed Dec. 29, 1999, priority of the filing date of each application which are hereby claimed under 35 U.S.C. §120 or §119(e).

FIELD OF THE INVENTION

[0002] The present invention relates to methods of inhibiting tumor cell adhesion and/or invasion and/or local tumor cell metastasis while simultaneously treating pain, and/or inflammation, and/or smooth muscle spasm and/or necrosis during surgical procedures using peripartitive, local delivery of a combination of therapeutic agents.

BACKGROUND OF THE INVENTION

[0003] Endoscopy is a surgical procedure in which a camera, attached to a remote light source and video monitor, is inserted into a body cavity (e.g., joint, peritoneal cavity, bladder, thorax, etc.) through a small portal incision in the overlying skin and body wall. Through similar portal incisions, surgical instruments may be placed in a body cavity, their use guided by arthroscopic visualization. As endoscopes' skills have improved, an increasing number of operative procedures, once performed by "open" surgical techniques, now can be accomplished endoscopically. Such procedures include, for example, epiploectomy, cholecystectomy and cardiac surgery. As a result of widening surgical indications and the development of small diameter endoscopes, pediatric endoscopy has become routine.

[0004] Throughout each endoscopic procedure, physiologic irrigation fluid (e.g., normal saline or lactated Ringers) is flushed continuously through the joint, distending the body cavity removing operative debris, thereby providing clearer visualization. U.S. Pat. No. 4,504,493 to Marshall discloses an isomolar solution of glycerol in water for a non-coagulative and optically clear irrigation solution for arthroscopy.

[0005] Irrigation is also used in other procedures, such as cardiovascular and general vascular diagnostic and therapeutic procedures, endologic procedures and the treatment of burns and any operative wounds. In each case, a physiologic fluid is used to irrigate a wound or body cavity or passage. Conventional physiologic irrigation fluids do not inhibit tumor cell adhesion and/or invasion and/or local tumor cell metastasis, nor do they provide analgesic, anti-inflammatory, anti-spasm and anti-vascular effects.

[0006] Cell adhesion molecules are important in cell-cell interaction and interactions between cells and components of the extracellular matrix. While these adhesive molecules are fundamental to diverse biological processes and regulate intracellular signaling events, these molecules are particularly important in the earliest stages of tumor metastasis that require adhesion and/or invasion of tumor cells. Specific cell adhesion molecules and proteins have been associated with the attachment and implantation of free tumor cells which occur during metastasis in a wide variety of human malignancies, including breast, prostate, liver, ovarian and bladder cancer. The diverse adhesion molecules, which mediate the adhesion interactions, are comprised of cellular surface receptor-ligand pairs. The cellular surface receptors constitute a group of transmembrane proteins that can be classified as members of related biological families or superfamilies based upon homologous structure and shared functional characteristics. Adhesion of cancer cells at secondary sites is known to be regulated by several families of adhesion proteins, including the CD44 proteoglycans, lectins and selectins. The primary functions of these receptors are to mediate cellular binding to the specific structural proteins that comprise the extracellular matrix (ECM) and to recognize membrane bound ligands mediating cell-cell adhesion. Cellular adhesion and invasion can also be facilitated by proteases, such as the metalloproteinases (MMPs) and their natural inhibitors, tissue inhibitors of metalloproteinases (TIMPs).

[0007] Surgical trauma has been found to increase the frequency of tumor implantation at the sites of surgical injury and wound healing. One of the consequences of surgical trauma to malignant tissues is the dissemination of free tumor cells locally at the operative site. For example, patients with pancreatic cancer often exhibit peritoneal dissemination and hepatic metastasis after undergoing surgery. Adhesive molecules and receptors mediating the attachment of free-floating tumor cells and implantation at surgical sites and at sites of wound healing are frequently present on numerous other normal cell types. Surgical trauma also stimulates and potentiates the production and release of proteases from tumor cells, inflammatory cells, and components of the extracellular matrix. Thus, a physiological approach aimed at interfering with the function of cell adhesion molecules to decrease tumor cell adhesion and inhibit the production and activation of proteases is to deliver the therapeutic agents only to the tissues at risk for local tumor metastasis. Since the process of free tumor-cell attachment and invasion into the extracellular matrix or other cells during surgery is a dynamic process involving specific interactions temporally related to the operative trauma, the optimal time for pharmacological intervention is at the time of surgery. Discovery of the role of multiple adhesive proteins, adhesion receptors, and proteases in the metastatic spread of cancer enables development of pharmacological compounds that block the attachment of tumor cells to extracellular matrix proteins and/or inhibit tumor cell invasion during surgical procedures.

[0008] Alleviating pain and reducing its postoperative problems is an area of special focus in clinical medicine, especially with the growing number of outpatient operations performed each year. The most widely used agents, cyclooxygenase inhibitors (e.g., ibuprofen) and opioids (e.g., morphine, fentanyl), have significant side effects including gastrointestinal irritation, bleeding and respiratory

245
125

depression. The high incidence of nausea and vomiting related to opioids is especially problematic in the postoperative period. Therapeutic agents aimed at treating postoperative pain while avoiding detrimental side effects are not easily developed because the molecular targets for these agents are distributed widely throughout the body and mediate diverse physiological actions. Despite the significant clinical need to inhibit pain and inflammation, as well as vasospasm, smooth muscle spasm and restenosis, methods for the delivery of inhibitors of pain, inflammation, spasm and restenosis at effective dosages while minimizing adverse systemic side effects have not been developed. As an example, conventional (i.e., intravenous, oral, subcutaneous or intramuscular) methods of administration of opiates in therapeutic doses frequently is associated with significant adverse side effects, including severe respiratory depression, changes in mood, mental clouding, profound nausea and vomiting.

[0009] Prior studies have demonstrated the ability of endogenous agents, such as serotonin (5-hydroxytryptamine, sometimes referred to herein as "5-HT"), bradykinin and histamine, to produce pain and inflammation. Sicuteri, F., et al., *Serotonin-Bradykinin Potentiation in the Pain Receptors in Man*, *Life Sci.* 4, pp. 309-316 (1965); Rosenthal, S. R., *Histamine as the Chemical Mediator for Cutaneous Pain*, *J. Invest. Dermat.* 69, pp. 98-105 (1977); Richardson, B. P., et al., *Identification of Serotonin M-Receptor Subtypes and their Specific Blockade by a New Class of Drugs*, *Nature* 316, pp. 126-131 (1985); Whalley, E. T., et al., *The Effect of Kinin Agonists and Antagonists*, *Neuropharmacol. Arch. Pharmacol.* 36, pp. 652-57 (1987); Lang, E., et al., *Chemo-Sensitivity of Fine Afferents from Rat Skin In Vitro*, *J. Neurophysiol.* 63, pp. 887-901 (1990).

[0010] For example, 5-HT applied to a human blister base (denuded skin) has been demonstrated to cause pain that can be inhibited by 5-HT₁ receptor antagonists. Richardson et al., (1985). Similarly, peripherally applied bradykinin produces pain that can be blocked by bradykinin receptor antagonists. Sicuteri et al., 1965; Whalley et al., 1987; Dray, A., et al., *Bradykinin and Inflammatory Pain*, *Trends Neurosci.* 16, pp. 99-104 (1993). Peripherally applied histamine produces vasodilation, itching and pain that can be inhibited by histamine receptor antagonists. Rosenthal, 1977; Douglas, W.W., "Histamine and 5-Hydroxytryptamine (Serotonin) and their Antagonists", in Goodman, L. S., et al., ed., *The Pharmacological Basis of Therapeutics*, MacMillan Publishing Company, New York, pp. 605-638 (1985); Rumore, M. M., et al., *Analgesic Effects of Antihistamines*, *Life Sci* 36, pp. 403-416 (1985). Combinations of these three agonists (5-HT, bradykinin and histamine) applied together have been demonstrated to display a synergistic pain-causing effect, producing a long-lasting and intense pain signal. Sicuteri et al., 1965; Richardson et al., 1985; Kessier, W., et al., *Excitation of Cutaneous Afferent Nerve Endings In Vitro by a Combination of Inflammatory Mediators and Conditioning Effect of Substance P*, *Exp. Brain Res.* 91, pp. 467-476 (1992).

[0011] In the body, 5-HT is located in platelets and in central neurons, histamine is found in mast cells, and bradykinin is produced from a larger precursor molecule during tissue trauma, pH changes and temperature changes. Because 5-HT can be released in large amounts from platelets at sites of tissue injury, producing plasma levels 20-fold

greater than resting levels (Ashton, J. H., et al., *Serotonin as a Mediator of Cyclic Flow Variations in Senescent Canine Coronary Arteries*, *Circulation* 73, pp. 572-578 (1986)), it is possible that endogenous 5-HT plays a role in producing postoperative pain, hyperalgesia and inflammation. In fact, activated platelets have been shown to excite peripheral nociceptors in vitro. Ringkamp, M., et al., *Activated Human Platelets in Plasma Excite Nociceptors in Rat Skin, In Vitro*, *Neurosci. Lett.* 170, pp. 103-106 (1994). Similarly, histamine and bradykinin also are released into tissues during trauma. Kimura, E., et al., *Changes in Bradykinin Level in Coronary Sinus Blood After the Experimental Occlusion of a Coronary Artery*, *Am Heart J* 85, pp. 635-647 (1973); Douglas, 1985; Dray et al. (1993).

[0012] In addition, prostaglandins also are known to cause pain and inflammation. Cyclooxygenase inhibitors, e.g., ibuprofen, are commonly used in non-surgical and postoperative settings to block the production of prostaglandins, thereby reducing prostaglandin-mediated pain and inflammation. Flower, R. J., et al., *Analgesic-Antipyretics and Anti-Inflammatory Agents: Drugs Employed in the Treatment of Gout*, in Goodman, L. S., et al., ed., *The Pharmacological Basis of Therapeutics*, MacMillan Publishing Company, New York, pp. 674-715 (1983). Cyclooxygenase inhibitors are associated with some adverse systemic side effects when applied conventionally. For example, indomethacin or fenofenac have well recognized gastrointestinal and renal adverse side effects.

[0013] As discussed, 5-HT, histamine, bradykinin and prostaglandins cause pain and inflammation. The various receptors through which these agents mediate their effects on peripheral tissues have been known and/or debated for the past two decades. Most studies have been performed in rats or other animal models. However, there are differences in pharmacology and receptor sequences between human and animal species. There have been no studies conclusively demonstrating the importance of 5-HT, bradykinin or histamine in producing postoperative pain in humans.

[0014] Furthermore, antagonists of these mediators currently are not used for postoperative pain treatment. A class of drugs, termed 5-HT and norepinephrine uptake antagonists, which includes amitriptyline, has been used orally with moderate success for chronic pain conditions. However, the mechanisms of chronic versus acute pain states are thought to be considerably different. In fact, two studies in the acute pain setting using amitriptyline perioperatively have shown no pain-relieving effect of amitriptyline. Levine, J. D., et al., *Desipramine Enhances Opiate Postoperative Analgesia*, *Pain* 27, pp. 45-49 (1986); Kendrick, J. M., et al., *Low-Dose Amitriptyline as an Adjuvant to Opioids for Postoperative Orthopedic Pain: a Placebo-Controlled Trial Period*, *Pain* 52, pp. 325-30 (1993). In both studies the drug was given orally. The second study noted that oral amitriptyline actually produced a lower overall sense of well being in postoperative patients, which may be due to the drug's affinity for multiple amine receptors in the brain.

[0015] Amitriptyline, in addition to blocking the uptake of 5-HT and norepinephrine, is a potent 5-HT receptor antagonist. Therefore, the lack of efficacy in reducing postoperative pain in the previously mentioned studies would appear to conflict with the proposal of a role for endogenous 5-HT in acute pain. There are a number of reasons for the lack of

278
6/27

acute pain relief found with amitriptyline in these two studies. (1) The first study (Lewin et al., 1996) used amitriptyline preoperatively for one week up until the night prior to surgery whereas the second study (Kortch et al., 1993) only used amitriptyline postoperatively. Therefore, no amitriptyline was present in the operative site tissues during the actual tissue injury phase, the time at which 5-HT is purported to be released. (2) Amitriptyline is known to be extensively metabolized by the liver. With oral administration, the concentration of amitriptyline in the operative site tissues may not have been sufficiently high for a long enough time period to inhibit the activity of postoperatively released 5-HT in the second study. (3) Since multiple inflammatory mediators exist, and studies have demonstrated synergism between the inflammatory mediators, blocking only one agent (5-HT) may not sufficiently inhibit the inflammatory response to tissue injury.

[0016] There have been a few studies demonstrating the ability of extremely high concentrations (1%-3% solutions—i.e., 10-30 mg per milliliter) of histamine, (H₁) receptor antagonists to act as local anesthetics for surgical procedures. This anesthetic effect is not believed to be mediated via H₁ receptors but, rather, due to a non-specific interaction with neuronal membrane sodium channels (similar to the action of lidocaine). Given the side effects (e.g., excitation) associated with these high "anesthetic" concentrations of histamine receptor antagonists, local administration of histamine receptor antagonists currently is not used in the perioperative setting.

SUMMARY OF THE INVENTION

[0017] In one aspect, the present invention is directed towards preventing and treating tumor cell adhesion, and/or invasion and/or local metastasis in patients undergoing surgical procedures. The invention describes methods and pharmaceutical compositions based upon a combination of agents that will inhibit tumor cell attachment and/or invasion, and/or local metastasis during surgical procedures, and chemokinesically inhibit pain, and/or inflammation, and/or smooth muscle spasm and/or restenosis associated with the operation. According to one aspect of the invention, a method is provided for reducing or preventing tumor cell adhesion, and/or invasion and/or local metastasis, which comprises administering directly to the operative site a composition which includes a combination of two or more chemokinesically active agents, at least one of which is an anti-tumor adhesion or anti-invasion or anti-local metastasis agent, to a pharmacokinetically effective carrier for delivery in an irrigated fluid. Chemokinesically active agents include, but are not limited to, all components that act directly or indirectly to modulate or alter the biological, biochemical or biophysical state of a cell, including agents that alter the electrical potential of the plasma membrane, the binding of ligands to a receptor, the enzymatic activity or expression level of cellular receptors, enzyme inhibitors or activators, inhibitors of protein-protein interactions, RNA-protein interactions, or DNA-protein interactions. For example, functional receptor antagonists may include monoclonal antibodies that competitively inhibit receptor binding sites, soluble receptors that reduce the free ligand concentration available to activate a receptor, inhibitors of receptor signaling pathways, activators and inhibitors of intracellular or extracellular enzymes and agents that modulate the binding of transcription factors to DNA.

[0018] Specifically, the present invention provides a pharmaceutical method of treating tumor cell adhesion and/or invasion and/or local metastasis using a combination of agents delivered locally and peripherally to achieve maximal therapeutic benefit. The use of a combination of agents overcomes the limitations of existing therapeutic approaches which rely on the use of a single agent to block the multifactorial tumor cell adhesion and invasion processes which are modulated by numerous proinflammatory cytokines and receptors that are linked to the inflammatory response arising from surgical procedures. Proinflammatory cytokines have been reported to stimulate the expression of adhesion receptors and metalloproteinases present on both tumor cells and normal cells, thereby increasing their adhesive and invasive properties. A combination of an anti-adhesion agent and an anti-inflammatory agent, for example, may provide an additive or synergistic benefit in the pharmaceutical composition.

[0019] This invention utilizes the approach of combining agents that act simultaneously on molecular targets associated with tumor cell adhesion, and/or tumor cell invasion, and/or metastasis, and/or inflammation, and/or pain, and/or smooth muscle spasm, and/or restenosis and delivering these agents to the operative site throughout the surgical procedure. These combinations of agents will be able to achieve a preemptive inhibition of tumor cell adhesion and/or invasion during the entire period of the surgical procedure while also preemptively inhibiting pain, and/or inflammation, and/or smooth muscle spasm and/or restenosis. Inhibition of a single adhesion receptor-ligand interaction through specific delivery is likely to lead to adverse reactions since these molecules also function to deliver signals to normal cells. For example, CD44 receptor binding plays a physiological role in the immune response of normal T-cells and other hematopoietic cells and, therefore, inhibition of CD44 binding could lead to undesirable effects on the immune system.

[0020] Specifically, the present invention provides pharmaceutical compositions of chemokinesically active agents that are based on a combination of at least two agents that act simultaneously on distinct molecular targets. At least one agent is an anti-tumor cell adhesion or anti-invasion or anti-local metastasis agent that directly reduces or prevents the attachment of tumor cells to either the extracellular matrix or to other cells (both normal and tumor). Suitable agents for inclusion in the pharmaceutical composition will be further characterized by a requirement for pharmacologically selective and specificity which limits interactions of the agent to a single family (or class) of receptors or a single enzyme family (e.g., CD44, integrins, selectins, protein tyrosine kinases, ADAMs, and MAP Kinases). A particular suitable agent may interact specifically with one or more receptor subtypes (or isotype) while exhibiting specificity for the receptor family. Each suitable agent will associate with its molecular target through a specific molecular mechanism which can be characterized by a defined stoichiometry (typically 1:1) for the ligand-receptor (or inhibitor-enzyme) complex and which can be characterized by its equilibrium binding or kinetic constant.

[0021] At least one second agent belongs to a class of receptor antagonists, enzyme inhibitors or cytokines that possess anti-pain, anti-inflammatory, anti-spasm, and/or anti-restenosis activity. The optimal drug combination methods at least one agent drawn from a class of anti-tumor

cell adhesion and/or anti-invasion agents which include receptor antagonists that act to inhibit and reduce the activity or the expression of a cell adhesion receptor molecular target (e.g., integrin receptor antagonists, CD34 receptor antagonists and selectin receptor antagonists) or a proteinase inhibitor.

[0022] In addition, other suitable agents for inclusion in an optimal drug combination that are functional anti-tumor cell adhesion agents, which act to inhibit cellular signal transduction pathways, activated by cell adhesion receptors. The molecular targets that comprise these pathways include membrane associated and intracellularly localized enzymes that transduce and integrate the signals produced by activated cell surface adhesion receptors. As examples, these agents include inhibitors of the enzymes belonging to the following families: protein tyrosine kinase, protein kinase C, and adenosine-activated protein kinase (MAPK). Such enzyme inhibitors may interact with a particular member or members of the kinase family through specific mechanisms with are characterized by both a defined selectivity (typically 1:1) of the enzyme-inhibitor complex and which can be characterized by equilibrium inhibition constants.

[0023] Despite a number of experimental studies, an effective treatment for preventing tumor cell adhesion and/or invasion during surgical procedures has not been developed previously. It is the object of the present invention to provide a method for the preoperative treatment of tumor cell adhesion and/or invasion and/or local metastasis during surgical procedures employing irrigation fluids for the continuous delivery of therapeutic agents. Existing methods of delivery do not provide a means to initiate delivery of pharmacological agents directly to the operative site and maintain drug levels at or above therapeutically effective concentrations throughout the surgical procedure. Due to the use of large volumes of irrigation fluid during certain surgical procedures (e.g., laparoscopic surgery), loss of the agents in the irrigation fluid provides a method to prevent diffusion of the agents and maintain therapeutic levels. Problems associated with systematic delivery of therapeutic peptides, proteins and small molecules as potential anti-tumor cell adhesion/invasion, and anti-metastasis agents, including toxicity, pharmacokinetic stability and poor pharmacokinetic profiles, may be reduced or obviated by local delivery of these therapeutic agents to an irrigation fluid directly to the operative site.

[0024] A multiple drug combination can be delivered via irrigation locally and perivascularly (i.e., intra-operative delivery alone or intra-operative delivery together with pre-operative and/or post-operative delivery). This invention also provides for an anti-tumor adhesion and/or anti-invasion and/or local metastasis agent to be delivered in combination with one or more analgesic and/or anti-inflammatory and/or anti-apoptosis and/or pro-apoptosis agents.

[0025] A significant advantage of the invention is derived from the rapid onset of pharmacological action. Direct, local delivery of the anti-tumor adhesion agents initiated at the onset of the surgical procedure and continued during the surgical procedure (i.e., perioperatively) has the potential to inhibit one of the earliest steps of metastasis, the initial adhesion process. The immediate and constant delivery of therapeutically effective concentrations of anti-adhesion and/or invasion agents is expected to preceptively inhibit the initial attachment of tumor cells to both the extracellular

matrix and other cells and subsequent invasion into these tissues. Studies have found that the highest rate of tumor implantation occurred when tumor cells were injected immediately after surgery, indicative of the critical timing for therapeutic inhibitors of the adhesion process.

[0026] The method of delivery and pharmacological composition of the present invention provide distinct advantages which include: 1) a combination drug therapy directed to the multifactorial causes of tumor cell adhesion/invasion/local metastasis, inflammation, pain, vascular muscle spasm and metastasis during surgical procedures, 2) local delivery of the drug combination achieves an instantaneous therapeutic concentration of anti-tumor adhesion agents at the operative site, 3) continuous delivery of therapeutic agents in an irrigation solution provides a constant drug concentration in a therapeutically effective range at the operative site during a surgical procedure, 4) local delivery permits a reduction in total drug dose and dosing frequency compared to systematic delivery, and 5) direct, local delivery to the surgical site enables use of novel, pharmacologically active agents, such as certain peptides and nucleotides, which cannot be delivered systemically.

[0027] The present invention further provides a solution comprising a mixture of multiple agents in low concentrations directed at inhibiting locally the mediators of pain, inflammation, spasm and metastasis in a physiologic electrolyte carrier fluid. The invention also provides a method for perioperative delivery of the irrigation solution containing these agents directly to a surgical site, where it works locally at the receptor and enzyme levels to preceptively inhibit pain, inflammation, spasm and metastasis at the site. Due to the local perioperative delivery method of the present invention, a desired therapeutic effect can be achieved with lower doses of agents than are necessary when employing other methods of delivery (i.e., intravenous, intramuscular, subcutaneous and oral). The anti-pain/anti-inflammation agents in the solution include agents selected from the following classes of receptor antagonists and agonists and enzyme activators and inhibitors, each class acting through a differing molecular mechanism of action for pain and inflammation inhibition: (1) serotonin receptor antagonists, (2) serotonin receptor agonists, (3) histamine receptor antagonists, (4) benzylamine receptor antagonists, (5) histamine inhibitors, (6) tachykinin receptor antagonists, including neuregulin, and dermorphin, receptor subtype antagonists, (7) calcitonin gene-related peptide (CGRP) receptor antagonists, (8) interleukin receptor antagonists, (9) inhibitors of enzymes active in the synaptic pathway for arachidonic acid metabolism, including (a) phospholipase inhibitors, including P₁A, isoform inhibitors and P₁C, isoform inhibitors, (b) cyclooxygenase inhibitors, and (c) lipooxygenase inhibitors, (10) prostaglandin receptor antagonists including eicosanoid EP-1 and EP-4 receptor subtype antagonists and thromboxane receptor subtype antagonists, (11) leukotriene receptor antagonists including leukotriene B₂ receptor subtype antagonists and leukotriene D₄ receptor subtype antagonists, (12) opioid receptor agonists, including μ -opioid, δ -opioid, and κ -opioid receptor subtype agonists, (13) pain receptor agonists and antagonists including P₂ receptor antagonists and P₂ receptor agonists, and (14) selective triphosphatic (ATP)-sensitive potassium channel openers. Each of the above agents functions either as an anti-inflammatory agent and/or as an anti-nociceptive, i.e.,

anti-pain or analgesic, agent. The selection of agents from these classes of compounds is tailored for the particular application.

[0028] Several preferred embodiments of the solution of the present invention also include anti-spasm agents for particular applications. For example, anti-spasm agents may be included alone or in combination with anti-pain/anti-inflammation agents in solutions used for vascular procedures to limit vasospasm, and anti-spasm agents may be included for urologic procedures to limit spasm in the urinary tract and bladder wall. For such applications, anti-spasm agents are utilized in the solution. For example, an anti-pain/anti-inflammation agent that also serves as an anti-spasm agent may be included. Suitable anti-inflammatory/anti-pain agents that also act as anti-spasm agents include serotonin receptor antagonists, tachykinin receptor antagonists, and ATP-sensitive potassium channel openers. Other agents which may be utilized in the solution specifically for their anti-spasm properties include calcium channel antagonists, endothelin receptor antagonists and the nitric oxide donors (enzyme activators).

[0029] Specific preferred embodiments of the solution of the present invention for use in cardiovascular and general vascular procedures include anti-restenosis agents, which most preferably are used in combination with anti-spasm agents. Suitable anti-restenosis agents include: (1) antiplatelet agents including: (a) thrombin inhibitors and receptor antagonists, (b) adenosine diphosphate (ADP) receptor antagonists (also known as perinceptor, receptor antagonists), (c) thromboxane inhibitors and receptor antagonists and (d) platelet membrane glycoprotein receptor antagonists; (2) inhibitors of cell adhesion molecules, including (a) selectin inhibitors and (b) integrin inhibitors; (3) anti-chemotactic agents; (4) interleukin receptor antagonists (which also serve as anti-pain/anti-inflammation agents); and (5) intracellular signaling inhibitors including: (a) protein kinase C (PKC) inhibitors and protein tyrosine kinase inhibitors, (b) modulators of intracellular protein tyrosine phosphatases, (c) inhibitors of Src homology (SH2) domains, and (d) calcium channel antagonists. Such agents are useful in preventing restenosis of arteries treated by angioplasty, rotational atherectomy or other cardiovascular or general vascular therapeutic or diagnostic procedure.

[0030] The present invention also provides a method for manufacturing a medicament compounded as a dilute irrigation solution for use in continuously irrigating an operative site or wound during an operative procedure. The method entails dissolving in a physiologic electrolyte carrier fluid at least one inhibitor of tumor cell adhesion, invasion and/or metastasis and preferably a plurality of anti-pain/anti-inflammatory agents, and for some applications anti-spasm agents and/or anti-restenosis agents, each agent included at a concentration of preferably no more than 100,000 nanomolar, and more preferably no more than 10,000 nanomolar.

[0031] The method of the present invention provides for the delivery of a dilute combination of at least one inhibitor of tumor cell adhesion, invasion and/or metastasis and preferably multiple receptor antagonists and agonists and enzyme inhibitors and activators directly to a wound or operative site, during therapeutic or diagnostic procedures for the inhibition of pain, inflammation, spasm and restenosis. Since the active ingredients in the solution are being

locally applied directly to the operative tissues in a continuous fashion, the drugs may be used efficaciously at extremely low doses relative to those doses required for therapeutic effect when the same drugs are delivered orally, intramuscularly, subcutaneously or intravenously. As used herein, the term "local" encompasses application of a drug in and around a wound or other operative site, and excludes oral, subcutaneous, intravenous and intramuscular administration. The term "continuous" as used herein encompasses uninterrupted application, repeated application at frequent intervals (e.g., repeated intravascular boluses at frequent intervals intraprocedurally), and applications which are uninterrupted except for brief cessations such as to permit the introduction of other drugs or agents or procedural equipment, such that a substantially constant predetermined concentration is maintained locally at the wound or operative site.

[0032] The advantages of low dose applications of agents are three-fold. The most important is the absence of systemic side effects which often limit the usefulness of these agents. Additionally, the agents selected for particular applications in the solutions of the present invention are highly specific with regard to the mediators on which they work. This specificity is maintained by the low dosages utilized. Finally, the cost of these active agents per operative procedure is low.

[0033] The advantages of local administration of the agents via luminal irrigation or other fluid application are the following: (1) local administration guarantees a known concentration at the target site, regardless of interpatient variability in metabolism, blood flow, etc.; (2) because of the direct mode of delivery, a therapeutic concentration is obtained instantaneously and, thus, improved dosage control is provided; and (3) local administration of the active agents directly to a wound or operative site also substantially reduces degradation of the agents through extracellular processes, e.g., first- and second-pass metabolism, that would otherwise occur if the agents were given orally, intravenously, subcutaneously or intramuscularly. This is particularly true for those active agents that are peptides, which are metabolized rapidly. Thus, local administration permits the use of compounds or agents which otherwise could not be employed therapeutically. For example, some agents in the following classes are peptide: bradykinin receptor antagonists; tachykinin receptor antagonists; opioid receptor agonists; CGRP receptor antagonists; and interleukin receptor antagonists. Local, continuous delivery to the wound or operative site minimizes drug degradation or metabolism while also providing for the continuous replacement of that portion of the agent that may be degraded, to ensure that a local therapeutic concentration, sufficient to maintain receptor occupancy, is maintained throughout the duration of the operative procedure.

[0034] Local administration of the solution perioperatively throughout a surgical procedure in accordance with the present invention produces a preemptive analgesic, anti-inflammatory, anti-spasmodic or anti-restenotic effect. As used herein, the term "perioperative" encompasses application intraprocedurally, pre- and intra-procedurally, intra- and postprocedurally, and pre-, intra- and postprocedurally. To maximize the preemptive anti-inflammatory, analgesic (for certain applications), antispasmodic (for certain applications) and antirestenotic (for certain applications) effects, the solutions of the present invention are most preferably

applied per-, intra- and postoperatively. By occupying the target receptors or inactivating or activating targeted enzymes prior to the initiation of significant operative trauma locally, the agents of the present solution modulate specific pathways to preemptively inhibit the targeted pathologic processes. If inflammatory mediators and processes are preemptively inhibited in accordance with the present invention before they can exert tissue damage, the benefit is more substantial than if given after the damage has been initiated.

[0035] Inhibiting more than one tumor cell adhesion, invasion and/or metastasis, inflammatory, sprout or metastasis modulator by application of the multiple agent solution of the present invention is useful to dramatically reduce the degree of cell adhesion, invasion and/or metastasis, inflammation, pain, and sprout, and theoretically should reduce metastasis. The irrigation solutions of the present invention include combinations of drugs, each solution acting on multiple receptors or enzymes. The drug agents are then simultaneously effective against a combination of pathologic processes, including tumor cell adhesion, invasion and/or metastasis, pain and inflammation, vasospasm, smooth muscle spasm and restenosis. The action of these agents is considered to be synergistic, in that the multiple receptor antagonists and inhibitory agonists of the present invention provide a disproportionately increased efficacy in combination relative to the efficacy of the individual agents. The synergistic action of several of the agents of the present invention are discussed, by way of example, below in the detailed descriptions of these agents.

[0036] In addition to arthroscopy, the solution of the present invention may also be applied locally to any human body cavity or passage, operative wound, traumatic wound (e.g., burn) or to any operative/interventional procedure in which irrigation can be performed. These procedures include, but are not limited to, endoscopic procedures, cardiovascular and general vascular diagnostic and therapeutic procedures, endoscopic procedures and oral, dental and periodontal procedures. As used hereafter, the term "wound", unless otherwise specified, is intended to include surgical wounds, operative/interventional sites, traumatic wounds and burns.

[0037] Used preoperatively, the solution should result in a clinically significant decrease in operative site pain and inflammation relative to currently-used irrigation fluids, thereby decreasing the patient's postoperative analgesic (i.e., opiate) requirement and, when appropriate, allowing earlier patient mobilization of the operative site. No extra effect on the part of the surgeon and operating room personnel is required to use the present solution relative to conventional irrigation fluids.

BRIEF DESCRIPTION OF THE DRAWINGS

[0038] The present invention will now be described in greater detail, by way of example, with reference to the accompanying drawings in which:

[0039] FIG. 1 provides a schematic overview of a generic vascular coil showing molecular length and flow of signaling information leading to constriction, secretion and/or proliferation. The integration of extrinsic signals through receptors, ion channels and other membrane proteins are common to platelets, endothelia, endothelial cells and smooth muscle cells. Representative examples of molecular

targets are included for major groups of molecules which are therapeutic targets of drugs included in the solutions of the present invention.

[0040] FIG. 2 provides a detailed diagram of the signaling pathways illustrating "cross-talk" between G-protein coupled receptor (GPCR) pathways and receptor tyrosine kinase (RTK) pathways in a vascular smooth muscle cell. Only representative proteins in each pathway have been shown to simplify the flow of information. Activation of GPCRs leads to increases in intracellular calcium and increased protein kinase C (PKC) activity and subsequent smooth muscle constriction or spasm. In addition, "cross-talk" to the RTK signaling pathway occurs through activation of Pyk2 (a newly discovered protein tyrosine kinase) and PI3K-X (an undifferentiated protein tyrosine kinase), triggering proliferation. Conversely, while activation of RTKs directly initiates proliferation, "cross-talk" to the GPCR pathway occurs at the level of PKC activity and calcium levels. LCB designates ligand-gated receptor, and MAPK designates mitogen-activated protein kinase. These interactions define the basis for synergistic interactions between molecular targets modulating spasm and restenosis. The GPCR signaling pathway also mediates signal transduction (FIGS. 3 and 7) leading to pain transmission in other cell types (e.g., neurons).

[0041] FIG. 3 provides a diagram of the G-Protein Coupled Receptor (GPCR) pathway. Specific molecular sites of action for some drugs in a preferred arthroscopic solution of the present invention are identified.

[0042] FIG. 4 provides a diagram of the G-Protein Coupled Receptor (GPCR) pathway including the signaling proteins responsible for "cross-talk" with the Growth Factor Receptor signaling pathway. Specific molecular sites of action for some drugs in a preferred cardiovascular and general vascular solution of the present invention are identified. (See also FIG. 5).

[0043] FIG. 5 provides a diagram of the Growth Factor Receptor signaling pathway including the signaling proteins responsible for "cross-talk" with the G-Protein Coupled Receptor signaling pathway. Specific molecular sites of action for some drugs in a preferred cardiovascular and general vascular solution of the present invention are identified. (See also FIG. 4).

[0044] FIG. 6 provides a diagram of the G-Protein Coupled Receptor pathway including the signaling proteins responsible for "cross-talk" with the Growth Factor Receptor signaling pathway. Specific molecular sites of action for some drugs in a preferred analgesic solution are identified.

[0045] FIG. 7 provides a diagram of the G-Protein Coupled Receptor pathway. Specific molecular sites of action for some drugs in a preferred general surgical wound solution of the present invention are identified.

[0046] FIG. 8 provides a diagram of the mechanism of action of nitric oxide (NO) donor drugs and NO causing relaxation of vascular smooth muscle. Physiologically, certain hormones and transmitters can activate a form of NO synthase in the endothelial cell through elevated intracellular calcium resulting in increased synthesis of NO. NO donors may generate NO extracellularly or be metabolized to NO within the smooth muscle cell. Endothelial NO can diffuse across the endothelial cell or directly enter the smooth muscle cell. The primary target of NO is the soluble gas-

nylate cyclase (GC), leading to activation of a cGMP-dependent protein kinase (PKG) and subsequent extension of calcium from the smooth muscle cell via a membrane pump. NO also hyperpolarizes the cell by opening potassium channels which in turn cause closure of voltage-sensitive calcium channels. Thus, the synergistic interactions of calcium channel antagonists, potassium channel openers and NO donors are evident from the above signal transduction pathway.

[0047] FIGS. 9, 10A and 10B provide charts of the percent of vasoconstriction-versus time in control arteries, in the proximal segment of subject arteries, and in the distal segment of subject arteries, respectively, for the animal study described in EXAMPLE VII herein demonstrating the effect on vasoconstriction of infusion with histamine and serotonin antagonists, used in the solutions of the present invention, during balloon angioplasty.

[0048] FIGS. 11 and 12 provide charts of plasma extravasation versus dosage of amitriptyline, used in the solutions of the present invention, delivered intravenously and intrarterially, respectively, to knee joints in which extravasation has been induced by introduction of 5-hydroxytryptamine in the animal study described in EXAMPLE VIII herein.

[0049] FIGS. 13, 14 and 15 provide charts of mean vasoconstriction (negative values) or vasodilation (positive values), $\pm$ standard error of the mean for the proximal (FIG. 13), mid (FIG. 14) and distal (FIG. 15) segments of arteries treated with saline (N=4) or with a solution formulated in accordance with the present invention (N=7), at the immediate and 15 minute post-rotational atherectomy time points in the animal study of Example XIII described herein.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0050] In accordance with the present invention, methods and solutions are provided for reducing or preventing tumor cell adhesion, and/or invasion and/or local metastasis, which comprises administering directly to the operative site a composition which includes a combination of two or more metabolically active agents, at least one of which is an anti-tumor adhesion or anti-invasion or anti-local metastasis agent, in a pharmaceutically effective carrier for delivery in an irrigation fluid.

1. Inhibitors of Cell Adhesion and Invasion Molecules

[0051] A. Metalloproteinase Antagonists and Tissue Inhibitors of Metalloproteinases (TIMPs)

[0052] Matrix metalloproteinases (MMPs) are a family of zinc-dependent neutral endopeptidases whose enzymatic activity is capable of controlled degradation of the extracellular matrix (ECM). This activity serves as a key control factor in the adhesion, invasive capacity, metastasis, growth, and angiogenesis of tumors. In humans, cloning and sequencing have identified 17 members of this family. These members are divided into subgroups of collagenases, gelatinases, stromelysins and stromelysin-like MMPs, membrane-type-MMPs, and novel MMPs.

[0053] The MMPs share common structural and functional characteristics. All families to date have at least three

domains: a prodomain which contains a conserved cysteine residue and which is lost on enzyme activation; a catalytic domain of 106 to 119 residues which contains conserved structural metal-binding sites; and a highly conserved zinc-binding active site domain of 52 to 58 amino acids.

[0054] Cells do not generally constitutively express MMPs, but rather their expression is rapidly induced in response to exogenous signals, cytokines or growth factors and altered cell-matrix and cell-cell interactions. Exceptions to this rule are MMP-8 and MMP-9 that are stored in secretory granules of neutrophils and eosinophils, and MMP-7 that is stored in secretory epithelial cells.

[0055] Expression of MMPs is primarily regulated at the level of transcription, and their proteolytic activity is regulated by zymogen activation and inhibition of activity. Extracellular signals such as cytokines (IL-1, tumor necrosis factor, etc.) and others activate the AP-1 transcription factor complex composed of members of Jun and Fos proteins, which bind to the AP-1 cis-element and activate transcription of the corresponding MMP gene. Most MMPs are secreted as latent precursors (zymogens), which are proteolytically activated in the extracellular space with the exception of MMP-11 and MT1-MMP, which are activated prior to their secretion by Golgi-associated furin-like proteases.

[0056] The activity of MMPs in the extracellular space is controlled by the tissue inhibitors of matrix metalloproteinases (TIMPs), a family of natural inhibitors. Thus far, four members of this family have been identified (TIMP-1, 2, 3, 4) and well characterized. These TIMPs have similar inhibitory activities against most of the MMPs, but differ with respect to their interactions with proMMPs, solubility, regulation of expression, and tissue specific expression. TIMP-3 unlike other TIMPs inhibits the activity of TNF- α -converting enzyme (TACE), suggesting a role in modulating inflammation. TGF- β , IL-1, IL-6, TNF- α , EGF, and glucocorticoids regulate TIMP-1 at the transcriptional level. TIMP-2 is expressed constitutively and TIMP-4 expression is restricted. TIMP-3 expression is up-regulated by mitogens, phorbol esters and TGF- β .

[0057] The MMPs have been shown to facilitate tumor cell invasion and metastasis by at least three mechanisms. In a physiological sense, first, the MMPs can modulate tumor cell adhesion. This process is necessary for cells to attach and move through the ECM. Cell transfection studies altering the ratio of MMP-2 to TIMP-2 have demonstrated variation in the adhesive phenotype of tumor cells. Next, the proteinase action of MMPs can degrade ECM macromolecules such as collagens, laminins, and proteoglycans allowing tumor cell invasion. Finally, MMPs can act on ECM components or other proteins to activate biological functionality. For example, laminin-5 is degraded by MMP-2 to produce a soluble chemotactic fragment.

[0058] The classic role of MMPs to degrade ECM components, and in particular the basement membrane is considered critical for tumor cell invasion. Experimentally, the necessity for protease action in tumor cell invasion has been demonstrated using the chemoinvasion assay. Abundant expression of distinct MMPs occurs in invasive primary tumors or their metastases. The level of MMP-1 expression correlates with a poor prognosis of colorectal and esophageal cancer and the expression of MMP-2 and MMP-3 are

closely related to lymph node metastasis. Expression of MMP-2, TIMP-2 and MT1-MMP correlates with poor prognosis in bladder cancer. MMP-7 knockout mice show reduction in intestinal tumorigenesis and MMP-2 deficient mice show reduced angiogenesis and tumor progression. Infiltration of inflammatory cells is also a prominent feature of many malignant tumors, and they can be a source of MMPs, contributing to tumor cell invasion. These inflammatory cells also produce cytokines, which can enhance MMP expression by tumor and stromal cells leading to further tumor cell invasion.

[0059] The TIMPs also play a role in tumor cell invasion. The ability of TIMPs 1, 2, 3, and 4 to inhibit tumor growth has been shown by over-expressing them in various human and rodent models. In melanoma cells, over-expression of TIMP-2 inhibits the growth of tumors implanted in the skin of SCID mice. This growth inhibition seems independent of angiogenesis but dependent on the collagen matrix. Current concepts on the role of TIMPs in cancer now focus on inhibition of tumor invasion, metastasis, and regulation of ECM homeostasis.

[0060] Based upon *in vitro*, *in vivo*, *in situ*, and clinical studies, inhibition of MMP activity can inhibit adhesion, invasion, and metastasis of neoplastic cells and effectively suppress tumor growth and metastasis. Prevention of tumor growth can be accomplished by inhibition of MMP expression or activity at multiple steps in the synthetic pathway of MMPs.

[0061] Inhibition of MMP transcription can be accomplished by blocking signaling pathways regulating MMP transcription directly or by inhibiting transcription factors responsible for activating transcription of MMP genes. Inhibition of signaling pathways involved in AP-1 activation, the MAPKs (ERK1,2/SAPK/JNK or p38) can markedly inhibit the expression of MMPs and the invasion of malignant cells *in vitro*. Expression of dominant-negative transcription factors, which requires an effective method of gene therapy *in vivo*, may be used to inhibit MMP production. For example, expression of dominant negative c-Jun has been shown to inhibit the induction of MMPs 1,2,3,10 and 14 as well as the *in vitro* invasion of keratinocytes. Retinoids as inhibitors of AP-1 activity could also be used to prevent MMP gene expression in selected human carcinomas.

[0062] Another method for inhibiting expression of specific MMPs is to use antisense RNAs. Antisense oligonucleotides for MMP-7 have been shown to inhibit invasion of colon carcinoma cells *in vitro* and *in vivo*. An MMP-9 antisense-ribozyme expression construct has been shown to inhibit expression of MMP-9 and the invasion of rat osteocarcinoma cells.

[0063] The most extensively studied area of inhibiting tumor cell invasion via inhibition of MMPs has been the development of compounds to block MMP activity. Synthetic MMP inhibitors (MMPIs), such as hydroxamate inhibitors, are small peptide analogs of fibrillar collagen, which specifically interact with the zinc in the catalytic site of MMPs and inhibit their activity. Currently, several of these agents are in clinical trials for treating invasive tumors. The first class to be developed was the broad-spectrum MMPIs, which nonspecifically inhibit multiple MMPs. Examples are batimastat (BB-94) with poor oral bioavailability requiring local administration and marimastat (BB-

2516) which can be orally administered. Results of pre-clinical studies show these agents to inhibit tumor invasion, metastasis, and growth. Next, development of selective agents for targeting of certain MMPs was accomplished. Since peptide-based MMP inhibitors are costly to produce and generally have poor bioavailability, non-peptidic inhibitors have been developed through rational design based on X-ray crystallographic information of the MMP active site. Examples of non-peptidic inhibitors are CGS27023A (Novartis), AG3340 (Agouron), and the fenibufen derivative BAY12-9566 (Bayer). In addition, tetracyclines devoid of their anti-microbial effect have been developed to block host derived MMPs. This class of chemically modified non-microbial tetracyclines (CMTs) has been shown to block the expression of MMP 2, 3 and 8, by multiple mechanisms and have also been shown to induce apoptosis of malignant cells. Most recently, bisphosphonates have been identified as MMP inhibitors and the aggrecanase-1 inhibitors, SE206, BB-16, and XS309 have been shown to have good potency. Finally, the ability of TIMPs to potently and specifically inhibit MMP activity has raised interest in their use. TIMPs 1,2,3, and 4 can inhibit invasion of malignant cells *in vitro* and *in vivo*.

[0064] In one aspect, the present invention provides for administering directly to an operative site via irrigation solution one or more MMP inhibitors in combination with at least one additional anti-pain and/or anti-inflammatory and/or anti-spasm and/or anti-restenosis agent that would be effective in preventing or inhibiting tumor cell adhesion, invasion, and metastasis. Inhibitors and antagonists may act at the level of MMP transcription, translation, secretion, activation, or degradation.

[0065] One skilled in the art will appreciate that the choice of a MMP inhibitor as a therapeutic agent for a patient will, in part, determine the amounts of the agents to be administered for any particular treatment protocol and that these amounts can be readily determined.

[0066] MMP inhibitors suitable for use in the present invention are listed in the Table below.

TABLE 1

Metalloproteinase Antagonists and TIMPs		
Agent	Therapeutic Preferred Concentration	Max Preferred Concentration
Batimastat	0.1-10,000	100
Marimastat	0.1-100,000	100
CGS27023A	1-10,000	1000
AG3340	0.1-10,000	100
Bay 12-9566	10-1,000,000	10,000
CMT 1	0.1-1000 mg/kg	100 mg/kg
Marocycline	100-500,000	100,000
SE206	10-1,000,000	10,000
BB16	10-1,000,000	10,000
XS309	100-10,000,000	100,000
Antisense RNA	0.5-5,000	5,000
MMPIs	0.1-10,000	1,000

[0067] B. CD44 Receptor Antagonists and Inhibitors of CD44 Signaling

[0068] CD44 is a transmembrane glycoprotein that comprises a family of surface receptors composed of numerous variant isoforms. The CD44 receptor is found in a wide

Oct. 16, 2003

variety of tissues including the central nervous system, lung, epidermis, liver, colon and pancreas. This family of related cell surface adhesion molecules are multifunctional proteins expressed in both normal and malignant tissues. CD44 is encoded by a single gene containing 20 exons, 10 of which (v1-v10) are variant exons inserted by alternative splicing. The standard isoform of CD44 (CD44s), which is ubiquitously expressed, does not contain sequences encoded by these variant exons. Numerous variant isoforms of CD44 (CD44v) which contain different combinations of exons (v1-v10) inserted into the extracellular domain are restricted in their expression to proliferating epithelial cells, activated lymphocytes and malignant cells.

[0069] Recent studies have demonstrated that the CD44 protein is the primary receptor for hyaluronate in humans. Since CD44 is the principal transmembrane receptor for this extracellular matrix glycosaminoglycan, CD44 has also been termed the hyaluronate receptor. It can also bind some other extracellular matrix ligands (chondroitin sulfate, heparin sulfate, and fibronectin) with lower affinity.

[0070] This CD44 receptor-ligand interaction is required for many normal cellular processes including cellular adhesion (organization and migration), hyaluronate degradation, lymphocyte activation, lymphocyte homing into inflammatory sites, and release of cytokines. Additional specialized functions include assembly of a pericellular matrix during chondrogenesis and wound healing. Interactions between CD44 receptor and hyaluronic acid (HA) deliver important signals to normal and transformed CD44 bearing cells. In common with many other cell surface receptors, cells that express CD44 regulate expression of this receptor in response to ligand binding.

[0071] The CD44 molecule is an 85 kD glycosylated polypeptide with N-terminal sequence homology to cartilage link proteins. Isoforms of CD44 of varying sizes have been described on many cell types. Variations in the size of CD44 isoforms occur due to glycosylation differences and to the inclusion of chondroitin sulfate molecules in CD44. The 85 kD form has been identified in serum, plasma and synovial fluid. Alternative splicing creates a hematopoietic form of the molecule, CD44H, and additional endopep. Alternative splicing results in changes in protein glycosylation and provides a mechanism for the regulation of binding activity of CD44. Thus, the CD44 molecule, by existing in several isoforms and also in its wide cellular distribution and functional association with other adhesion molecules, is a multifunctional proinflammatory molecule involved in immune cell activation as well as metastasis of certain tumor cell types.

[0072] The predominant isoform found on human leukocytes is CD44H. Both hyaluronate and CD44 mAb binding to monocytes induces IL-1 release. On T cells, hyaluronate and CD44 mAb ligation of CD44 have dyspeptic effects. CD44 mAbs against T cell triggering while hyaluronate suppresses T cell triggering. Finally, CD44 mAbs and polyclonal anti-CD44 serum have been shown to inhibit the binding of lymphocytes to endothelial venules in inflammatory sites such as synovium.

[0073] The physiological functions of CD44 indicate that it plays a role in the metastatic spread of tumors. CD44 peptides, such as hyaluronate-mediated adhesion, cellular motility, and adhesion to lymphoid tissue, are among several

that are required by invasive and metastatic tumor cells. In vivo experiments indicate that tumor cells transfected to overexpress specific CD44 isoforms display enhanced metastatic potential. Of the numerous CD44 isoforms, specific isoforms enhance tumor cell metastasis more efficiently than others do. Metastatic potential can be conferred to non-metastasizing cell lines by transfection with a variant of CD44 and high levels of CD44 are associated with several types of malignant tumors.

[0074] A number of studies have reported that human tumors display specific alterations in CD44 isoform expression, and have further shown that the extent of clinical disease in specific tumors correlates with the CD44 isoform expression pattern. As an example, it was found that expression of a splice variant of CD44 was required for adenocarcinoma cells to metastasize and a monoclonal antibody (mAb) against this particular CD44 variant prevented metastasis. In addition, a wide range of epithelial and mesenchymal malignancies express high levels of CD44H and a variety of variant isoforms of CD44. Specifically, reports have documented CD44 variant expression as a common feature of epithelial ovarian cancer.

[0075] Many studies have investigated the pattern of CD44 distribution in tumors. The presence of the CD44 standard and the CD44-v isoform on the surface of gastric cancer cells was found to be significantly related to a higher tumor-induced mortality and a shorter survival time for patients. Intestinal-type gastric carcinomas predominantly express the CD44-v isoform that provides the ability for these tumor cells to metastasize. There is substantial evidence that integrin receptors and different isoforms of the CD44 receptor are altered following the malignant transformation of colonic mucosa into adenomas and invasive carcinomas and which are correlated with their metastatic potential. Expression of the CD44-v isoform has been associated with adverse prognosis of colorectal cancer due to the development of tumor metastasis and adhesion. These data suggest that CD44 plays an important role in tumor metastasis and that a variety of molecules that inhibit CD44 receptor interaction with its natural ligands could be used for therapy.

[0076] At the cellular level, recent studies have characterized cytoplasmic signal transduction pathways for CD44 in activated endothelial cells that involve tyrosine kinases. HA binding activity of CD44 is linked to cellular activation in some cell types. Addition of degradation products of hyaluronan (3 to 10 disaccharides) to cells induces rapid tyrosine phosphorylation of multiple proteins, which is sustained. Increased phosphorylation of the CD44 receptor was also observed. Pretreatment of cells with either anti-CD44-ovocytin antibody or a non-selective inhibitor of tyrosine kinase activity inhibited both the induced protein tyrosine phosphorylation and the proliferation response. Protein kinase C (PKC) activity was increased two-to-three fold in the membranes of treated cells. Furthermore, it was shown that PKC activation triggered the cytoplasmic kinase cascade involving Raf-1 kinase, MAP kinase (MEK-1), and extracellular signal-regulated kinase (ERK-1). ERK is a dual-specificity kinase that controls expression of proteins relevant to tumorigenesis, as well as tumor cell proliferation, and motility.

[0077] In summary, phosphorylation of the CD44 receptor results in an increase in tyrosine phosphorylation, leading to

the activation of a cytoplasmic cascade, early response gene activation and cellular proliferation. Thus, an alternative, indirect approach to inhibit CD44 activation and signaling would be to employ inhibitors of CD44-activated cellular signaling pathways, rather than utilizing direct CD44 receptor antagonists. Tyrosine-kinase inhibitors, PKC inhibitors (e.g., calphostin) or ERK inhibitors could be employed as agents that would block CD44-mediated signaling proteins and provide novel targets for therapeutic agents.

[0076] One of the critical events in tumor growth and metastasis is the interaction between tumor cells and host tissue stroma that is mediated by different combinations of adhesion receptors on different tumor cell types. Several lines of evidence indicate that interaction between the CD44 receptor expressed on tumor cells and tissue stromal HA can enhance growth and invasiveness of certain tumors. Transformation of colon mucosa to carcinoma is associated with overexpression of several CD44 alternative splice variants. The importance of CD44-hyaluronate interaction in tumor development is made clear by the disruption of CD44-hyaluronate interaction by soluble recombinant CD44, which was shown to inhibit tumor formation by lymphoma, and melanoma cells transfected with CD44. The differential inhibitory effect of soluble wild-type and mutant CD44-Ig fusion proteins on melanoma growth in vivo was demonstrated by local administration of a mutant, nonhyaluronate binding, CD44-Ig fusion protein which had no effect on subcutaneous melanoma growth in mice whereas the administration of wild-type CD44-Ig blocked tumor development.

[0077] The present invention provides for administering a CD44 inhibitor or CD44 receptor antagonist in combination with at least one additional anti-pain and/or anti-inflammatory and/or anti-spasm and/or anti-restlessness agent which would be effective in preventing or inhibiting tumor cell adhesion and metastasis while inhibiting one or more of the other undesirable processes associated with surgical procedures. Inhibitors and antagonists may act directly by physical association and binding to the cell surface receptor to prevent binding of activating ligands or may act as indirect inhibitors, by inhibiting distinct molecules associated with CD44 signal transduction.

[0080] Direct receptor antagonists include monoclonal or polyclonal antibodies made against variants of CD44, or fragments thereof, which can be used as inhibitors of HA binding to CD44 and can be employed as therapeutic agents. Anti-CD44 monoclonal antibodies that can be employed include mAbs that recognize epitopes present on all isoforms of CD44 or suitable mAbs that recognize only pretranscriptionally modified forms of CD44, isoform (variant)-specific anti-CD44 mAbs have been described previously (H12, A1G3, A3D86) in U.S. Pat. No. 5,863,540 and the mAbs Dm7 and BU52. Other monoclonal antibodies suitable for the present invention include anti-CD44 mAbs directed against unique CD44 isoforms that are produced as a result of alternative splicing with an variable exon.

[0081] The present invention discloses the use of a recombinantly produced, chimeric soluble CD44 (sCD44) protein, in which the extracellular domain, or a portion thereof, of a CD44 receptor is covalently linked to a constant domain of an IgG molecule which may be used as an anti-tumor, anti-cell adhesion and anti-metastasis agent. In particular, and by way of illustration, a chimeric polypeptide (recombinant chimera) comprising the extracellular domain of the CD44 receptor extracellular polypeptide coupled to the C12 and C13 regions of a monoclonal IgG1 heavy chain polypeptide

could be employed. A second example is a chimeric fusion construct comprised of the HA ligand binding domain of the CD44 receptor with portions of the Ig antibody (termed Fc fusion soluble receptors) that have been created for CD44 receptors. The molecular form of the active soluble CD44 receptor can be either monomeric or dimeric. Methods have been established to test soluble CD44 antibody binding to the various isoforms of CD44 expressed on cell surfaces.

[0082] A second method for inhibition of CD44-hyaluronate receptor-ligand binding is to employ hyaluronate oligosaccharides of defined size (hyaluronate oligomers) to inhibit tumor formation by saturating the CD44 receptors with excess ligand. One study found that hyaluronate oligomers injected at concentrations as low as 1 mg/ml inhibited melanoma growth. Thus, the local delivery of these oligomers can inhibit CD44 interaction with its natural substrate and provide a suitable method for the control of local tumor development.

[0083] One skilled in the art will appreciate that the choice of a specific anti-CD44 monoclonal antibody or CD44 peptide sequence as a therapeutic agent for a patient will, in part, determine the amount of the agents to be administered for any particular treatment protocol and that these amounts can be readily determined. Those skilled in the art will appreciate that the amount of the peptide, protein or antibody to be administered for a particular treatment protocol may be a function of a particular CD44 domain associated with a pathologic clinical condition, and may be a function of a particular cell type mediating metastasis.

[0084] CD44 receptor antagonists suitable for use as anti-adhesion and/or anti-invasion and/or anti-metastasis agents in the surgical application of the current invention, delivered in combination with anti-pain and/or anti-inflammatory and/or anti-spasm and/or anti-restlessness agents, are listed in the Table below.

TABLE 2

CD44 Receptor Antagonists

Agent	Therapeutic Potential (Toxicities (μg/ml) Concentration (μg/ml))	Mean Potential Concentration (μg/ml)
anti-CD44 mAb Dm7	0.1-1000	100
anti-CD44 mAb BU52	0.1-1000	100
anti-CD44 mAb F12	0.1-1000	100
anti-CD44 mAb A1G3	0.1-1000	100
anti-CD44 mAb A1G3	0.1-1000	100
chimeric anti-CD44-Fc	0.1-1000	100
anti-CD44 FcB	0.1-1000	100
hyaluronate oligomers	0.1-1000	100
soluble CD44 receptor	0.1-1000	100

[0085] C. Integrin Receptor Antagonists and Inhibitors of Integrin Signaling

[0086] Integrins are a superfamily of cell surface receptors involved in cell-cell and cell-matrix adhesion. These receptors play a fundamental role in the regulation of numerous cellular functions such as cell differentiation and migration, maintenance of tissue architecture, blood vessel formation and reactive programmed cell death. In addition, the integrins have been implicated in cancer cell differentiation, tumor progression and metastasis due to their important role in mediating tumor cell interactions with the extracellular matrix and endothelial cells. Integrin expression and function are altered in many malignant cells, although changes in integrin expression vary between different tumor types.

Specific integrin receptor subtypes on tumor cells are capable of mediating attachment to many adhesive proteins that are components of the extracellular matrix, activated platelets and endothelial cells at sites of surgical trauma.

[0007] The integrins are a family of heterodimeric, transmembrane cell receptors that are expressed on a wide variety of cells. The receptor family includes at least 14 known α -subunits and 8 β -subunits that associate with each other to form numerous subtype combinations that demonstrate differing ligand specificities. The α -subunit appears to be a critical determinant of ligand specificity and integrins containing α demonstrate specificity for vitronectin, $\alpha 5$ (for fibronectin, and $\alpha 3$ for collagen/laminin. Numerous integrin heterodimer subunit combinations have been found on a variety of tumor cells that promote their binding to fibronectin, laminin, vitronectin, fibrinogen, collagen, and thrombospondin. Vascular cell adhesion molecule-1 (VCAM-1) is the endothelial cell ligand for two leukocyte integrins, $\alpha 4 \beta 1$ and $\alpha 4 \beta 7$. Mucosal addressin cell adhesion molecule 1 (MAdCAM-1) is also recognized as a ligand for $\alpha 4 \beta 7$ integrin.

[0008] Interactions between fibronectin and several subtypes of integrin receptors that bind to it play particularly important roles at several stages of tumor development and influence the process of malignant metastasis. Fibronectin is an extracellular glycoprotein consisting of repeating units of amino acids. A single gene encodes it and alternative splicing allows formation of multiple isoforms. Specific protein domains enable the molecule to interact with a variety of cells through both integrin and non-integrin receptors. Fibronectin has at least two independent cell adhesion regions with different receptor specificities. The cell adhesive domains in the central portion of fibronectin is comprised of at least two distinct amino acid sequences, an Arg-Gly-Asp (RGD) sequence and a Pro-Ile-Ser-Arg-Asn (PIRSN) sequence. The $\alpha 5 \beta 1$ fibronectin-specific integrin binds to the central RGD/PIRSN site. The $\alpha 4 \beta 1$ integrin binds to the IICS site. Peptide and antibody inhibitors of fibronectin and integrin functions have been shown to be effective inhibitors of metastasis, and are potentially important agents for the control of tumor-cell adhesion.

[0009] Integrin-activated pathways mediated by intracellular kinases and the adapter proteins are particularly important for integrin receptor-mediated oncogenic dependence. Recently, signal transduction studies in a variety of cell types demonstrated that integrin receptor binding to extracellular matrix proteins rapidly generates intracellular signals via enhanced tyrosine phosphorylation and have established the role of the focal adhesion kinase (FAK) protein-tyrosine kinase (PTK) in linking integrin receptors to intracellular signaling pathways. FAK associates with several different cytoplasmic signaling proteins such as Src-family PTKs and several SH2-domain proteins (Shc, Grb2 and Py-3-kinase). This enables FAK to function within a network of integrin-stimulated signaling pathways leading to the activation of targets such as the ERK and JNK. Mitogen-activated protein kinase pathway. These signaling mechanisms provide a substrate for the therapeutic potential of tyrosine kinase inhibitors as anti-adhesion agents based upon their action as direct inhibitors of integrin receptor-mediated signaling at a point proximal to the receptor in the signal transduction cascade.

[00090] A peptide sequence itself responsible for the cell attachment to the fibronectin ligand for the integrin receptor (arginine-glycine-aspartic acid) has provided a basis for the development of therapeutic agents since the integrin-binding activity of adhesive proteins can be reproduced by short synthetic peptides containing the RGD sequence. Peptides containing the RGD sequence have been shown to inhibit tumor cell attachment in vitro. Agents that bind selectively to only one or a few of the RGD-directed integrins have been prepared by cyclizing peptides with selected sequences flanking the RGD motif and by synthesizing RGD mimics. The development of a series of peptide analogs of the RGD sequence of fibronectin have been synthesized and their anti-metastatic effects in vivo and inhibitory effects on tumor cell invasion in vitro have been examined.

[00091] Cellular and animal studies have shown that anti-adhesion peptides and polypeptides are useful for the prevention of peritoneal dissemination of certain forms of cancer. For example, a study using the peptide integrin antagonists γ -tyrosyl-selenoyl-glycyl-seryl-arginine (YISRL), acetyl-argyl-glycyl-seranyl-succinimide (Ac-RGDS-NH2) and arginyl-glycyl-aspartic acid (RGD) examined the effect on the adhesion and invasiveness of gastric cancer cell lines using a putrescine-coating cell line, OCUM-2MD3. It was reported that both $\alpha 2 \beta 1$ and $\alpha 3 \beta 1$ integrin expression was markedly increased on OCUM-2MD3 cells and the ability of these cells to bind to the extracellular matrix was also significantly higher than that of control cells. The adhesion polypeptides, YISRL and RGD, and two RGD derivatives significantly inhibited the adhesion and invasiveness of OCUM-2MD3 cells to the cadherin-coated ECM in a cell-specific manner. The survival of nude mice with peritoneal dissemination given YISRL or RGD sequences intraperitoneally was longer than that of untreated mice. A therapeutic approach based upon interfering with tumor cell attachment with integrin-binding peptides has been shown to be an effective anti-metastatic strategy in animal experiments and the frequency of tumor implantation at sites of surgical trauma is also reduced if cells are preexposed to fibrinogen, laminin or peptides containing the RGD motif.

[00092] These studies and others suggest that inhibition of specific integrin receptor-ligand interactions by use of synthetic fibronectin fragments, peptide analogs and mimics containing the RGD sequence, or antibodies represents a useful approach for the development of clinically useful antagonists for subtype-specific integrin receptors. A number of these peptides, such as those disclosed within U.S. Pat. No. 5,627,263, have been found to be more effective in inhibiting tumor cell adhesion and tumor metastasis than the original RGD peptide, and are disclosed for use in the present invention in combination with other agents. In particular, the present invention provides for the use of peptides and peptide analogs which are specific for fibronectin-binding integrins, in particular the $\alpha 4$, $\beta 1$ integrin. In addition, specific agents for inhibition of binding to $\alpha 5$, $\alpha 6$ and $\alpha 9$ integrin subunits as part of $\beta 1$ integrin heterodimers are also provided.

[00093] An additional class of inhibitors is the naturally occurring disintegrins, which include a family of small, highly immunogenic, cysteine-rich polypeptides purified from snake venoms, which contain the RGD sequence. Disintegrins can competitively inhibit integrin-ligand inter-

266
123

actions and have been shown to inhibit cell adhesion interactions in a variety of systems. Specific snake venom-derived disintegrins have been shown to be 2000 times more potent than short, synthetic, linear RGD-containing peptides in blocking fibrinogen-dependent platelet aggregation. The greater potency of the disintegrin molecules stems from amino acids surrounding the RGD sequence and intrachain disulfide bridges that constrain the RGD sequence in an appropriate conformation. Specific disintegrins block the adhesive functions of integrin cell surface receptors and thereby inhibit integrin-dependent cell reactions in a variety of cell types and tissues. The disintegrin kistrin was shown by affinity crosslinking to specifically bind with high affinity to $\alpha V\beta 3$ and not to $\alpha 5\beta 1$ or other abundant integrins. The related disintegrin echistatin specifically inhibited ^{125}I -labeled kistrin binding to $\alpha V\beta 3$, while a structurally distinct disintegrin, decorin had 1000-fold lower affinity.

[0094] Two recently isolated disintegrins from the venom of Chinese viper (*Agkistrodon ussuriensis*), marmarinin 1 (US-1) and 2 (US-2) have been characterized as potent inhibitors of cell adhesion. Both polypeptides are composed of 71 amino acids and are characterized by sequences that show strong similarities to other disintegrins. US-1 had a typical Arg-Gly-Asp (RGD) sequence, which is responsible for blocking the binding of fibrinogen to the receptor. In US-2, the corresponding sequence was Lys-Gly-Asp (KGD). US-2 also inhibited platelet aggregation, but the IC_{50} s were about ten times higher. US-1 also dose-dependently inhibited the adhesion of human melanoma cells to fibrinogen and fibronectin with an IC_{50} of 17.33 nM, while US-2 did not inhibit the cell adhesion to fibronectin.

[0095] An additional heterodimeric disintegrin, EC3 (Mr=14,762), isolated from *Echis carinatus* venom is a potent antagonist of $\alpha 4$ integrins. Each subunit contains 67 residues and displays a high degree of homology to other disintegrins. EC3 inhibited adhesion of cells expressing $\alpha 4\beta 1$ and $\alpha 4\beta 7$ integrins to natural ligands such as vascular cell adhesion molecule 1 (VCAM-1) and mucosal addressin cell adhesion molecule 1 (MAdCAM-1) with IC_{50} s of 6-30 nM, adhesion of K562 cells ($\alpha 5\beta 1$) to fibronectin with IC_{50} of 150 nM, and the adhesion of $\alpha 11\beta 3$ Chinese hamster ovary cells to fibrinogen with IC_{50} of 500 nM.

[0096] Examples of integrin antagonists suitable for the present invention are listed below. As an example, for each of the listed agents, the preferred and most preferred concentrations of an irrigation solution containing the listed agent are provided, such concentrations expected to be therapeutically effective.

TABLE 3

Therapeutic and Preferred Concentrations
of Integrin Receptor Antagonists

Compounds	Therapeutic Preferred Concentrations (nM)	Most Preferred Concentrations (nM)
RGD	5-50000	5000
GRGDSP	5-50000	5000
YIGSR	5-50000	5000
CAKTRDCLGA	0.1-10000	100
GRGDSPK	0.1-1000	10
GRGDTP	0.1-1000	10
SDURD	0.1-1000	10
RGDSASSRP	0.1-1000	10

TABLE 3-continued

Therapeutic and Preferred Concentrations
of Integrin Receptor Antagonists

Compounds	Therapeutic Preferred Concentrations (nM)	Most Preferred Concentrations (nM)
cyclo(RGD)-D-Phe-Val	0.1-1000	10
Tetramisyl(DRGDS) ₂	0.1-1000	10
US-1	0.01-1000	3
Kistrin	0.1-1000	10
EC-3	0.1-1000	1

[0097] D. Selectin Receptor Antagonists and Inhibitors of Selectin Signaling

[0098] Adhesion of malignant cells to the vascular endothelial surface involves a family of adhesion receptors similar to those involved in the recruitment of inflammatory cells to these sites. Selectins are involved in a cascade of sequential molecular steps following endothelial cell (EC) activation. The selectin family consists of E-selectin (ELAM-1), P-selectin (GMP-140), and L-selectin (LECAM-1). The carbohydrate determinants, sialyl Lewis X (SLe^x) and sialyl Lewis X (SLe^a), which are frequently expressed on human cancer cells, serve as ligands for E-selectin, which is expressed on vascular endothelial cells. These carbohydrate determinants are involved in the adhesion of cancer cells to vascular endothelium and thus contribute to metastasis of cancer. The selectins are inducible endothelial-expressed adhesion molecules involved in leukocyte recruitment. The initial adhesion mediated by these molecules triggers activation of integrin molecules through the action of several cytokines. The degree of expression of the carbohydrate ligands at the surface of cancer cells is well correlated with the frequency of metastasis. Monoclonal antibodies directed to SLe^x or SLe^a blocked adhesion of tumor cells (leukemia, colon carcinoma, and histiocytic lymphoma cells) to EC and platelets. Also selectin expression is frequently up-regulated on breast carcinoma endothelium.

[0099] P selectin, also known as GMP-140 or PADGEM, is a membrane glycoprotein located in secretory granules of resting (unstimulated) platelets and endothelium. When mediation activates these cells, P-selectin is rapidly redistributed to the plasma membrane. The selectins constitute a family of structurally and functionally related molecules. Structural motifs common to each of these molecules include an N-terminal lectin-like domain followed by an EGF-like region, a series of consensus repeats related to those in complement-binding proteins, a transmembrane domain, and a short cytoplasmic tail. P selectin is the receptor for neutrophils and monocytes when it is expressed on activated platelets and endothelium. This property facilitates rapid adhesion of leukocytes to endothelium at regions of tissue injury as well as platelet-leukocyte interactions at sites of inflammation and hemorrhage. Studies also have found that P-selectin binds to tumor cells in a variety of tissue sections and that it binds to the cell surface of a number of cell lines derived from carcinomas. Acting in concert with other adhesion molecules, P-selectin participates in tumor metastasis and is thus a target for drugs that block adhesion receptor function.

[0100] Studies supporting a role for selectins in metastasis are based upon the adhesion of human colon carcinoma cell

lines to selectins using an *in vitro* flow model. Recombinant forms of P-selectin and Chinese hamster ovary cells expressing P-selectin supported attachment and rolling of KM12-L4 colon carcinoma cells and this effect was abolished by pretreatment of the KM12-L4 cells with neuraminidase. KM12-L4 cells interact with P-selectin through a PSGL-1-independent adhesion pathway. An E-selectin-IgG chimera was also found to support sialylated moiety-dependent adhesion of colon carcinoma cells under fluid flow. Thus, sialylated moieties are involved in the selectin mediated adhesion of human cancer cells to IL-1-stimulated endothelium under flow conditions. Furthermore, the efficiency of E-selectin-mediated binding of human colon carcinoma cells to human and mouse EC has been found to be correlated with the metastatic potential of the cancer cells.

[0101] Recent studies evaluated the role of E-selectin-sialyl Lewis x (SLe^x)-sialyl Lewis a (SLe^a) interaction in mediating *in vitro* adhesion of two human colon cancer cell lines, HT-29 and COLO 201, to human umbilical cord endothelial cells (HUVEC). Colon cancer cell lines had a strong expression of carbohydrate epitopes and it was established that adhesion of HT-29 and COLO 201 cells to IL-1-stimulated HUVEC could be inhibited by a monoclonal antibody directed against E-selectin. Prior incubation of cells with two different antibodies directed against SLe^x and antibodies directed against related Lewis epitopes, Le^x and Le^a, had no significant effect on adhesion. Three antibodies directed against SLe^x differed in their capacity to inhibit the adhesion of HT-29 and COLO 201 cells. Thus, the SLe^x epitope is important for adhesion of colon cancer cells mediated predominantly by E-selectin.

[0102] Additional studies have demonstrated that pretreatment of HUVEC with tumor necrosis factor- α (TNF- α) augmented the binding of the COLO 205 carcinoma cell line. The increased adherence was both concentration- and time-dependent with maximal tumor cell attachment found at 4 hr. This result was consistent with increased expression of the adhesion molecule E-selectin on the endothelium. Incubation of TNF-stimulated HUVECs with IB11, an anti-E-selectin mAb, prior to the addition of COLO 205 resulted in complete inhibition of adherence of the tumor cells. These studies confirm the utility of specific antibodies directed against E-selectins to inhibit tumor cell attachment to endothelial cell targets. Other studies have found that pretreatment with either an anti-P-selectin or an anti-L-selectin monoclonal antibody (i.e., MAb PB 1.3 and MAb DREG-200), or a sialyl Lewis^x-containing oligosaccharide (SLe^x-OS) are effective in inhibiting cell adhesion.

[0103] Similar *in vitro* and *in vivo* studies have established a role for selectins in the process of metastasis using SW1990 cells derived from a human pancreatic malignancy. SW1990 cells also strongly express SLe^x and SLe^a antigens, CD44H, and β 1 integrin. These cells exhibit binding activity to IL-1-activated HUVECs and human peritoneal mesothelial cells. The adhesion leading to implantation of cancer cells to endothelial cells was inhibited by treatment with the antibodies against SLe^x and against β 1 integrin. In animal studies, treatments with the antibodies against SLe^x and β 1 integrin each inhibited the development of liver metastasis in nude mice with SW1990 cells and prolonged their survival.

[0104] Elucidation of the signal transduction properties of the selectins has revealed a common mechanism shared by

other cell adhesion receptors. Studies using HT-29 human colon carcinoma cells, which adhere specifically to an E-selectin-IgG chimera, have shown that, upon adhesion to E-selectin, there is an increase in the amount of tyrosine phosphorylation of several proteins in HT-29 cell lysates. This effect is specific for adhesion to E-selectin, since addition of an E-selectin blocking monoclonal antibody caused a significant decrease in tyrosine phosphorylation relative to E-selectin alone. A kinase assay showed a dose-dependent and significant decrease in c-src activity upon adhesion to E-selectin, which correlates with an increase in phosphorylation of Tyr 527, the negative regulatory tyrosine. These studies identify a signaling pathway involving the E-selectin ligand on HT-29 cells and c-src.

[0105] Other studies have demonstrated that lymphocyte binding to P-selectin induces tyrosine phosphorylation of distinct proteins. Activation appears to occur at the initial contact with surface adhesion molecules. The P-selectin effect was time dependent, demonstrating an early response after 10 min and a maximum effect at 30 min. Identified proteins included pp125 focal adhesion kinase (FAK) and paxillin. Treatment with a tyrosine kinase inhibitor, genistein, or with the protein kinase C inhibitor, staurosporine, resulted in decreased pp125 FAK phosphorylation. These signaling mechanisms provide a rationale for the therapeutic potential of tyrosine kinase inhibitors as anti-adhesion agents based upon their action as direct inhibitors of selectin receptor-mediated signaling. The rapid signaling properties of the selectin receptors underscore the requirement for delivery of the therapeutic agent at the beginning of the surgical procedure to provide a preemptive inhibitory effect.

[0106] This invention provides a method for inhibiting the spread of metastatic tumor cells by administering to a patient a pharmaceutical composition containing a therapeutically effective amount of an anti-E-selectin specific mAb or antibody fragment, and/or an anti-P-selectin specific mAb or antibody fragment, and/or an anti-L-selectin specific mAb or antibody fragment, and/or an anti-sialyl Lewis^x (SLe^x) mAb in combination with either one or more anti-inflammatory and/or anti-pain and/or anti-spasm and/or anti-restlessness agents.

[0107] Studies have also found that heparin inhibited the binding of selectins to their carbohydrate ligands. Heparin (enoxaparin) inhibition of selectin interactions is expected to decrease selectin-related tumor cell adhesion.

[0108] Examples of selectin antagonists suitable for the present invention are listed below. For each of the listed agents, the preferred and most preferred concentrations of an irrigation solution containing the listed agent are provided, such concentrations expected to be therapeutically effective.

TABLE 4

Therapeutic and Preferred Concentrations of
Selectin Receptor Antagonists

Agent	Therapeutic Preferred Concentration (mg/ml)	Most Preferred Concentration (mg/ml)
anti-SLe ^x mAb PB 1.3	0.1-1000	100
anti-SLe ^a mAb DREG-200	0.1-1000	100

TABLE 4-continued

Therapeutic and Preferred Concentrations of Selectin Receptor Antagonists		
Agent	Therapeutic Preferred Concentration (μg/ml)	Most Preferred Concentration (μg/ml)
Sirt-OS	0.1-1000	100
anti-E-selectin mAb BB11	0.1-10000	1000
anti-P-selectin IgG	0.1-10000	1000
anti-E-selectin IgG	1.0-10000	1000
enoxiparin	0.1-1000	100

[0109] From the molecular and cellular mechanisms of action defined for the classes of agents identified herein, these agents are expected to exhibit tumor cell anti-adhesion, anti-invasion and/or anti-metastatic actions when applied perioperatively in an irrigation solution. These agents are expected to be effective drugs when delivered in an irrigation solution during surgical procedures involving identified or occult malignancies. The method of delivery and the compositions for inclusion in the irrigation are expected to be useful in procedures involving the peritoneal, abdominal, thoracic, pleural, mediastinal, urogenital, epididymal, intra-theatal, and joint cavities including, but not limited to, operations indicated for oncological treatment of ovarian, gastric, pancreatic and colon cancer. Each metabolically active anti-tumor adhesion agent may be delivered in combination with one or more other anti-pain and/or anti-inflammatory and/or anti-spasm and/or anti-restenosis agents. Suitable anti-tumor agents for inclusion in the pharmaceutical composition will be further characterized by a requirement for pharmacological selectivity and specificity which limits interactions of the agent to a single family (or class) of receptors or a single enzyme family (e.g., CD44, integrins, selectins, protein tyrosine kinases, MMPs and MAP Kinases). A particular suitable agent may interact specifically with one or more receptor subtypes (or isotypes) while exhibiting specificity for the receptor family. Each suitable agent will associate with its molecular target through a specific molecular mechanism which can be characterized by a defined stoichiometry (typically 1:1) for the ligand-receptor (or inhibitor-enzyme) complex and which can be characterized by its equilibrium binding or kinetic constant. These agents may include small molecule drugs, natural or synthetic peptides or polypeptides, polypeptides, proteins, recombinant chimeric proteins, monoclonal or polyclonal antibodies, oligonucleotides or gene therapy vectors (viral and nonviral).

[0110] For example, an agent such as an integrin receptor antagonist can exert its actions on any cells associated with the fluid spaces of the peritoneal cavity and structures comprising the cavity that are involved in normal function or are present due to a pathological condition. These cells and structures include, but are not limited to: epithelial cells; mesothelial cells; inflammatory cells including lymphocytes, macrophages, mast cells, monocytes, eosinophils; and other cells including endothelial cells, smooth muscle cells, and fibroblasts; and all combinations of the above.

[0111] The present invention also provides for formulations of the active therapeutic agent(s) which may be delivered in a formulation useful for introduction and adminis-

tration to the operative site that would enhance the delivery, uptake, stability or pharmacokinetics of the combination of anti-adhesion, anti-invasion and/or anti-metastatic agents and other agents. Such a formulation could include, but is not limited to, microparticles, microspheres or nanoparticles composed of proteins, carbohydrates, synthetic organic compounds, or inorganic compounds. Examples of formulation molecules include, but are not limited to, lipids capable of forming liposomes or other ordered lipid structures, cationic lipids, hydrophilic polymers, polycations (e.g., protamine, spermidine and polylysine), peptide or synthetic ligands and antibodies capable of targeting materials to specific cell types, gels, slow release matrices, soluble and insoluble particles, as well as other formulation elements known to those skilled in the art.

[0112] The present invention provides for the delivery of a combination of anti-tumor adhesion and/or anti-invasion and/or anti-local metastatic drugs, present either as multiple pharmacologically active substances within a homogeneous (e.g., a single encapsulated microsphere) or as a discrete mixture of individual delivery vehicles (e.g., a group of microspheres encapsulating one or more agents). Examples of formulation molecules include, but are not limited to, hydrophilic polymers, polycations (e.g., protamine, spermidine, polylysine and chitosan), peptide or synthetic ligands and antibodies capable of targeting materials to specific cell types, gels, slow release matrices, soluble and insoluble particles, as well as formulation elements not listed.

[0113] The present invention provides for the local delivery of a combination of tumor cell anti-adhesion drug(s) via an irrigation solution, such irrigation solution containing the drugs which are present at therapeutically effective low concentrations and enabling the drugs to be delivered directly to the desired tissue. The drug-containing irrigation solution may be employed intra-operatively, intra- and pre-operatively, intra- and post-operatively or pre-, intra- and post-operatively in connection with a surgical procedure.

[0114] Conventional methods used for drug delivery have required systemic (e.g., oral, intramuscular, intravenous, subcutaneous) administration which necessitates higher concentrations of drugs (and higher total doses) to be administered to the patient in order to achieve significant therapeutic concentrations at the pathologically affected tissue. Systemic administration also results in high concentrations in tissues other than the targeted tissue which is undesirable and, depending on the dose, may result in adverse side effects. These systemic methods subject the drug to second-pass metabolism and rapid degradation, thereby limiting the duration of the effective therapeutic concentration. Since the combinations of tumor cell anti-adhesion, anti-invasion and anti-metastasis agents (with or without one or more anti-pain and/or anti-inflammatory and/or anti-spasm and/or anti-restenosis agents) are administered directly to the operative site by irrigation, vascular perfusion is not required to carry the drug to the targeted tissue. This significant advantage allows for the local delivery of a lower therapeutically effective total dose for a variety of tumor cell anti-adhesion, anti-local metastasis drugs than would otherwise be possible via other routes of administration.

[0115] In other aspects, the irrigation solutions of the present invention comprise a dilute solution of at least one inhibitor of tumor cell adhesion, invasion and/or metastasis

and preferably multiple pain/inflammation inhibitory agents, anti-spasm agents and anti-restenosis agents in a physiologic carrier. The carrier is a liquid, which as used herein is intended to encompass biocompatible solvents, suspensions, polymerizable and non-polymerizable gels, pastes and salves. Preferably the carrier is an aqueous solution which may include physiologic electrolytes, such as normal saline or lactated Ringer's solution.

[0116] The anti-inflammation/anti-pain agents are selected from the group consisting of: (1) serotonin receptor antagonists; (2) serotonin receptor agonists; (3) histamine receptor antagonists; (4) bradykinin receptor antagonists; (5) kallikrein inhibitors; (6) tachykinin receptor antagonists, including neurokinin₁ and neurokinin₂ receptor subtype antagonists; (7) calcitonin gene-related peptide (CGRP) receptor antagonists; (8) interleukin receptor antagonists; (9) inhibitors of enzymes active in the synthetic pathway for arachidonic acid metabolites, including (a) phospholipase inhibitors, including PLA₂ isoform inhibitors and PLC₁ isoform inhibitors (b) cyclooxygenase inhibitors, and (c) lipoxygenase inhibitors; (10) prostaglandin receptor antagonists including cyclooxygenase EP-1 and EP-4 receptor subtype antagonists and thromboxane receptor subtype antagonists; (11) leukotriene receptor antagonists including leukotriene B₂ receptor subtype antagonists and leukotriene D₄ receptor subtype antagonists; (12) opioid receptor agonists, including μ -opioid, δ -opioid, and κ -opioid receptor subtype agonists; (13) purinoceptor agonists and antagonists including P_{2U} receptor antagonists and P_{2Y} receptor agonists; and (14) adenosine triphosphate (ATP)-sensitive potassium channel openers.

[0117] Suitable anti-inflammatory/anti-pain agents which also act as anti-spasm agents include serotonin receptor antagonists, tachykinin receptor antagonists, ATP-sensitive potassium channel openers and calcium channel antagonists. Other agents which may be utilized in the solution specifically for their anti-spasm properties including endothelin receptor antagonists, calcium channel antagonists and the nitric oxide donors (enzyme activators).

[0118] Specific preferred embodiments of the solution of the present invention for use in cardiovascular and general vascular procedures include anti-restenosis agents, which most preferably are used in combination with anti-spasm agents. Suitable anti-restenosis agents include: (1) antiplatelet agents including: (a) thrombin inhibitors and receptor antagonists, (b) adenosine diphosphate (ADP) receptor antagonists (also known as purinoceptor, receptor antagonists), (c) thromboxane inhibitors and receptor antagonists and (d) platelet membrane glycoprotein receptor antagonists; (2) inhibitors of cell adhesion molecules, including (a) selectin inhibitors and (b) integrin inhibitors, (3) anti-chemotactic agents; (4) interleukin receptor antagonists (which also serve as anti-pain/anti-inflammation agents); and (5) intracellular signaling inhibitors including: (a) protein kinase C (PKC) inhibitors and protein tyrosine phosphatases, (b) modulators of intracellular protein tyrosine kinase inhibitors, (c) inhibitors of Src homology₂ (SH2) domains, and (d) calcium channel antagonists. Such agents are useful in preventing restenosis of arteries treated by angioplasty, rotational atherectomy or other cardiovascular or general vascular therapeutic procedure.

[0119] In each of the surgical solutions of the present invention, the agents are included in low concentrations and

are delivered locally in low doses relative to concentrations and doses required with conventional methods of drug administration to achieve the desired therapeutic effect. It is impossible to obtain an equivalent therapeutic effect by delivering similarly dosed agents via other (i.e., intravenous, subcutaneous, intramuscular or oral) routes of drug administration since drugs given systemically are subject to first- and second-pass metabolism. The concentration of each agent is determined in part based on its dissociation constant, K_d . As used herein, the term dissociation constant is intended to encompass both the equilibrium dissociation constant for its respective agonist-receptor or antagonist-receptor interaction and the equilibrium inhibitory constant for its respective activator-enzyme or inhibitor-enzyme interaction. Each agent is preferably included at a low concentration of 0.1 to 10,000 times K_d nanomolar, except for cyclooxygenase inhibitors, which may be required at larger concentrations depending on the particular inhibitor selected. Preferably, each agent is included at a concentration of 1.0 to 1,000 times K_d nanomolar and most preferably at approximately 100 times K_d nanomolar. These concentrations are adjusted as needed to account for dilution in the absence of metabolic transformation at the local delivery site. The exact agents selected for use in the solution, and the concentration of the agents, varies in accordance with the particular application, as described below.

[0120] A solution in accordance with the present invention can include just a single or multiple inhibitor(s) of tumor cell adhesion, invasion and/or metastasis, pain/inflammation inhibitory agent(s), a single or multiple anti-spasm agent(s), a combination of inhibitors of tumor cell adhesion, invasion and/or metastasis, anti-spasm and pain/inflammation inhibitory agents, or anti-restenosis agents from the enumerated classes, at low concentration. However, due to the aforementioned synergistic effect of multiple agents, and the desire to broadly block pain and inflammation, spasm and restenosis, it is preferred that multiple agents be utilized.

[0121] The surgical solutions constitute a novel therapeutic approach by combining multiple pharmacologic agents acting at distinct receptor and enzyme molecular targets. To date, pharmacologic strategies have focused on the development of highly specific drugs that are selective for individual receptor subtypes and enzyme isoforms that mediate responses to individual signaling neurotransmitters and hormones. As an example, endothelin peptides are some of the most potent vasoconstrictors known. Selective antagonists that are specific for subtypes of endothelin (ET) receptors are being sought by several pharmaceutical companies for use in the treatment of numerous disorders involving elevated endothelin levels in the body. Recognizing the potential role of the receptor subtype ET_A in hypertension, these drug companies specifically are targeting the development of selective antagonists to the ET_A receptor subtype for the anticipated treatment of coronary vasospasm. This standard pharmacologic strategy, although well accepted, is not optimal since many other vasoconstrictor agents (e.g., serotonin, prostaglandins, cyclooxygenase, etc.) simultaneously may be responsible for initiating and maintaining a vasospastic episode (see FIGS. 2 and 4). Furthermore, despite inactivation of a single receptor subtype or enzyme, activation of other receptor subtypes or enzymes and the resultant signal transmission often can trigger a cascade effect. This explains the significant difficulty in employing a single receptor-specific drug to block a pathophysiologic process in

which multiple transmitters play a role. Therefore, targeting only a specific individual receptor subtype, such as 5-HT_{1A} , is likely to be ineffective.

[0122] In contrast to the standard approach to pharmacologic therapy, the therapeutic approach of the present surgical solutions is based on the rationale that a combination of drugs acting simultaneously on distinct molecular targets is required to inhibit the full spectrum of events that underlie the development of a pathophysiologic state. Furthermore, instead of targeting a specific receptor subtype alone, the surgical solutions are composed of drugs that target common molecular mechanisms operating in different cellular physiologic processes involved in the development of pain, inflammation, vasospasm, smooth muscle spasm and restenosis (see FIG. 1). In this way, the cascading of additional receptors and enzymes in the nociceptive, inflammatory, spasmodic and restenotic pathways is minimized by the surgical solutions. In these pathophysiologic pathways, the surgical solutions inhibit the cascade effect both "upstream" and "downstream".

[0123] An example of "upstream" inhibition is the cyclooxygenase antagonists in the setting of pain and inflammation. The cyclooxygenase enzymes (COX_1 and COX_2) catalyze the conversion of arachidonic acid to prostaglandin H which is an intermediate in the biosynthesis of inflammatory and nociceptive mediators including prostaglandins, leukotrienes, and thromboxanes. The cyclooxygenase inhibitors block "upstream" the formation of these inflammatory and nociceptive mediators. This strategy precludes the need to block the interactions of the seven described subtypes of prostaglandin receptors with their natural ligands. A similar "upstream" inhibitor included in the surgical solutions is apertin, a kallikrein inhibitor. The enzyme kallikrein, a serine protease, cleaves the high molecular weight kininogens in plasma to produce bradykinins, important mediators of pain and inflammation. By inhibition of kallikrein, apertin effectively inhibits the synthesis of bradykinin, thereby providing an effective "upstream" inhibition of these inflammatory mediators.

[0124] The surgical solutions also make use of "downstream" inhibitors to control the pathophysiologic pathways. In vascular smooth muscle preparations that have been precontracted with a variety of neurotransmitters (e.g., serotonin, histamine, endothelin, and thromboxane) implicated in coronary vasospasm, ATP-sensitive potassium channel openers (KCOs) produce smooth muscle relaxation which is concentration dependent (Quast et al., 1994; Kashiwamura et al., 1994). The KCOs, therefore, provide a significant advantage to the surgical solutions in the settings of vasospasm and smooth muscle spasm by providing "downstream" anti-spasmodic effects that are independent of the physiologic combination of agonists initiating the spasmodic event (see FIGS. 2 and 4). Similarly, NO donors and voltage-gated calcium channel antagonists can limit vasospasm and smooth muscle spasm initiated by multiple mediators known to act earlier in the spasmodic pathway.

II. Anti-Inflammation/Anti-Pain Agents

[0125] The following is a description of suitable drugs falling in the aforementioned classes of anti-inflammation/anti-pain agents, as well as suitable concentrations for use in solutions, of the present invention. While not wishing to be

limited by theory, the justification behind the selection of the various classes of agents which is believed to render the agents operative is also set forth.

[0126] A. Serotonin Receptor Antagonists

[0127] Serotonin (5-HT) is thought to produce pain by stimulating serotonin (5-HT_1) and/or serotonin (5-HT_2) receptors on nociceptive neurons in the periphery. Most researchers agree that 5-HT_2 receptors on peripheral nociceptors mediate the immediate pain sensation produced by 5-HT (Richardson et al., 1985). In addition to inhibiting 5-HT -induced pain, 5-HT_2 receptor antagonists, by inhibiting nociceptor activation, also may inhibit neurogenic inflammation. Barnes P. J., et al., *Modulation of Neurogenic Inflammation: Novel Approaches to Inflammatory Disease*, Trends in Pharmacological Sciences 11, pp. 185-189 (1990). A study in rat ankle joints, however, claims the 5-HT_2 receptor is responsible for nociceptor activation by 5-HT . Clubb, B. D., et al., *A Study of 5-HT -Receptors Associated with Afferent Nerves Located in Normal and Inflamed Rat Ankle Joints*, Agents Actions 25, pp. 216-18 (1988). Therefore, activation of 5-HT_2 receptors also may play a role in peripheral pain and neurogenic inflammation.

[0128] One goal of the solution of the present invention is to block pain and a multitude of inflammatory processes. Thus, 5-HT_2 and 5-HT_1 receptor antagonists are both suitably used, either individually or together, in the solution of the present invention, as shall be described subsequently. Amitriptyline (Elavil™) is a suitable 5-HT_2 receptor antagonist for use in the present invention. Amitriptyline has been used clinically for numerous years as an anti-depressant, and is found to have beneficial effects in certain chronic pain patients. Mefenopramide (Reglan™) is used clinically as an anti-emetic drug, but displays moderate affinity for the 5-HT_2 receptor and can inhibit the actions of 5-HT at this receptor, possibly inhibiting the pain due to 5-HT release from platelets. Thus, it also is suitable for use in the present invention.

[0129] Other suitable 5-HT_2 receptor antagonists include imipramine, trazodone, desipramine and ketanserin. Ketanserin has been used clinically for its anti-hypertensive effects. Hedner, T., et al., *Effects of a New Serotonin Antagonist, Ketanserin, in Experimental and Clinical Hypertension*, Am J of Hypertension, pp. 317s-23s (July 1988). Other suitable 5-HT_2 receptor antagonists include citalopride and ondansetron. The cardiovascular and general vascular solution also may contain a serotonin_{1B} (also known as serotonin_{1D}) antagonist because serotonin has been shown to produce significant vascular spasm via activation of the serotonin receptors in humans. Kaumann, A. J., et al., *Variable Participation of 5-HT_1 -like Receptors and 5-HT_2 Receptors in Serotonin-Induced Contraction of Human Isolated Coronary Arteries*, Circulation 90, pp. 1141-53 (1994). Suitable serotonin_{1B} receptor antagonists include yohimbine, N-[methoxy-3-(4-methyl-1-piperazinyl)phenyl]-2-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl) [1,1'-biphenyl]-4-carboxamide ("GR127935") and methiothepin. Therapeutic and preferred concentrations for use of these drugs in the solution of the present invention are set forth in Table 5.

TABLE 5

Therapeutic and Preferred Concentrations of Pain/Inflammation Inhibitory Agents		
Class of Agent	Therapeutic Concentrations (Nanomolar)	Preferred Concentrations (Nanomolar)
Serotonin₁ Receptor Antagonists:		
amitriptyline	0.1-1,000	50-500
amipramine	0.1-1,000	50-500
doxepin	0.1-2,000	50-500
doxepamine	0.1-1,000	50-500
lithium salt	0.1-1,000	50-500
Serotonin₂ Receptor Antagonists:		
trazodone	0.01-100	0.05-50
methoxyphenol	10-10,000	200-2,000
clonidine	0.1-1,000	20-200
clonidine	0.1-1,000	20-200
Serotonin_{1B} (Human 1D₂) Antagonists:		
yohimbine	0.1-1,000	50-500
GR127933	0.1-1,000	10-500
methoxyphenol	0.1-500	1-100

[0130] B. Serotonin Receptor Agonists

[0131] 5-HT_{1A}, 5-HT_{1B} and 5-HT_{1D} receptors are known to inhibit adenylyl cyclase activity. Thus including a low dose of these serotonin_{1A}, serotonin_{1B} and serotonin_{1D} receptor agonists in the solution should inhibit neurons mediating pain and inflammation. The same action is expected from serotonin_{1B} and serotonin_{1D} receptor agonists because these receptors also inhibit adenylyl cyclase.

[0132] Buspirone is a suitable 1A receptor agonist for use in the present invention. Sumatriptan is a suitable 1A, 1B, 1D and 1F receptor agonist. A suitable 1B and 1D receptor agonist is dihydroergotamine. A suitable 1E receptor agonist is ergotamine. Therapeutic and preferred concentrations for these receptor agonists are provided in Table 6.

TABLE 6

Therapeutic and Preferred Concentrations of Pain/Inflammation Inhibitory Agents		
Class of Agent	Therapeutic Concentrations (Nanomolar)	Preferred Concentrations (Nanomolar)
Serotonin_{1A} Agonists:		
buspirone	1-1,000	10-200
sumatriptan	1-1,000	10-200
Serotonin_{1B} Agonists:		
dihydroergotamine	0.1-1,000	10-200
sumatriptan	1-2,000	10-200
Serotonin_{1D} Agonists:		
dihydroergotamine	0.1-1,000	10-200
sumatriptan	1-1,000	10-200
Serotonin_{1E} Agonists:		
ergotamine	10-2,000	100-1,000
Serotonin_{1F} Agonists:		
sumatriptan	1-1,000	10-200

[0133] C. Histamine Receptor Antagonists

[0134] Histamine receptors generally are divided into histamine₁ (H₁) and histamine₂ (H₂) subtypes. The classic inflammatory response to the peripheral administration of histamine is mediated via the H₁ receptor. Douglas, 1955. Therefore, the solution of the present invention preferably includes a histamine H₁ receptor antagonist. Promethazine (Phenergan™) is a commonly used anti-emetic drug which potently blocks H₁ receptors, and is suitable for use in the present invention. Interestingly, this drug also has been shown to possess local anesthetic effects but the concentrations necessary for this effect are several orders higher than that necessary to block H₁ receptors, thus, the effects are believed to occur by different mechanisms. The histamine receptor antagonist concentration in the solution is sufficient to inhibit H₁ receptors involved in nociceptor activation, but not to achieve a "local anesthetic" effect, thereby eliminating the concern regarding systemic side effects.

[0135] Histamine receptors also are known to mediate vasomotor tone in the coronary arteries. In vitro studies in the human heart have demonstrated that the histamine₂ receptor subtype mediates contraction of coronary smooth muscle. Ginsburg, R. et al., *Histamine Provocation of Clinical Coronary Artery Spasm: Implications Concerning Pathogenesis of Variant Angina Pectoris*, American Heart J., Vol. 102, pp. 819-822, (1980). Some studies suggest that histamine-induced hypercontractility in the human coronary system is most pronounced in the proximal arteries in the setting of atherosclerosis and the associated denudation of the arterial endothelium. Keitel, M. et al., *Different Histamine Actions in Proximal and Distal Human Coronary Arteries in Vitro*, Cardiovascular Research 24, pp. 614-622, (1990). Therefore, histamine receptor antagonists may be included in the cardiovascular irrigation solution.

[0136] Other suitable H₁ receptor antagonists include terfenadine, diphenhydramine, amitriptyline, mepyramine and triprolidine. Because amitriptyline is also effective as a serotonin₁ receptor antagonist, it has a dual function as used in the present invention. Suitable therapeutic and preferred concentrations for each of these H₁ receptor antagonists are set forth in Table 7.

TABLE 7

Therapeutic and Preferred Concentrations of Pain/Inflammation Inhibitory Agents		
Class of Agent	Therapeutic Concentrations (Nanomolar)	Preferred Concentrations (Nanomolar)
Histamine₁ Receptor Antagonists:		
promethazine	0.1-1,000	50-200
diphenhydramine	0.1-1,000	50-200
amitriptyline	0.1-1,000	50-500
terfenadine	0.1-1,000	50-500
mepyramine (pyramine)	0.1-1,000	5-200
triprolidine	0.01-100	5-20

[0137] D. Bradykinin Receptor Antagonists

[0138] Bradykinin receptors generally are divided into bradykinin₁ (B₁) and bradykinin₂ (B₂) subtypes. Studies have shown that acute peripheral pain and inflammation

produced by bradykinin are mediated by the B₂ subtype whereas bradykinin-induced pain in the setting of chronic inflammation is mediated via the B₁ subtype. Perkins, M. N., et al., *Antinociceptive Activity of the Bradykinin B₁ and B₂ Receptor Antagonists, des-Arg¹⁰, [Leu⁸]-BK and HOE 140, in Two Models of Persistent Hyperalgesia in the Rat*, Pain 53, pp. 191-97 (1993); Dray, A., et al., *Bradykinin and Inflammatory Pain*, Trends Neurosci 16, pp. 99-104 (1993), each of which references is hereby expressly incorporated by reference.

[0139] At present, bradykinin receptor antagonists are not used clinically. These drugs are peptides (small proteins), and thus they cannot be taken orally, because they would be digested. Antagonists to B₁ receptors block bradykinin-induced acute pain and inflammation. Dray et al., 1993. B₁ receptor antagonists inhibit pain in chronic inflammatory conditions. Perkins et al., 1993; Dray et al., 1993. Therefore, depending on the application, the solution of the present invention preferably includes either or both bradykinin B₁ and B₂ receptor antagonists. For example, arthroscopy is performed for both acute and chronic conditions, and thus an irrigation solution for arthroscopy could include both B₁ and B₂ receptor antagonists.

[0140] Suitable bradykinin receptor antagonists for use in the present invention include the following bradykinin receptor antagonists: the [des-Arg¹⁰] derivative of D-Arg-(Hyp¹-Thr²-D-Tic³-Oic⁴)-BK ("the [des-Arg¹⁰] derivative of [HOE 140]", available from Hoechst Pharmaceuticals); and [Leu⁸] des-Arg¹⁰-BK. Suitable bradykinin receptor antagonists include: [D-Phe⁷]-BK; D-Arg-(Hyp¹-Thr²-D-Phe³)-BK ("NPC 349"); D-Arg-(Hyp¹-D-Phe³)-BK ("NPC 567"); and D-Arg-(Hyp¹-Thr²-D-Tic³-Oic⁴)-BK ("HOE 140"). These compounds are more fully described in the previously incorporated Perkins et al. 1993 and Dray et al. 1993 references. Suitable therapeutic and preferred concentrations are provided in Table 8.

TABLE 8

Therapeutic and Preferred Concentrations of Pain/Inflammation Inhibitory Agents		
Class of Agent	Therapeutic Concentrations (Nanomolar)	Preferred Concentrations (Nanomolar)
Bradykinin Receptor Antagonists:		
[Leu ⁸] des-Arg ¹⁰ -BK	1-1,000	50-500
[des-Arg ¹⁰] derivative of HOE 140	1-1,000	50-500
[Leu ⁸] [des-Arg ¹⁰] kallidin	0.1-500	10-500
Bradykinin Receptor Antagonists:		
[D-Phe ⁷]-BK	100-10,000	200-5,000
NPC 349	1-1,000	50-500
NPC 567	1-1,000	50-500
HOE 140	1-1,000	50-500

[0141] E. Kallikrein Inhibitors

[0142] The peptide bradykinin is an important mediator of pain and inflammation, as noted previously. Bradykinin is produced as a cleavage product by the action of kallikrein on high molecular weight kininogens in plasma. Therefore kallikrein inhibitors are believed to be therapeutic in inhibiting bradykinin production and resultant pain and inflammation. A suitable kallikrein inhibitor for use in the present

invention is apelinin. Suitable concentrations for use in the solutions of the present invention are set forth below in Table 9.

TABLE 9

Therapeutic and Preferred Concentrations of Pain/Inflammation Inhibitory Agents		
Class of Agent	Therapeutic Concentrations (Nanomolar)	Preferred Concentrations (Nanomolar)
Kallikrein Inhibitors:		
Apelinin	0.1-1,000	50-500

[0143] F. Tachykinin Receptor Antagonists

[0144] Tachykinins (TKs) are a family of structurally related peptides that include substance P, neurokinin A (NKA) and neurokinin B (NKB). Neurokinins are the major source of TKs in the periphery. An important general effect of TKs is neuronal stimulation, but other effects include endothelium-dependent vasodilation, plasma protein extravasation, mast cell recruitment and degranulation and stimulation of inflammatory cells. Maggi, C. A., *Gen. Pharmacol.*, Vol. 22, pp. 1-24 (1991). Due to the above combination of physiological actions mediated by activation of TK receptors, targeting of TK receptors is a reasonable approach for the promotion of analgesia and the treatment of neurogenic inflammation.

1. Neurokinin Receptor Subtype Antagonists

[0145] Substance P activates the neurokinin receptor subtype referred to as NK₁. Substance P is an undecapeptide that is present in sensory nerve terminals. Substance P is known to have multiple actions which produce inflammation and pain in the periphery after C-fiber activation, including vasodilation, plasma extravasation and degranulation of mast cells. Levine, J. D., et al., *Peptides and the Primary Afferent Nociceptor*, J. Neurosci 13, p. 2273 (1993). A suitable Substance P antagonist is ([D-Pro¹]spiro-gamma-lactam[Leu¹⁰,Trp¹¹]phthalocyanine-(1,11)) ("GR 82334"). Other suitable antagonists for use in the present invention which act on the NK₁ receptor are: 1-irmino-2-(2-methoxyphenyl)-ethyl)-7,7-diphenyl-4-perhydropyrimidinolone(3aR, 7aR) ("RP 67580"); and 2S,3S-cis-3-(2-methoxybenzylamino)-2-benzhydryliquinolizidine ("CP 96,345"). Suitable concentrations for these agents are set forth in Table 10.

TABLE 10

Therapeutic and Preferred Concentrations of Pain/Inflammation Inhibitory Agents		
Class of Agent	Therapeutic Concentrations (Nanomolar)	Preferred Concentrations (Nanomolar)
Neurokinin Receptor Subtype Antagonists		
GR 82334	1-1,000	10-500
CP 96,345	1-10,000	100-1,000
RP 67580	0.1-1,000	100-1,000

2. Neurokinin₂ Receptor Subtype Antagonists

[0146] Neurokinin A is a peptide which is colocalized in sensory neurons with substance P and which also promotes inflammation and pain. Neurokinin A activates the specific neurokinin receptor referred to as NK₂. Edmonds-Alt, S., et al., *A Potent and Selective Non-Peptide Antagonist of the Neurokinin A (NK₂) Receptor*, *Life Sci.* 50:PL111 (1992). In the urinary tract, TKs are powerful spasmogens acting through only the NK₂ receptor in the human bladder, as well as the human uterus and rectum. Maggi, C. A., *Gen. Pharmacol.*, Vol. 22, pp. 1-24 (1991). Thus, the desired drugs for inclusion in a surgical solution for use in urological procedures would contain an antagonist to the NK₂ receptor to reduce spasm. Examples of suitable NK₂ antagonists include: ((S)-N-methyl-N-[4-(4-acetylamino-4-phenylpiperidino)-2-(3,4-dichlorophenyl)butyl]benzamide ("1-SR 48968"); Met-Asp-Trip-Phe-Dap-Leu ("MEN 10,627"); and cyc(Gln-Trip-Phe-Gly-Leu-Met) ("1, 659,877"). Suitable concentrations of these agents are provided in Table 11.

TABLE 11

Therapeutic and Preferred Concentrations of Pain/Inflammation Inhibitory Agents		
Class of Agent	Therapeutic Concentrations (Nanomolar)	Preferred Concentrations (Nanomolar)
Neurokinin ₂ Receptor Subtype Antagonists		
MEN 10,627	1-1,000	10-1,000
1,659,877	10-10,000	100-10,000
(1-SR 48968	10-10,000	100-10,000

[0147] G. CGRP Receptor Antagonists

[0148] Calcitonin gene-related peptide (CGRP) is a peptide which is also colocalized in sensory neurons with substance P, and which acts as a vasodilator and potentiates the actions of substance P. Brzin, S. D., et al., *Inflammatory Oedema Induced by Synergism Between Calcitonin Gene-Related Peptide (CGRP) and Mediators of Increased Vascular Permeability*, *Br. J. Pharmacol.* 99, p. 203 (1985). An example of a suitable CGRP receptor antagonist is 1-CGRP-(8-37), a truncated version of CGRP. This polypeptide inhibits the activation of CGRP receptors. Suitable concentrations for this agent are provided in Table 12.

TABLE 12

Therapeutic and Preferred Concentrations of Pain/Inflammation Inhibitory Agents		
Class of Agent	Therapeutic Concentrations (Nanomolar)	Preferred Concentrations (Nanomolar)
CGRP Receptor Antagonist		
1-CGRP-(8-37)	1-1,000	10-500

[0149] H. Interleukin Receptor Antagonist

[0150] Interleukins are a family of peptides, classified as cytokines, produced by leukocytes and other cells in response to inflammatory mediators. Interleukins (IL) may

be potent hyperalgesic agents peripherally. Ferreira, S. H., et al., *Interleukin-10 as a Potent Hyperalgesic Agent Antagonized by a Tripeptide Analogue*, *Nature* 334, p. 698 (1988). An example of a suitable IL-10 receptor antagonist is Lys-D-Pro-Thr, which is a truncated version of IL-10. This tripeptide inhibits the activation of IL-10 receptors. Suitable concentrations for this agent are provided in Table 13.

TABLE 13

Therapeutic and Preferred Concentrations of Pain/Inflammation Inhibitory Agents		
Class of Agent	Therapeutic Concentrations (Nanomolar)	Preferred Concentrations (Nanomolar)
Interleukin Receptor Antagonist		
Lys-D-Pro-Thr	1-1,000	10-500

[0151] 1. Inhibitors of Enzymes Active in the Synthetic Pathway for Arachidonic Acid Metabolites

1. Phospholipase Inhibitors

[0152] The production of arachidonic acid by phospholipase A₂ (PLA₂) results in a cascade of reactions that produces numerous mediators of inflammation, known as eicosanoids. There are a number of stages throughout this pathway that can be inhibited, thereby decreasing the production of these inflammatory mediators. Examples of inhibition at these various stages are given below.

[0153] Inhibition of the enzyme PLA₂ isoform inhibits the release of arachidonic acid from cell membranes, and therefore inhibits the production of prostaglandins and leukotrienes resulting in decreased inflammation and pain. Glier, K. B., *Regulation of Phospholipase A₂ Enzymes: Selective Inhibitors and Their Pharmacological Potential*, *Adv. Pharmacol.* 32, p. 31 (1995). An example of a suitable PLA₂ isoform inhibitor is maroalide. Suitable concentrations for this agent are included in Table 14. Inhibition of the phospholipase C₁ (PLC₁) isoform also will result in decreased production of prostaglandins and leukotrienes, and, therefore, will result in decreased pain and inflammation. An example of a PLC₁ isoform inhibitor is 1-[6-(17β-3-methoxyestra-1,3,5(10)-trien-17-yl)amino]hexyl]-1H-pyrrole-2,5-dione.

TABLE 14

Therapeutic and Preferred Concentrations of Pain/Inflammation Inhibitory Agents		
Class of Agent	Therapeutic Concentrations (Nanomolar)	Preferred Concentrations (Nanomolar)
PLA ₂ Isoform Inhibitor		
maroalide	100-100,000	500-10,000

2. Cyclooxygenase Inhibitors

[0154] Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used as anti-inflammatory, anti-pyretic, anti-thrombotic and analgesic agents. Lewis, R. A., *Prostaglandins and Leukotrienes*, In: *Textbook of Rheumatology*, 3d

ed. (Kelley W. N., et al., eds.), p. 258 (1989). The molecular targets for these drugs are type I and type II cyclooxygenases (COX-1 and COX-2). These enzymes are also known as Prostaglandin H Synthase (PGHS)-1 (constitutive) and -2 (inducible), and catalyze the conversion of arachidonic acid to Prostaglandin H which is an intermediate in the biosynthesis of prostaglandins and thromboxanes. The COX-2 enzyme has been identified in endothelial cells, macrophages, and fibroblasts. This enzyme is induced by IL-1 and endotoxin, and its expression is upregulated at sites of inflammation. Constitutive activity of COX-1 and induced activity of COX-2 both lead to synthesis of prostaglandins which contribute to pain and inflammation.

[0155] NSAIDs currently on the market (diclofenac, naproxen, indomethacin, ibuprofen, etc.) are generally non-selective inhibitors of both isoforms of COX, but may show greater selectivity for COX-1 over COX-2, although this ratio varies for the different compounds. Use of COX-1 and 2 inhibitors to block formation of prostaglandins represents a better therapeutic strategy than attempting to block interactions of the natural ligands with the seven described subtypes of prostanoid receptors. Reported antagonists of the eicosanoid receptors (EP-1, EP-2, EP-3) are quite rare and only specific, high affinity antagonists of the thromboxane A₂ receptor have been reported. Wallace, J. and Cirino, G. *Trends in Pharm. Sci.*, Vol. 15 pp. 405-406 (1994).

[0156] The oral, intravenous or intramuscular use of cyclooxygenase inhibitors is contraindicated in patients with ulcer disease, gastritis or renal impairment. In the United States, the only available injectable form of this class of drugs is ketorolac (ToradolTM), available from Syntex Pharmaceuticals, which is conventionally used intramuscularly or intravenously in postoperative patients but, again, is contraindicated for the above-mentioned categories of patients. The use of ketorolac, or any other cyclooxygenase inhibitor(s), in the solution in substantially lower dosages than currently used perioperatively may allow the use of this drug in otherwise contraindicated patients. The addition of a cyclooxygenase inhibitor to the solutions of the present invention adds a distinct mechanism for inhibiting the production of pain and inflammation during arthroscopy or other therapeutic or diagnostic procedures.

[0157] Preferred cyclooxygenase inhibitors for use in the present invention are ketorolac and indomethacin. Of these two agents, indomethacin is less preferred because of the relatively high dosages required. Therapeutic and preferred concentrations for use in the solution are provided in Table 15.

TABLE 15

Therapeutic and Preferred Concentrations of Pain/Inflammation Inhibitory Agents		
Class of Agent	Therapeutic Concentrations (Nanomolar)	Preferred Concentrations (Nanomolar)
<u>Cyclooxygenase Inhibitors:</u>		
Ketorolac	100-10,000	500-5,000
Indomethacin	1,000-500,000	10,000-200,000

3. Lipooxygenase Inhibitors

[0158] Inhibition of the enzyme lipooxygenase inhibits the production of leukotrienes, such as leukotriene B₄, which is known to be an important mediator of inflammation and pain. Lewis, R. A., *Prostaglandins and Leukotrienes*, in: *Textbook of Rheumatology*, 3d ed. (Kelley W. N., et al., eds.), p. 258 (1989). An example of a 5-lipoxygenase antagonist is 2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadienyl)-1,4-benzoquinone ("AA 861"), suitable concentrations for which are listed in Table 16.

TABLE 16

Therapeutic and Preferred Concentrations of Pain/Inflammation Inhibitory Agents		
Class of Agent	Therapeutic Concentrations (Nanomolar)	Preferred Concentrations (Nanomolar)
<u>Lipoxygenase Inhibitors:</u>		
AA 861	100-10,000	500-5,000

J. Prostanoid Receptor Antagonists

[0160] Specific prostanoids produced as metabolites of arachidonic acid mediate their inflammatory effects through activation of prostanoid receptors. Examples of classes of specific prostanoid antagonists are the eicosanoid EP-1 and EP-4 receptor subtype antagonists and the thromboxane receptor subtype antagonists. A suitable prostaglandin E₂ receptor antagonist is 8-chlorodibenz[h,i][1,4]oxazepino-10(11H)-carboxylic acid, 2-acetylhydrazide ("SC 19220"). A suitable thromboxane receptor subtype antagonist is [15-[1α, 3β(5Z), 3β, 4α]-7-[3-[2-(phenylamino)-carbonyl]hydrazino] methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptanoic acid ("SQ 29548"). Suitable concentrations for these agents are set forth in Table 17.

TABLE 17

Therapeutic and Preferred Concentrations of Pain/Inflammation Inhibitory Agents		
Class of Agent	Therapeutic Concentrations (Nanomolar)	Preferred Concentrations (Nanomolar)
<u>Eicosanoid EP-1 Antagonists:</u>		
SC 19220	100-10,000	500-5,000

K. Leukotriene Receptor Antagonists

[0161] The leukotrienes (LTB₄, LTC₄, and LTD₄) are products of the 5-lipoxygenase pathway of arachidonic acid metabolism that are generated enzymatically and have important biological properties. Leukotrienes are implicated in a number of pathological conditions including inflammation. Specific antagonists are currently being sought by many pharmaceutical companies for potential therapeutic intervention in these pathologies. Halushka, P. V., et al., *Annu. Rev. Pharmacol. Toxicol.* 29: 213-239 (1989); Ford-Hutchinson, A. *Crit. Rev. Immunol.* 10: 1-12 (1990). The LTB₄ receptor is found in certain immune cells including eosinophils and neutrophils. LTB₄ binding to these receptors

results in chemotaxis and lysosomal enzyme release thereby contributing to the process of inflammation. The signal transduction process associated with activation of the LTD₄ receptor involves G-protein-mediated stimulation of phosphatidylinositol (PI) metabolism and elevation of intracellular calcium (see FIG. 2).

[0162] An example of a suitable leukotriene B₄ receptor antagonist is SC (+)(S)-7-(3-(2-(cyclopropylmethyl)-3-methoxy-4-((methylamino)-carbonyl)phenoxy(propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-propanoic acid ("SC 53228"). Concentrations for this agent that are suitable for the practice of the present invention are provided in Table 18. Other suitable leukotriene B₄ receptor antagonists include [3-(2-(7-chloro-2-quinolinyl)ethoxy)phenyl][3-(dimethylamino-3-oxopropyl)thio] methylthiopropionic acid ("MK 0571") and the drugs LY 66,071 and IC120,3219. MK 0571 also acts as a LTD₄ receptor subtype antagonist.

TABLE 18

Therapeutic and Preferred Concentrations of Pro-Inflammation Inhibitory Agents		
Class of Agent	Therapeutic Concentrations (Nanomolar)	Preferred Concentrations (Nanomolar)
Leukotriene B ₄ Antagonists		
SC 53228	100-10,000	500-5,000

[0163] L. Opioid Receptor Agonists

[0164] Activation of opioid receptors results in anti-nociceptive effects and, therefore, agonists to these receptors are desirable. Opioid receptors include the μ -, δ - and κ -opioid receptor subtypes. The μ -receptors are located on sensory neuron terminals in the periphery and activation of these receptors inhibits sensory neuron activity. Basbaum, A. I., et al., *Opiate Analgesia: How Central is a Peripheral Target?*, N. Engl. J. Med., 325:1168 (1991). δ - and κ -receptors are located on sympathetic efferent terminals and inhibit the release of prostaglandins, thereby inhibiting pain and inflammation. Taiwo, Y. O., et al., *Kappa- and Delta-Opioids Block Sympathetically Dependent Hyperalgesia*, J. Neurosci., Vol. 11, page 928 (1991). The opioid receptor subtypes are members of the G-protein coupled receptor superfamily. Therefore, all opioid receptor agonists interact and initiate signaling through their cognate G-protein coupled receptor (see FIGS. 3 and 7). Examples of suitable μ -opioid receptor agonists are fentanyl and lly-D-Ala-Gly-[N-MePhe]-NH(CH₂)₂-OH ("DAMGO"). An example of a suitable δ -opioid receptor agonist is [D-Pen²,D-Pen³]enkephalin ("DPDPE"). An example of a suitable κ -opioid receptor agonist is (trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidyl)cyclohexyl]-benzene acetamide ("U50,488"). Suitable concentrations for each of these agents are set forth in Table 19.

TABLE 19

Therapeutic and Preferred Concentrations of Pain-Inflammation Inhibitory Agents		
Class of Agent	Therapeutic Concentrations (Nanomolar)	Preferred Concentrations (Nanomolar)
μ -Opioid Agonists		
DAMGO	0.1-100	0.5-20
fentanyl	0.01-50	1-20
lly-D-Ala-Gly-[N-MePhe]-NH(CH ₂) ₂ -OH	0.1-500	10-200
PL 017	0.25-50	0.25-10
δ -Opioid Agonists		
DPDPE	0.1-500	1.0-100
κ -Opioid Agonists		
U50,488	0.1-500	1.0-100

[0165] M. Purinoreceptor Antagonists and Agonists

[0166] Extracellular ATP acts as a signaling molecule through interactions with P₂ purinoreceptors. One major class of purinoreceptors are the P_{2X} purinoreceptors which are ligand-gated ion channels possessing intrinsic ion channels permeable to Na⁺, K⁺, and Ca²⁺. P_{2X} receptors described in sensory neurons are important for primary afferent neurotransmission and nociception. ATP is known to depolarize sensory neurons and plays a role in nociceptor activation since ATP released from damaged cells stimulates P_{2X} receptors leading to depolarization of nociceptive nerve-fiber terminals. The P_{2X} receptor has a highly restricted distribution (Chen, C. C., et al., *Nature*, Vol. 377, pp. 428-431 (1995)) since it is selectively expressed in sensory C-fiber nerves that run into the spinal cord and many of these C-fibers are known to carry the receptors for painful stimuli. Thus, the highly restricted localization of expression for the P_{2X} receptor subunits make these subtypes excellent targets for analgesic action (see FIGS. 3 and 7).

[0167] Suitable antagonists of P_{2X}/ATP purinoreceptors for use in the present invention include, by way of example, suramin and pyridoxylphosphate-6-azophenyl-2,4-disulfonic acid ("PPADS"). Suitable concentrations for these agents are provided in Table 20.

[0168] Agonists of the P_{2Y} receptor, a G-protein coupled receptor, are known to effect smooth muscle relaxation through elevation of inositol triphosphate (IP₃) levels with a subsequent increase in intracellular calcium. An example of a P_{2Y} receptor agonist is 2-mo-S-ATP.

TABLE 20

Therapeutic and Preferred Concentrations of Pain-Inflammation Inhibitory Agents		
Class of Agent	Therapeutic Concentrations (Nanomolar)	Preferred Concentrations (Nanomolar)
Purinoreceptor Antagonists		
suramin	100-100,000	1,000-100,000
PPADS	100-100,000	10,000-100,000

[0169] N, Adenosine Triphosphate (ATP)-Sensitive Potassium Channel Openers

[0170] ATP-sensitive potassium channels have been discovered in numerous tissues, including vascular and non-vascular smooth muscle and brain, and binding studies using radiolabeled ligands have confirmed their existence. Opening of these channels causes potassium (K^+) efflux and hyperpolarizes the cell membrane (see FIG. 2). This hyperpolarization induces a reduction in intracellular free calcium through inhibition of voltage-dependent calcium (Ca^{2+}) channels and receptor-operated Ca^{2+} channels. These combined actions drive the cell (e.g., smooth muscle cell) into a relaxed state or one which is more resistant to activation and, in the case of vascular smooth muscle, results in vasorelaxation. K^+ channel openers (KCOs) have been characterized as having potent antihypertensive activity in vivo and vasorelaxant activity in vitro (see FIG. 4). K^+ channel openers (KCOs) also have been shown to prevent stimulus coupled secretion and are considered to act on prejunctional neuronal receptors and thus will inhibit effects due to nerve stimulation and release of inflammatory mediators. Qian, U., et al., *Cellular Pharmacology of Potassium Channel Openers in Vascular Smooth Muscle*, Cardiovasc. Res., Vol. 28, pp. 805-810 (1994).

[0171] Synergistic interactions between endothelin (ETA) antagonists and openers of ATP-sensitive potassium channels (KCOs) are expected in achieving vasorelaxation or smooth muscle relaxation. A rationale for dual use is based upon the fact that these drugs have different molecular mechanisms of action in promoting relaxation of smooth muscle and prevention of vasospasm. An initial intracellular calcium elevation in smooth muscle cells induced by the ET_A receptor subsequently triggers activation of voltage-dependent channels and the entry of extracellular calcium which is required for contraction. Antagonists of the ET_A receptor will specifically block this receptor mediated effect but not block increases in calcium triggered by activation of other G-protein coupled receptors on the muscle cell.

[0172] Potassium-channel opener drugs, such as pinacidil, will open these channels causing K^+ efflux and hyperpolarization of the cell membrane. This hyperpolarization will act to reduce contraction mediated by other receptors by the following mechanisms: (1) it will induce a reduction in intracellular free calcium through inhibition of voltage-dependent Ca^{2+} channels by reducing the probability of opening L-type or T-type calcium channels, (2) it will restrain agonist induced (receptor operated channels) Ca^{2+} release from intracellular sources through inhibition of inositol triphosphate (IP_3) formation, and (3) it will lower the efficiency of calcium as an activator of contractile proteins. Consequently, combined actions of these two classes of drugs will clamp the target cells into a relaxed state or one which is more resistant to activation.

[0173] Suitable ATP-sensitive K^+ channel openers for the practice of the present invention include: (-)-pinacidil; cromakalim; nicorandil; minoxidil; N-cyclo-N-[1,1-dimethyl-2,2,3,3-tetrahydropyridyl]-N-(3-pyridinyl)guanidine ("P 1075"); and N-cyclo-N-(2-ethoxyethyl)-3-pyridinecarboxamide monomethanesulphonate ("KRN 2391"). Concentrations for these agents are set forth in Table 21.

TABLE 21

Class of Agent	Therapeutic and Preferred Concentrations of Poly(Infammation) Inhibitory Agents	
	Therapeutic Concentrations (Nanomolar)	Preferred Concentrations (Nanomolar)
ATP-Sensitive K^+ Channel Openers:		
cromakalim	10-10,000	100-10,000
nicorandil	10-10,000	100-10,000
minoxidil	10-10,000	100-10,000
P 1075	0.1-1,000	10-1,000
KRN 2391	1-10,000	100-1,000
(-)-pinacidil	1-10,000	100-1,000

III. Anti-Spasm Agents

[0174] A. Multifunction Agents

[0175] Several of the anti-pain/anti-inflammatory agents described above also serve to inhibit vasoconstriction or smooth muscle spasm. As such, these agents also perform the function of anti-spasm agents, and thus are beneficially used in vascular and urologic applications. Anti-inflammatory/anti-pain agents that also serve as anti-spasm agents include: serotonin receptor antagonists, particularly, serotonin₂ antagonists; tachykinin receptor antagonists and ATP-sensitive potassium channel openers.

[0176] B. Nitric Oxide Donors

[0177] Nitric oxide donors may be included in the solutions of the present invention particularly for their anti-spasm activity. Nitric oxide (NO) plays a critical role as a molecular mediator of many physiological processes, including vasodilation and regulation of normal vascular tone. Within endothelial cells, an enzyme known as NO synthase (NOS) catalyzes the conversion of L-arginine to NO which acts as a diffusible second messenger and mediates responses in adjacent smooth muscle cells (see FIG. 8). NO is continuously formed and released by the vascular endothelium under basal conditions which inhibits contractions and controls basal coronary tone and is produced in the endothelium in response to various agonists (such as acetylcholine) and other endothelium dependent vasodilators. Thus, regulation of NO synthase activity and the resultant levels of NO are key molecular targets controlling vascular tone (see FIG. 8). Muramatsu, K., et al., *Coron. Artery Dis.*, Vol. 5, pp. 815-820 (1994).

[0178] Synergistic interactions between NO donors and openers of ATP-sensitive potassium channels (KCOs) are expected to achieve vasorelaxation or smooth muscle relaxation. A rationale for dual use is based upon the fact that these drugs have different molecular mechanisms of action in promoting relaxation of smooth muscle and prevention of vasospasm. There is evidence from cultured coronary arterial smooth muscle cells that the vasoconstrictors: vasopressin, angiotensin II and endothelin, all inhibit K_{ATP} currents through inhibition of protein kinase A. In addition, it has been reported that K_{ATP} currents in bladder smooth muscle is inhibited by muscarinic agonists. The actions of NO in mediating smooth muscle relaxation occur via independent molecular pathways (described above) involving protein kinase G (see FIG. 8). This suggests that the

combination of the two classes of agents will be more efficacious in relaxing smooth muscle than employing a single class of agent alone.

[0179] Suitable nitric oxide donors for the practice of the present invention include nitroglycerin, sodium nitroprusside, the drug FK 409, FR 144420, 3-morpholinocyanidamine, or lisinidomine chlorohydrate, ("SIN-1"), and S-nitroso-N-acetylpenicillamine ("SNAP"). Concentrations for these agents are set forth in Table 22.

TABLE 22

Therapeutic and Preferred Concentrations of Eosin Inhibitory Agents		
Class of Agent	Therapeutic Concentrations (Nanomolar)	Preferred Concentrations (Nanomolar)
Nitric Oxide Donors:		
Nitroglycerin	10-10,000	100-1,000
sodium nitroprusside	10-10,000	100-1,000
SIN-1	10-10,000	100-1,000
SNAP	10-10,000	100-1,000
FK 409 (NOR-1)	1-1,000	10-100
FR 144420 (NOR-4)	10-10,000	100-1,000

[0180] C. Endothelin Receptor Antagonists

[0181] Endothelin is a 21 amino acid peptide that is one of the most potent vasoconstrictors known. Three different human endothelin peptides, designated ET-1, ET-2 and ET-3 have been described which mediate their physiological effects through at least two receptor subtypes referred to as ET_A and ET_B receptors. The heart and vascular smooth muscle contain predominantly ET_A receptors and this subtype is responsible for contraction in these tissues. Furthermore, ET_A receptors have often been found to mediate contractile responses in isolated smooth muscle preparations. Antagonists of ET_A receptors have been found to be potent antagonists of human coronary artery contractions. Thus, antagonists to the ET_A receptor should be therapeutically beneficial in the perioperative inhibition of coronary vasospasm and may additionally be useful in inhibition of smooth muscle contraction in urological applications. Miller, R. C., et al., *Trends in Pharmacol. Sci.*, Vol. 14, pp. 54-60 (1993).

[0182] Suitable endothelin receptor antagonists include: cyclo(D-Asp-Pro-D-Val-Leu-D-Trp) ("BQ 123"); (N,N-hexamethylene)-carbamoyl-Leu-D-Trp-(CH₂)₁₀-D-Trp-OH ("BQ 610"); (R)-2-[(R)-2-[(S)-2-[(1-hexahydro-1H-azepinyl)-carbonyl]amino-4-methyl-pentanoyl)] amino-3-[(1-methyl-1H-indolyl)]propionylamino-3-(2-pyridyl) propionic acid ("FR 139317"); cyclo(D-Asp-Pro-D-Ile-Leu-D-Trp) ("JK 301"); cyclo(D-Ser-Pro-D-Val-Leu-D-Trp) ("JK 302"); 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide ("BMS 182874"); and N-[1-Formyl-N-[N-[(hexahydro-1H-azepin-1-yl)carbonyl]-L-leucyl]-D-tryptophyl]-D-tryptophan ("BQ 610"). Concentrations for a representative three of these agents is set forth in Table 23.

TABLE 23

Therapeutic and Preferred Concentrations of Seven Inhibitory Agents		
Class of Agent	Therapeutic Concentrations (Nanomolar)	Preferred Concentrations (Nanomolar)
Endothelin Receptor Antagonists		
BQ 123	0.01-1,000	10-1,000
FR 139317	1-100,000	100-10,000
BQ 610	0.01 to 10,000	10-1,000

[0183] D. Ca²⁺ Channel Antagonists

[0184] Calcium channel antagonists are a distinct group of drugs that interfere with the transmembrane flux of calcium ions required for activation of cellular responses mediating neuroinflammation. Calcium entry into platelets and white blood cells is a key event mediating activation of responses in these cells. Furthermore, the role of bradykinin receptors and neurokinin receptors (NK₁ and NK₂) in mediating the neuroinflammation signal transduction pathway includes increases in intracellular calcium, thus leading to activation of calcium channels on the plasma membrane. In many tissues, calcium channel antagonists, such as nifedipine, can reduce the release of arachidonic acid, prostaglandins, and leukotrienes that are evolved by various stimuli. Moncada, S., Flower, R. and Vane, J. in *Goodman's and Gilman's Pharmacological Basis of Therapeutics*, (7th ed.), Mac-Millan Publ. Inc., pp. 660-5 (1995).

[0185] Calcium channel antagonists also interfere with the transmembrane flux of calcium ions required by vascular smooth muscle for contractions. This effect provides the rationale for the use of calcium channel antagonists perioperatively during procedures in which the goal is to alleviate vasospasm and promote relaxation of smooth muscle. The dihydropyridines, including nifedipine, act as specific inhibitors (antagonists) of the voltage-dependent gating of the L-type subtype of calcium channels. Systemic administration of the calcium channel antagonist nifedipine during cardiac surgery previously has been utilized to prevent or minimize coronary artery vasospasm. Scialberger, R., et al., *Circulation*, Vol. 83, pp. 460-468 (1991).

[0186] Calcium channel antagonists, which are among the anti-spasm agents useful in the present invention, exhibit synergistic effect when combined with other agents of the present invention. Calcium (Ca²⁺) channel antagonists and nitric oxide (NO) donors interact in achieving vasorelaxation or smooth muscle relaxation, i.e., in inhibiting spasm activity. A rationale for dual use is based upon the fact that these two classes of drugs have different molecular mechanisms of action, may not be completely effective in achieving relaxation used alone, and may have different time periods of effectiveness. In fact, there are numerous studies showing that calcium channel antagonists alone cannot achieve complete relaxation of vascular muscle that has been precontracted with a receptor agonist.

[0187] The effect of nifedipine, used alone and in combination with nitroglycerin, on spasm of the internal mammary artery (IMA) showed that the combination of the two drugs produced a large positive synergistic effect in the

prevention of contraction (Lin et al., 1994). These studies provide a scientific basis for combination of a calcium channel antagonist and nitric oxide (NO) donor for the efficacious prevention of vasospasm and relaxation of smooth muscle. Examples of systemic administration of nitroglycerin and nifedipine during cardiac surgery to prevent and treat myocardial ischemia or coronary artery vasospasm have been reported (Cohen et al., 1983; Scheibinger et al., 1991).

[0188] Calcium channel antagonists also exhibit synergistic effect with endothelin receptor subtype A (ET_A) antagonists. Yanagisawa and coworkers observed that dihydropyridine antagonists blocked effects of ET-1, an endogenous agonist at the ET_A receptor in coronary arterial smooth muscle, and hence speculated that ET-1 is an endogenous agonist of voltage-sensitive calcium channels. It has been found that the sustained phase of intracellular calcium elevation in smooth muscle cells induced by ET_A receptor activation requires extracellular calcium and is at least partially blocked by nifedipine. Thus, the inclusion of a calcium channel antagonist would be expected to synergistically enhance the actions of an ET_A antagonist when combined in a surgical solution.

[0189] Calcium channel antagonists and ATP-sensitive potassium channel openers likewise exhibit synergistic action. Potassium channels that are ATP-sensitive (K_{ATP}) couple the membrane potential of a cell to the cell's metabolic state via sensitivity to adenosine nucleotides. K_{ATP} channels are inhibited by intracellular ATP but are stimulated by intracellular nucleotide diphosphates. The activity of these channels is controlled by the electrochemical driving force to potassium and intracellular signals (e.g., ATP or a G-protein), but are not gated by the membrane potential per se. K_{ATP} channels hyperpolarize the membrane and thus allow them to control the resting potential of the cell. ATP-sensitive potassium currents have been discovered in skeletal muscle, brain, and vascular and nonvascular smooth muscle. Binding studies with radiolabeled ligands have confirmed the existence of ATP-sensitive potassium channels which are the receptor targets for the potassium-channel opener drugs such as pinacidil. Opening of these channels causes potassium efflux and hyperpolarizes the cell membrane. This hyperpolarization (1) induces a reduction in intracellular free calcium through inhibition of voltage-dependent Ca²⁺ channels by reducing the probability of opening L-type or T-type calcium channels, (2) restrains agonist induced (at receptor operated channels) Ca²⁺ release from intracellular sources through inhibition of inositol triphosphate (IP₃) formation, and (3) lowers the efficiency of calcium as an activator of contractile proteins. The combined actions of these two classes of drugs (ATP-sensitive potassium channel openers and calcium channel antagonists) will clamp the target cells into a relaxed state or one which is more resistant to activation.

[0190] Finally, calcium channel antagonists and tachykinin and bradykinin antagonists exhibit synergistic effects in mediating neuroinflammation. The role of neurokinin receptors in mediating neuroinflammation has been established. The neurokinin₁ (NK₁) and neurokinin₂ (NK₂) receptor (members of the G-protein coupled superfamily) signal transduction pathway includes increases in intracellular calcium, thus leading to activation of calcium channels on the plasma membrane. Similarly, activation of bradykinin

(BK₂) receptors is coupled to increases in intracellular calcium. Thus, calcium channel antagonists interfere with a common mechanism involving elevation of intracellular calcium, part of which enters through L-type channels. This is the basis for synergistic interaction between calcium channel antagonists and antagonists to neurokinin and bradykinin receptors.

[0191] Suitable calcium channel antagonists for the practice of the present invention include nifedipine, nimodipine, lacidipine, isradipine and amlodipine. Suitable concentrations for these agents are set forth in Table 24.

TABLE 24

Therapeutic and Preferred Concentrations of Known Inhibitory Agents		
Class of Agent	Therapeutic Concentrations (Nanomolar)	Preferred Concentrations (Nanomolar)
<u>Calcium Channel Antagonists:</u>		
nifedipine	1-10,000	100-1,000
nimodipine	1-10,000	100-5,000
amlodipine	1-10,000	100-5,000
isradipine	1-10,000	100-5,000
lacidipine	1-10,000	100-5,000
amlodipine	1-10,000	100-5,000

IV. Anti-Restensia Agents

[0192] Solutions of the present invention utilized for cardiovascular and general vascular procedures may optionally also include an anti-restensia agent, particularly for angioplasty, rotational atherectomy and other interventional vascular uses. The following drugs are suitable for inclusion in the previously described cardiovascular and general vascular irrigation solutions when limitation of restensia is indicated. The following anti-restensia agents would preferably be combined with anti-spasm, and still more preferably also with anti-pain/anti-inflammation agents in the solutions of the present invention.

[0193] A. Antiplatelet Agents

[0194] At sites of arterial injury, platelets adhere to collagen and fibrinogen via specific cell surface receptors, and are then activated by several independent mediators. A variety of agonists are able to activate platelets, including collagen, ADP, thromboxane A₂, epinephrine and thrombin. Collagen and thrombin serve as primary activators at sites of vascular injury, while ADP and thromboxane A₂ act to recruit additional platelets into a growing platelet plug. The activated platelets degranulate and release other agents which serve as chemotactants and vasoconstrictors, thus promoting vasospasm and platelet accumulation. Thus, antiplatelet agents can be antagonists drawn from any of the above agonist-receptor targets.

[0195] Since platelets play such an important role in the coagulation cascade, oral antiplatelet agents have been routinely administered to patients undergoing vascular procedures. Indeed, because of this multiplicity of activators and observations that single antiplatelet agents are not effective, some investigators have concluded that a combined treatment protocol is necessary for effectiveness. Recently, Willenson and coworkers reported the intravenous use of 3

combined agents, ridozel (an antagonist of thromboxane A₂), ketanserin (a serotonin antagonist) and clopidogrel (an ADP antagonist). They found that the combination of 3 antagonists inhibited several relevant platelet functions and reduced neointimal proliferation in a canine coronary angioplasty model (JACC Abstracts, February 1995). It is still uncertain which approach to treatment of coronary thrombosis will be most successful. One possibility would be to include an antiplatelet agent and an antithrombotic agent in the cardiovascular and general vascular solutions of the present invention.

1. Thrombin Inhibitors and Receptor Antagonists

[0196] Thrombin plays a central role in vascular lesion formation and is considered the principal mediator of thrombogenesis. Thus, thrombus formation at vascular lesion sites during and after PTCA (percutaneous transluminal coronary angioplasty) or other vascular procedure is central to acute reocclusion and chronic restenosis. This process can be interrupted by application of direct anti-thrombins, including hirudin and its synthetic peptide analogs, as well as thrombin receptor antagonist peptides (Hartel, et al., 1995, Am. J. Cardiol. 75, 12B). Thrombin is also a potent growth factor which initiates smooth muscle cell proliferation at sites of vascular injury. In addition, thrombin also plays a role in modulating the effects of other growth factors such as PDGF (platelet-derived growth factor), and it has been shown that thrombin inhibitors reduce expression of PDGF mRNA subsequent to vascular injury induced by balloon angioplasty.

[0197] Hirudin is the prototype direct antithrombin drug since it binds to the catalytic site and the substrate recognition site (exosite) of thrombin. Animal studies using baboons have shown that this proliferative response can be reduced 80% using recombinant hirudin (Ciba-Geigy). Hirulog (Biogen) is a dodecapeptide modeled after hirudin, and binds to the active site of thrombin via a Phe-Pro-Arg linker molecule. Large clinical trials of hirudin and hirulog are underway to test their efficacy in reducing vascular lesions after PTCA and Phase II data on these inhibitors to date is positive, and both drugs are believed to be suitable in the solutions of the present invention. Preliminary results of a 1,200 patient trial with repeat angiographic assessment at 6 months to detect restenosis indicated superior short-term suppression of ischemic events with hirudin vs. heparin. An advantage of this approach is that no significant bleeding complications were reported. A sustained-release local hirulog therapy was found to decrease early thrombosis but not neointimal thickening after arterial stenting in pigs. Muller, D. et al., *Sustained-Release Local Hirulog Therapy Decreases Early Thrombosis but not Neointimal Thickening After Arterial Stenting*, Am. Heart J. 133, No. 2, pp. 211-218, (1996). In this study, hirulog was released from an heparinized polymer placed around the artery.

[0198] Other active anti-thrombin agents being tested which are theorized to be suitable for the present invention are argatroban (Texas Biotechnology) and efgatran (Lilly).

TABLE 25

Therapeutic and Preferred Concentrations of
Thrombin Inhibitory Agents

Class of Agent	Therapeutic/Preferred Concentrations (Nanomolar)	More preferred (Nanomolar)
<u>Thrombin Inhibitors and Receptor Antagonists:</u>		
hirudin	0.0013-30.0013-0.3	0.03
hirulog	0.2-20,000-2,000	200

2. ADP Receptor Antagonists (Purinceptor Antagonists)

[0199] Ticlopidine, an analog of ADP, inhibits both thromboxane and ADP-induced platelet aggregation. It is likely that ticlopidine blocks interaction of ADP with its receptor, thereby inhibiting signal transduction by this G-protein coupled receptor on the surface of platelet membranes. A preliminary study showed it to be more effective than aspirin in combination with dipyridamole. However, the clinical use of ticlopidine has been limited because it causes neutropenia. Clopidogrel, a ticlopidine analog, is thought to have fewer adverse side effects than ticlopidine and is currently being studied for prevention of ischemic events. It is theorized that these agents may be suitable for use in the solutions of the present invention.

3. Thromboxane Inhibitors and Receptor Antagonists

[0200] Agents currently utilized for conventional methods of treatment of thrombosis rely upon aspirin, heparin and plasminogen activators. Aspirin irreversibly acetylates cyclooxygenase and inhibits the synthesis of thromboxane A₂ and prostacyclin. While data support a benefit of aspirin for PTCA, the underlying efficacy of aspirin is considered as only partial or modest. This is likely due to platelet activation through thromboxane A₂ independent pathways that are not blocked by aspirin induced acetylation of cyclooxygenase. Platelet aggregation and thrombosis may occur despite aspirin treatment. Aspirin in combination with dipyridamole has also been shown to reduce the incidence of acute complication during PTCA but not the incidence of restenosis.

[0201] Two thromboxane receptor antagonists appear to be more efficacious than aspirin and are believed suitable for use in the solutions and methods of the present invention. Ticlopidine inhibits both thromboxane and ADP-induced platelet aggregation. Ridozel (R68060) is a combined thromboxane B₂ synthetase inhibitor and thromboxane-prostaglandin endoperoxide receptor blocker. It has been compared with salicylate therapy in an open-pilot study of patients undergoing PTCA administered in combination with heparin. Timmermans, C., et al., *Ridozel in the Setting of Percutaneous Transluminal Coronary Angioplasty*, Am. J. Cardiol. 68, pp. 463-466, (1991). Treatment consisted of administering a slow intravenous injection of 300 mg just prior to the start of the PTCA procedure and continued orally after 12 hrs with a dose of 300 mg twice daily. From this study, ridozel was found to be primarily successful since no

early acute reocclusion occurred in 30 patients. Bleeding complications did occur in a significant number (34%) of patients, and this appears to be a complicating factor that would require special care. The study confirmed that ticlopidine is a potent long-lasting inhibitor of thromboxane B2 synthetase.

[0202] B. Inhibitors of Cell Adhesion Molecules

1. Selectin Inhibitors

[0203] Selectin inhibitors block the interaction of a selectin with its cognate ligand or receptor. Representative examples of selectin targets at which these inhibitors would act include, but are not limited to, E-selectin and P-selectin receptors. Upjohn Co. has licensed rights to a monoclonal antibody developed by Cytel Corp that inhibits the activity of P-selectin. The product, CY 1748, is in preclinical development, with a potential indication being restenosis.

2. Integrin Inhibitors

[0204] The platelet glycoprotein IIb/IIIa complex is present on the surface of resting as well as activated platelets. It appears to undergo a transformation during platelet activation which enables it to serve as a binding site for fibrinogen and other adhesive proteins. Most promising new antiplatelet agents are directed at this integrin cell surface receptor which represents a final common pathway for platelet aggregation.

[0205] Several types of agents fit into the class of GPIIb/IIIa integrin antagonists. A monoclonal antibody, e7E3, (Centocor, Centocor, Malvern Pa.) has been intensively studied to date in a 3,000 patient PTCA study. It is a chimeric human/murine hybrid. A 0.25 mg/kg bolus of e7E3 followed by 10 µg/min intravenous infusion for 12 hrs produced greater than 80% blockade of GPIIb/IIIa receptors for the duration of the infusion. This was correlated with a greater than 80% inhibition of platelet aggregation. The antibody was coadministered with heparin and an increased risk of bleeding was noted. Additional information was obtained from the EPIC trial which showed a significant reduction in the primary end point, a composite of death rate, incidence of nonfatal myocardial infarction and need for coronary revascularization, and suggested a long term benefit. Teboug, (1995) Am. Heart J. 130, 673-679. A phase IV study (EPIC-OC) designed to address safety and efficacy issues with e7E3 Fab is planned or in progress. This monoclonal antibody can also be classified as a platelet membrane glycoprotein receptor antagonist directed against the glycoprotein IIb/IIIa receptor.

[0206] The platelet glycoprotein IIb/IIIa receptor blocker, integrilin, is a cyclic heptapeptide that is highly specific for this molecular target. In contrast to the antibody, it has a short biologic half-life (about 10 minutes). The safety and efficacy of integrilin was first evaluated in the Phase II Impact trial. Either 4 or 12 hour intravenous infusions of 1.0 µg/kg/min of integrilin were utilized (Topol, E., 1995 Am. J. Cardiol. 77B-33B). It was provided in combination with other agents (heparin, aspirin) and was shown to exhibit potent anti-platelet aggregation properties (>80%). A phase III study, the IMPACT II trial, of 4000 patients showed that integrilin markedly reduced ischemic events in patients who had undergone Rotablator atherectomy (JACC Abstracts,

1996). Suitable concentrations of the drugs e7E3 and integrilin for use in the present invention are set forth below.

[0207] In addition, two peptidomimetics, MK-383 (Merck) and RO 4483 (Hoffmann-LaRoche), have been studied in Phase II clinicals. Since these are both small molecules, they have a short half-life and high potency. However, these seem to also have less specificity, interacting with other closely related integrins. It is theorized that these peptidomimetics may also be suitable for use in the present invention.

TABLE 26

Therapeutic and Preferred Concentrations of Biotinylated Inhibitory Agents		
Class of Agent	Therapeutic/Preferred Concentrations (Nanomolar)	Most preferred (Nanomolar)
<u>Cell Adhesion Inhibitors</u>		
e7E3	0.1-50 (0.01-5,000)	500
Integrilin	0.1-100 (0.01-1000) nM	100 nM

[0208] C. Anti-Chemotactic Agents

[0209] Anti-chemotactic agents prevent the chemotaxis of inflammatory cells. Representative examples of anti-chemotactic targets at which these agents would act include, but are not limited to, F-Met-Leu-Phe receptors, IL-8 receptors, MCP-1 receptors, and MIP-1-1/RANTES receptors. Drugs within this class of agents are early in the development stage, but it is theorized that they may be suitable for use in the present invention.

[0210] D. Interleukin Receptor Antagonists

[0211] Interleukin receptor antagonists are agents which block the interaction of an interleukin with its cognate ligand or receptor. Specific receptor antagonists for any of the numerous interleukin receptors are early in the development process. The exception to this is the naturally occurring existence of a secreted form of the IL-1 receptor, referred to as IL-1 antagonist protein (IL-1AP). This antagonist binds IL-1 and has been shown to suppress the biological actions of IL-1, and is theorized to be suitable for the practice of the present invention.

[0212] E. Intracellular Signaling Inhibitors

1. Protein Kinase Inhibitors

a. Protein Kinase C (PKC) Inhibitors

[0213] Protein kinase C (PKC) plays a crucial role in cell-surface signal transduction for a number of physiological processes. PKC isozymes can be activated as downstream targets resulting from initial activation of either G-protein coupled receptors (e.g., serotonin, endothelin, etc.) or growth-factor receptors such as PDGF. Both of these receptor classes play important roles in mediating vascular spasm and restenosis subsequent to coronary balloon angioplasty procedures.

[0214] Molecular cloning analysis has revealed that PKC exists as a large family consisting of at least 8 subtypes (isozymes). These isozymes differ substantially in structure and mechanism for linking receptor activation to changes in

the proliferative response of specific cells. Expression of specific isozymes is found in a wide variety of cell types, including: platelets, neutrophils, myeloid cells, and smooth muscle cells. Inhibitors of PKC are therefore likely to effect signaling pathways in several cell types unless the inhibitor shows isozyme specificity. Thus, inhibitors of PKC can be predicted to be effective in blocking the proliferative response of smooth muscle cells and may also have an anti-inflammatory effect in blocking neutrophil activation and subsequent attachment. Several inhibitors have been described and initial reports indicate an IC_{50} of 50 μ M for calphostin C inhibitory activity. G-6203 (also known as Go 6976) is a new, potent PKC inhibitor with high selectivity for certain PKC isotypes with IC_{50} values in the 2-10 μ M range. Concentrations of these and another drug, GF 109203x, also known as Go 6850 or bisindolylmaleimide I (available from Warner-Lambert), that are believed to be suitable for use in the present invention are set forth below.

TABLE 27

Therapeutic and Preferred Concentrations of Receptor Tyrosine Kinase Agents		
Class of Agent	Therapeutic/Preferred Concentrations (Nanomolar)	More preferred (Nanomolar)
Protein Kinase C Inhibitors:		
calphostin C	0.5-50,000/100-5,000	500
GF 109203x	0.1-10,000/1-1,000	100
G-6203 (Go 6976)	0.1-10,000/1-1,000	100

b. Protein Tyrosine Kinase Inhibitors

[0215] Although there is a tremendous diversity among the numerous members of the receptor tyrosine-kinase (RTK) family, the signaling mechanisms used by these receptors share many common features. Biochemical and molecular genetic studies have shown that binding of the ligand to the extracellular domain of the RTK rapidly activates the intrinsic tyrosine kinase catalytic activity of the intracellular domain (see FIG. 5). The increased activity results in tyrosine-specific phosphorylation of a number of intracellular substrates which contain a common sequence motif. Consequently, this causes activation of numerous "downstream" signaling molecules and a cascade of intracellular pathways that regulate phospholipid metabolism, arachidonic acid metabolism, protein phosphorylation (involving mechanisms other than protein kinases), calcium mobilization and transcriptional activation (see FIG. 2). Growth-factor-dependent tyrosine kinase activity of the RTK cytoplasmic domain is the primary mechanism for generation of intracellular signals that lead to cellular proliferation. Thus, inhibitors have the potential to block this signaling and thereby prevent the proliferative response (see FIG. 5).

[0216] The platelet-derived growth factor (PDGF) receptor is of great interest as a target for inhibition in the cardiovascular field since it is believed to play a significant role both in atherosclerosis and restenosis. The release of PDGF by platelets at damaged surfaces of endothelium within blood vessels results in stimulation of PDGF receptors on vascular smooth muscle cells. As described above, this initiates a sequence of intracellular events leading to enhanced proliferation and neointimal thickening. An inhibi-

tor of PDGF kinase activity would be expected to prevent proliferation and enhance the probability of success following cardiovascular and general vascular procedures. Any of several related tyrosine kinase compounds have potential as specific inhibitors of PDGF-receptor tyrosine kinase activity (IC_{50} s in vitro in the 0.5-1.0 μ M range), since they have little effect on other protein kinases and other signal transduction systems. To date, only a few of the many tyrosine kinase compounds are commercially available, and suitable concentrations for these agents as used in the present invention are set forth below. In addition, statostrophine has been reported to demonstrate potent inhibitory effects against several protein tyrosine kinases of the src subfamily and a suitable concentration for this agent as used in the present invention also is set forth below.

TABLE 28

Therapeutic and Preferred Concentrations of Receptor Tyrosine Kinase Agents		
Class of Agent	Therapeutic/Preferred Concentrations (Nanomolar)	More preferred (Nanomolar)
Protein Kinase Inhibitors:		
imatinib A	10-100,000/100-10,000	10,000
tyrosinase AG1270	10-100,000/100-10,000	10,000
tyrosinase AG1275	10-100,000/100-10,000	10,000
statostrophine	1-100,000/10-10,000	1,000

2. Modulators of Intracellular Protein Tyrosine Phosphatases

[0217] Non-transmembrane protein tyrosine phosphatases (PTPases) containing src-homology, SH2 domains are known and nomenclature refers to them as SH-PTP1 and SH-PTP2. In addition, SH-PTP1 is also known as PTP1C, HCP or SHP. SH-PTP2 is also known as PTP1D or PTP2C. Similarly, SH-PTP1 is expressed at high levels in hematopoietic cells of all lineages and all stages of differentiation, and the SH-PTP1 gene has been identified as responsible for the motheaten (mo) mouse phenotype and this provides a basis for predicting the effects of inhibitors that would block its interaction with its cellular substrates. Stimulation of neutrophils with chemotactic peptides is known to result in the activation of tyrosine kinases that mediate neutrophil responses (Cui, et al., 1994 J. Immunol.) and PTPase activity modulates agonist induced activity by reversing the effects of tyrosine kinases activated in the initial phases of cell stimulation. Agents that could stimulate PTPase activity could have potential therapeutic applications as anti-inflammatory mediators.

[0218] These same PTPases have also been shown to modulate the activity of certain RTKs. They appear to counter-balance the effect of activated receptor kinases and thus may represent important drug targets. In vitro experiments show that injection of PTPase blocks insulin stimulated phosphorylation of tyrosyl residues on endogenous proteins. Thus, activators of PTPase activity could serve to reverse activation of PDGF-receptor action in restenosis, and are believed to be useful in the solutions of the present invention. In addition, receptor-linked PTPases also function as extracellular ligands, similar to those of cell adhesion

molecules. The functional consequences of the binding of a ligand to the extracellular domain have not yet been defined but it is reasonable to assume that binding would serve to modulate phosphatase activity within cells (Fasbender and Zinn, 1995, *Current Biology*, 5, 1367-1369). Such actions could block adhesion mediated by other cell surface adhesion molecules (NCAM) and provide an anti-inflammatory effect. No drugs have been developed yet for these applications.

3. Inhibitors of SH2 Domains (src Homology₂ Domains)

[0219] SH2 domains, originally identified in the *src* subfamily of protein tyrosine kinases (PTKs), are noncatalytic protein sequences and consist of about 100 amino acids conserved among a variety of signal transducing proteins (Cohen, et al., 1995). SH2 domains function as phosphotyrosine-binding modules and thereby mediate critical protein-protein associations in signal transduction pathways within cells (Pawson, Nature, 373:580, 1995). In particular, the role of SH2 domains has been clearly defined as critical for receptor tyrosine kinase (RTK) mediated signaling such as in the case of the platelet-derived growth factor (PDGF) receptor. Phosphotyrosine-containing sites on autophosphorylated RTKs serve as binding sites for SH2-proteins and thereby mediate the activation of biochemical signaling pathways (see FIG. 2) (Carpenter, G., FASEB J. 6:3283-3289, 1992; Sierke, S. and Koland, J. Biochem. 32:10102-10108, 1993). The SH2 domains are responsible for coupling the activated growth-factor receptors to cellular responses which include alterations in gene expression, and ultimately cellular proliferation (see FIG. 5). Thus, inhibitors that will selectively block the effects of activation of specific RTKs expressed on the surface of vascular smooth muscle cells are predicted to be effective in blocking proliferation and the restenosis process after PTCA or other vascular procedures. One RTK target of current interest is the PDGF receptor.

[0220] At least 20 cytosolic proteins have been identified that contain SH2 domains and function in intracellular signaling. The distribution of SH2 domains is not restricted to a particular protein family, but found in several classes of proteins, protein kinases, lipid kinases, protein phosphatases, phospholipases, Ras-controlling proteins and some transcription factors. Many of the SH2-containing proteins have known enzymatic activities while others (Grb2 and Crk) function as "linkers" and "adaptors" between cell surface receptors and "downstream" effector molecules (Marengere, L., et al., Nature 369:502-505, 1994). Examples of proteins containing SH2 domains with enzymatic activities that are activated in signal transduction include, but are not limited to, the *src* subfamily of protein tyrosine kinases (see pp60^{src}), abl, lck, fyn, fgr and others), phospholipaseCγ (PLCγ), phosphatidylinositol 3-kinase (PI-3-kinase), p21-ras GTPase activating protein (GAP) and SH2 containing protein tyrosine phosphatases (SH-PTases) (Seungyang, et al., Cell 72, 767-778, 1993). Due to the central role these various SH2-proteins occupy in transmitting signals from activated cell surface receptors into a cascade of additional molecular interactions that ultimately define cellular responses, inhibitors which block specific SH2 protein binding are desirable as agents for a variety of potential therapeutic applications.

[0221] In addition, the regulation of many immune/inflammatory responses is mediated through receptors that transmit signals through non-receptor tyrosine kinases containing SH2 domains. T-cell activation via the antigen specific T-cell receptor (TCR) initiates a signal transduction cascade leading to lymphokine secretion and T-cell proliferation. One of the earliest biochemical responses following TCR activation is an increase in tyrosine kinase activity. In particular, neutrophil activation is in part controlled through responses of the cell surface immunoglobulin G receptors. Activation of these receptors mediates activation of unidentified tyrosine kinases which are known to possess SH2 domains. Additional evidence indicates that several *src*-family kinases (lck, blk, fyn) participate in signal transduction pathways leading from cytokine and integrin receptors and hence may serve to integrate stimuli received from several independent receptor structures. Thus, inhibitors of specific SH2 domains have the potential to block many neutrophil functions and serve as anti-inflammatory mediators.

[0222] Efforts to develop drugs targeted to SH2 domains currently are being conducted at the biochemical in vitro and cellular level. Should such efforts be successful, it is theorized that the resulting drugs would be useful in the practice of the present invention.

4. Calcium Channel Antagonists

[0223] Calcium channel antagonists, previously described with relation to spasm inhibitory functions, also can be used as anti-restenotic agents in the cardiovascular and general vascular solutions of the present invention. Activation of growth factor receptors, such as PDGF, is known to result in an increase in intracellular calcium (see FIG. 2). Studies at the cellular level have shown that actions of calcium channel antagonists are effective at inhibiting mitogenesis of vascular smooth muscle cells.

F. Synergistic Interactions Derived from Therapeutic Combinations of Anti-Restenosis Agents and Other Agents Used in Cardiovascular and General Vascular Solutions

[0224] Given the complexity of the disease process associated with restenosis after PTCA or other cardiovascular or general vascular therapeutic procedure and the multiplicity of molecular targets involved, blockade or inhibition of a single molecular target is unlikely to provide adequate efficacy in preventing vasospasm and restenosis (see FIG. 2). Indeed, a number of animal studies targeting different individual molecular receptors and/or enzymes have not proven effective in animal models or have not yielded efficacy for both pathologies in clinical trials to date. (Freed, M., et al., *An Intensive Poly-pharmaceutical Approach to the Prevention of Restenosis: the Mervacor, Ace Inhibitor, Colchicine (BIG-MAC) Pura Trial*, J. Am. Coll. of Cardiol. 21, p. 33A, (1993); Serruya, P., et al., *PARK: the Post Angioplasty Restenosis Ketanserin Trial*, J. Am. Coll. of Cardiol. 21, p. 322A, (1993). Therefore, a therapeutic combination of drugs acting on distinct molecular targets and delivered locally appears necessary for clinical effectiveness in the therapeutic approach to vasospasm and restenosis. As described below, the rationale for this synergistic molecular targeted therapy is derived from recent advances in understanding fundamental biochemical mechanisms by which

vascular smooth muscle cells in the vessel wall transmit and integrate stimuli to which they are exposed during PTCA or other vascular interventional procedure.

1. "Crosstalk" and Convergence in Major Signaling Pathways

[0225] The molecular switches responsible for cell signaling have been traditionally divided into two major discrete signaling pathways, each comprising a distinct set of protein families that act as transducers for a particular set of extracellular stimuli and mediating distinct cell responses. One such pathway transduces signals from neurotransmitters and hormones through G-protein coupled receptors (GPCRs) to produce contractile responses using intracellular targets of trimeric G proteins and Ca^{2+} (see FIG. 2). These stimuli and their respective receptors mediate smooth muscle contraction and may induce vasospasm in the context of PTCA or other cardiovascular or general vascular therapeutic or diagnostic procedures. Examples of signaling molecules involved in mediating spasm through the GPCR pathway are 5-HT and endothelin for which antagonists have been included acting via their respective G-protein coupled receptors.

[0226] A second major pathway transduces signals from growth factors, such as PDGF, through tyrosine kinases, adaptor proteins and the Ras protein into regulation of cell proliferation and differentiation (see FIGS. 2 and 5). This pathway may also be activated during PTCA or other cardiovascular or general vascular procedure leading to a high incidence of vascular smooth muscle cell proliferation. An example of a restenosis drug target is the PDGF-receptor.

[0227] Signals transmitted from neurotransmitters and hormones stimulate either of two classes of receptors. G-protein-coupled receptors, composed of seven-beta transmembrane regions, or ligand-gated ion channels. "Downstream" signals from both kinds of receptors converge on controlling the concentration of cytoplasmic Ca^{2+} which triggers contraction in smooth muscle cells (see FIG. 2). Each GPCR transmembrane receptor activates a specific class of trimeric G proteins, including G_q , G_i or many others. G_i and/or G_{12} subunits activate phospholipase C_α , resulting in activation of protein kinase C (PKC) and an increase in the levels of cytoplasmic calcium by release of calcium from intracellular stores.

[0228] Growth factor signaling, such as mediated by PDGF, converges on regulation of cell growth. This pathway depends upon phosphorylation of tyrosine residues in receptor tyrosine kinases and "downstream" enzymes (phospholipase C_α , discussed above with regard to tyrosine kinases). Activation of the PDGF-receptor also leads to stimulation of PKC and elevation of intracellular calcium, common steps shared by the GPCRs (see FIG. 2). It is now recognized that ligand-independent "crosstalk" can transactivate tyrosine kinase receptor pathways in response to stimulation of GPCRs. Recent work has identified Shc, an adaptor protein in the tyrosine kinase/Ras pathway, as a key intermediary protein that relays messages from the GPCR pathway described above to the tyrosine kinase pathway (see FIG. 2) (Lee et al., 1993, Nature 376:737). Activation of Shc is calcium dependent. Thus, a combination of selective inhibitors which blocks transactivation of a common signaling pathway leading to vascular smooth muscle cell proliferation

will act synergistically to prevent spasm and restenosis after PTCA or other cardiovascular or general vascular procedure. Specific examples are briefly detailed below.

2. Synergistic Interactions Between PKC Inhibitors and Calcium Channel Antagonists

[0229] In this case synergistic interactions among PKC inhibitors and calcium channel antagonists in achieving vasorelaxation and inhibition of proliferation occur due to "crosstalk" between GPCR and tyrosine kinase signaling pathways (see FIG. 2). A rationale for dual use is based upon the fact that these drugs have different molecular mechanisms of action. As described above, GPCR stimulation results in activation of protein kinase C and an increase in the levels of cytoplasmic calcium by release of calcium from intracellular stores. Calcium-activated PKC is a central control point in the transmission of extracellular responses. "Crosstalk" from GPCR stimulated pathways through PKC can lead to mitogenesis of vascular smooth muscle cells and thus calcium channel antagonists will have the dual action of directly blocking spasm and further preventing activation of proliferation by inhibiting Shc activation. Conversely, the PKC inhibitor acts on part of the pathway leading to contraction.

3. Synergistic Effects of PKC Inhibitors, 5-HT₂ Antagonists and ET_A Antagonists

[0230] The 5-HT₂ receptor family contains three members designated 5-HT_{2A}, 5-HT_{2B}, and 5-HT_{2C}, all of which share the common property of being coupled to phosphatidylinositol turnover and increases in intracellular calcium (Hoyer et al., 1988, Hartig et al., 1989). The distribution of these receptors includes vascular smooth muscle and platelets and, due to their localization, these 5-HT receptors are important in mediating spasm, thrombosis and restenosis. It has been found that the sustained phase of intracellular calcium elevation in smooth muscle cells induced by ET_A receptor activation requires extracellular calcium and is at least partially blocked by nifedipine. Since activation of both 5-HT₂ receptors and ET_A receptors is mediated through calcium, the inclusion of a PKC inhibitor is expected to synergistically enhance the actions of antagonists to both of these receptors when combined in a surgical solution (see FIGS. 2 and 4).

4. Synergistic Effects of Protein Tyrosine Kinase Inhibitors and Calcium Channel Antagonists

[0231] The mitogenic effect of PDGF (or basic fibroblast growth factor or insulin-like-growth-factor-1) is mediated through receptors that possess intrinsic protein tyrosine kinase activity. The substrates for PDGF phosphorylation are many and lead to activation of mitogen-activated protein kinases (MAPK) and ultimately proliferation (see FIG. 5). The endothelin, 5-HT and thrombin receptors, which are members of the G-protein coupled superfamily, trigger a signal transduction pathway which includes increases in intracellular calcium, leading to activation of calcium channels on the plasma membrane. Thus, calcium channel antagonists interfere with a common mechanism employed by these GPCRs. It has recently been shown that activation of certain GPCRs, including endothelin and bradykinin, leads to a rapid increase in tyrosine phosphorylation of a number of intracellular proteins. Some of the proteins phos-

255
254

phorylated parallel these known necessary for mitogenic stimulation. The rapidity of the process was such that changes were detectable in seconds and the targets acted upon likely play a role in mitogenesis. These tyrosine phosphorylation events were not blocked by a selective PKC inhibitor or apparently mediated by increased intracellular calcium. Thus, since two independent pathways, the GPCR and tyrosine phosphorylation pathways, can drive the vascular smooth muscle cells into a proliferative state, it is necessary to block both independent signaling arms. This is the basis for the synergistic interaction between calcium channel antagonists and tyrosine kinase inhibitors in the surgical solution. Because the actions of the protein tyrosine kinase inhibitors in preventing vascular smooth muscle cell proliferation occur via independent molecular pathways (described above) from those involving calcium and protein kinase C, the combination of the two classes of drugs, calcium channel antagonists and protein tyrosine kinase inhibitors, is expected to be more efficacious in inhibiting spasm and restenosis than employing either single class of drug alone.

5. Synergistic Effects of Protein Tyrosine Kinase Inhibitors and Thrombin Receptor Antagonists

[0232] Thrombin mediates its action via the thrombin receptor, another member of the GPCR superfamily. Binding to the receptor stimulates platelet aggregation, smooth muscle cell contraction and mitogenesis. Signal transduction occurs through multiple pathways: activation of phospholipase (PLC) through G proteins and activation of tyrosine kinases. The activation of tyrosine kinase activity is also essential for mitogenesis of the vascular smooth muscle cells. Experiments have shown that inhibition with a specific tyrosine kinase inhibitor was effective in blocking thrombin-induced mitosis, although there were no effects on the PLC pathway as monitored by measurement of intracellular calcium (Weiss and Nuccitelli, 1992, *J. Biol. Chem.* 267:5603-5613). Because the actions of the protein tyrosine kinase inhibitors in preventing vascular smooth muscle cell proliferation occur via independent molecular pathways (described above) from those involving calcium and protein kinase C, the combination of protein tyrosine kinase inhibitors and thrombin receptor antagonists is anticipated to be more efficacious in inhibiting platelet aggregation, spasm and restenosis than employing either class of agent alone.

[0233] G. Cyclooxygenase-2 (COX-2) Inhibitors

[0234] Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used as anti-inflammatory, anti-pyretic, anti-thrombotic and analgesic agents (Lewis, R. A., *Prostaglandins and Leukotrienes*, in: *Textbook of Rheumatology*, 3d ed. (Kelley W., et al., eds.), p. 258 (1989). The molecular target for these drugs is the first enzyme in the prostaglandin synthetic pathway, referred to as prostaglandin endoperoxide synthase, or fatty acid cyclooxygenase. It is now appreciated that there are two forms of cyclooxygenase, termed cyclooxygenase-1 or type 1 (COX-1) and cyclooxygenase-2 or type 2 (COX-2). These isozymes are also known as Prostaglandin H Synthase (PGHS)-1 and PGHS-2, respectively. Both enzymes catalyze the conversion of arachidonic acid to unstable intermediates, PGG_2 and PGH_2 , which are intermediates in the biosynthesis of prostaglandins and thromboxanes. COX-1 is present in platelets and endothelial cells and exhibits constitutive activity. COX-2 has been

identified in endothelial cells, macrophages and fibroblasts, including synovial cells after treatment (induction) with cytokines.

[0235] The COX-2 isozyme is induced in settings of inflammation by cytokines and inflammatory mediators, such as IL-1, TNF- α and endotoxin, and its expression is upregulated at sites of inflammation. The large increase in activity of COX-2 above basal COX-1 activity concomitant with its upregulation, leads to synthesis of prostaglandins which contribute to pain and inflammation. Because COX-2 is usually expressed only in inflamed tissue or after exposure to mediators of inflammation, selective inhibitors may exhibit anti-inflammatory activity without simultaneous effects on constitutively expressed COX-1 activity present in platelets and other cell types which is considered the cause of undesirable side effects associated with use of nonselective NSAID drugs (e.g., clotting time, bleeding, renal and gastrointestinal).

[0236] It has been established that the two COX isozymes are pharmacologically distinct and therefore it has been possible to develop isozyme-specific (selective) cyclooxygenase inhibitors that are useful for anti-inflammatory therapy. A variety of biochemical, cellular and animal assays have been developed to assess the relative selectivity of inhibitors for the COX-1 and COX-2 isoforms. These assays include measurements of prostaglandin E₂ production in microsomes prepared from various cell types and bioassay systems using intact human cells. For any given drug, despite experimental variation in the degree of selectivity noted among assay systems and between biological sources, compounds that are selective inhibitors for COX-2 have been identified. In general, a criteria for defining selectivity is the ratio of the COX-1/COX-2 inhibitory constants (or COX-2/COX-1) obtained for a given biochemical or cellular assay system. The selectivity ratio accounts for different absolute IC_{50} values for inhibition of enzymatic activity that are obtained between microsomal and cellular assay systems (e.g., platelets and macrophages, cell lines stably expressing recombinant human COX isozymes).

[0237] Many of the conventional NSAIDs currently on the market (naproxen, indomethacin, ibuprofen) are generally nonselective inhibitors of both isoforms of COX, but may show greater selectivity for COX-1 over COX-2, although this ratio varies for the different compounds. The use of a COX-2 inhibitor to block formation of prostaglandins represents a preferred therapeutic strategy rather than attempting to block interactions of the endogenous prostanoid ligands, (such as PGE_2 , which are produced by COX-2 at the inflammatory site, with any of the eight described subtypes of prostanoid receptors. This approach is not currently feasible since selective and potent antagonists for all of the of the prostanoid receptors (EP-1, EP-2, EP-3, EP-4, DP, FP, IP and TP) do not exist.

[0238] A study by Riendeau and coworkers compared the selectivity of more than 45 NSAIDs and selective COX-2 inhibitors using sensitive microsomal and platelet assays for the inhibition of human COX-1 based on the production of prostaglandin E₂ by microsomes (Can J. Physiol. Pharmacol. (1997) 75:1088-95). In this study, among the compounds that were reported to show selectivity for COX-2 vs. COX-1, the rank order of potency was DuP 697>SC-58451, celecoxib>nimesulide>rofecoxib>piroxicam>NS-398=

286
125

RS-570675-SF*, 570665-SF*, S8125-fluoride-encapsul-).

745,337>US-U-7-614, with IC_{50} values ranging from 7 μ M to 17 μ M. A good correlation was obtained between the IC_{50} values for the inhibition of intraneural COX-1 and both the inhibition of TXB₂ production by Ca^{2+} ionophore challenged platelets and the inhibition of prostaglandin E₂ production by CHO cells stably expressing human COX-1. The intraneural assay was more sensitive to inhibition than cell-based assays and allowed the detection of inhibitory effects on COX-1 for all NSAIDs and selective COX-2 inhibitors examined with discrimination of their potency under conditions of limited availability of arachidonic acid.

[0229] From the molecular and cellular mechanisms of action defined for selective COX-2 inhibitors, such as carbonic, as well as natural studies, these compounds are expected to exhibit anti-inflammatory action when applied intraperitoneally in an irrigation solution directly to a tissue or a joint. In particular, it is expected to be an effective drug delivered by an irrigation solution during an arthroscopic, arthrologic, cardiovascular or general surgical procedure (perioperatively). For example, a selective COX-2 inhibitor may replace ketorolac, a relatively non-selective cyclooxygenase inhibitor, in Examples IV, V & VI. The selective COX-2 inhibitor may be delivered alone, or in combination with other small molecule drugs, peptides, proteins, recombinant enzyme proteins, antibodies, or gene therapy vectors (viral and nonviral) to the spaces of the joint, intracapsular tract, cardiovascular system or any cavity of the body. For example, the selective COX-2 inhibitor can exert its actions on any cells associated with the fluid spaces of the joint and structures comprising the joint, and which are involved in the normal function of the joint or are present due to a pathological condition. These cells and structures include, but are not limited to: synovial cells including both Type A fibroblast and type B macrophage cells; the cartilaginous components of the joint such as chondrocytes; cells associated with bone, including perivascular cells, osteoblasts, osteocytes, the immunological components such as inflammatory cells including lymphocytes, mast cells, macrophages, eosinophils, and other cells like fibroblasts, and combinations of the above cell types.

[0240] The selective COX-2 inhibitor may be delivered in a formulation useful for immersion and administration of the drug into the targeted tissue or joint that would enhance the delivery, uptake, stability or pharmacokinetics of the inhibitor drug. The formulations could include, but is not limited to, solubilizers using microparticles, microspheres or nanoparticles composed of lipids, proteins, carbohydrates, synthetic organic compounds, or inorganic compounds. Examples of formulation molecules include, but are not limited to, lipids capable of forming liposomes or other ordered lipid structures, esthetic lipids, hydrophilic polymers, polyurethanes (e.g. polyurethane, polyurethane, polyurethane), peptide or synthetic ligands and antibodies capable of targeting materials to specific cell types, gels, slow release matrices, soluble and insoluble particles, as well as formulation elements not listed.

[0241] The present invention describes the local delivery of a selective COX-2 inhibitor drug using an irrigation solution containing the drug which is present at low concentration and which enables the drug to be delivered directly to the affected tissue or joint. The drug-containing irrigation solution is employed perioperatively during a

surgical procedure. Other conventional methods used for drug delivery have required systemic administration (e.g., intramuscular, intravenous, subcutaneous, oral) which necessitates higher concentrations of COX-2 drugs (and higher total dose) to be administered in order to achieve significant therapeutic concentrations in the targeted tissue or joint. Systemic administration also results in high concentrations in tissues other than the targeted tissue which is undesirable and, depending on the dose, may result in adverse side effects (e.g., bleeding, ulceration). These systemic methods of delivery also subject the drug to second pass metabolism and rapid degradation, thereby limiting the duration of the effective therapeutic concentration. The drug in the irrigation solution is administered directly to the desired tissue which provides a significant advantage by allowing the delivery of the selective COX-2 inhibitor drug in a therapeutically effective lower concentration and therapeutically effective lower total dose than by other routes of administration. Furthermore, the use of a COX-2 inhibitor in the solution in substantially lower dosages than currently used perioperatively may allow the use of this drug in otherwise contraindicated patients.

[0242] Compounds suitable for the invention are listed in the Table below.

TABLE 39

Compound	Cytotoxicity: LD_{50} in mice	
	Therapeutic Potential (Concentration, μ M)	Medicinal Potential (Concentration, μ M)
DSP 977	0.3-3.000	600
SC-55831	3.3-1.201	600
valerolac	0.2-0.002	600
metenolone	0.2-0.000	500
valerolac	0.2-0.002	500
diclofenac	0.2-0.000	600
NS-398	0.2-0.002	600
L-765,357	0.2-0.002	1000
SC-58129	0.2-0.002	1000
SC-57666	0.2-0.002	1000
L-66246	0.2-0.002	1000

V. Method of Application

[0243] The solution of the present invention has applications for a variety of operative/interventional procedures, including surgical, diagnostic and therapeutic techniques. The irrigation solution is perioperatively applied during arthroscopic surgery of anatomic joints, arthrological procedures, cardiovascular and general vascular diagnostic and therapeutic procedures and for general surgery. As used herein, the term "perioperative" encompasses application intraprecedurally, pre- and intraoperatively, intra- and postoperatively, and pre-, intra- and postoperatively. Preferably the solution is applied preoperatively and/or postoperatively as well as intraoperatively. Such procedures conventionally utilize physiological irrigation fluids, such as normal saline or lactated Ringer's, applied to the surgical site by techniques well known in those of ordinary skill in the art. The method of the present invention involves substituting the anti-pain/anti-inflammatory/anti-spasmodic/analgesic irrigation solutions of the present invention for conventionally applied irrigation fluids. The irrigation solution is applied to the wound or surgical site prior to the

initiation of the procedure, preferably before tissue trauma, and continuously throughout the duration of the procedure, to preemptively block pain and inflammation, spasm and nociception. As used hereto throughout, the term "irrigation" is intended to mean the flushing of a wound or anatomic structure with a stream of liquid. The term "application" is intended to encompass irrigation and other methods of locally introducing the solution of the present invention, such as introducing a gelfoam version of the solution to the operative site, with the gelled solution then remaining at the site throughout the procedure. As used herein throughout, the term "continuously" is intended to also include situations in which there is repeated and frequent irrigation of wounds at a frequency sufficient to maintain a predetermined therapeutic local concentration of the applied agent, and applications in which there may be intermittent cessation of irrigation until flow is restarted by operating technique.

[0244] The concentrations listed for each of the agents within the solutions of the present invention are the concentrations of the agents delivered locally, in the absence of metabolic transformation, to the operative site in order to achieve a predetermined level of effect at the operative site. It is understood that the drug concentrations in a given solution may need to be adjusted to account for local dilution upon delivery. For example, in the cardiovascular application, if one assumes an average human coronary artery blood flow rate of 80 cc per minute and an average delivery rate for the solution of 5 cc per minute via a local delivery catheter (i.e., a blood flow-to-solution delivery ratio of 16 to 1), one would require that the drug concentrations within the solution be increased 16-fold over the desired *in vivo* drug concentrations. Solution concentrations are not adjusted to account for metabolic transformations or dilution by local body distribution because these circumstances are avoided by local delivery, as opposed to oral, intravenous, subcutaneous or intramuscular application.

[0245] Arthroscopic techniques for which the present solution may be employed include, by way of non-limiting example, partial meniscectomies and ligament reconstructions to the knee, shoulder arthroplasties, rotator cuff debridements, elbow arthroplasties, and wrist and ankle arthroplasties. The irrigation solution is continuously supplied intraoperatively to the joint at a flow rate sufficient to dislodge the joint capsule, to remove operative debris, and to enable unobstructed intra-articular visualization.

[0246] A suitable irrigation solution for control of pain and edema during such arthroscopic techniques is provided in Example I herein below. For arthroscopy, it is preferred that the solution include a combination, and preferably all, or any of the following: a anesthetic, receptor antagonist, a serotonin receptor agonist, a histamine, receptor antagonist, a serotonin receptor agonist acting on the 1A, 1B, 1D, 1F and/or 1E receptors, a bradykinin, receptor antagonist, a bradykinin, receptor agonist, and a cyclooxygenase inhibitor.

[0247] This solution utilizes extremely low doses of these pain and inflammation inhibitors, due to the local application of the agents directly to the operative site during the procedure. For example, less than 0.05 mg of amitriptyline (a suitable anesthetic and histamine, "anal" receptor antagonist) are needed per liter of irrigated fluid to provide the desired effective local tissue concentrations that would

inhibit 5-HT₁ and 11₁ receptors. This dosage is extremely low relative to the 10-25 mg of oral amitriptyline that is the usual starting dose for this drug. This same rationale applies to the anti-spasm and anti-nociception agents which are utilized in the solution of the present invention to reduce spasm associated with neurologic, cardiovascular and general vascular procedures and to inhibit receptors associated with cardiovascular and general vascular procedures. For example, less than 0.2 mg of etodolac (a suitable calcium channel antagonist) is required per liter of irrigated fluid to provide the desired effective local tissue concentrations that would inhibit the voltage-dependent gating of the L-type of calcium channels. This dose is extremely low compared to the single oral dose of etodolac which is 20 to 40 mg.

[0248] In each of the surgical solutions of the present invention, the agents are included in low concentrations and are delivered locally in low doses relative to concentrations and doses required with conventional methods of drug administration to achieve the desired therapeutic effect. It is impossible to obtain an equivalent therapeutic effect by delivering similarly dosed agents via other (i.e., intravenous, subcutaneous, intramuscular or oral) routes of drug administration above drugs given systemically are subject to first- and second-pass metabolism.

[0249] For example, using a rat model of arthroscopy, the inventors examined the ability of amitriptyline, a 5-HT₁ antagonist, to inhibit 5-HT-induced plasma extravasation in the rat knee in accordance with the present invention. This study, described more fully below in Example XII, compared the therapeutic dosing of amitriptyline delivered locally (i.e., intra-articularly) at the knee and intravenously. The results demonstrated that intra-articular administration of amitriptyline required only dosing levels approximately 200-fold less than were required via the intravenous route to obtain the same therapeutic effect. (Note that only a small fraction of the drug delivered intra-articularly is absorbed by the local synovial tissue, the difference in plasma drug levels between the two routes of administration is much greater than the difference in total amitriptyline dosing levels).

[0250] Practice of the present invention should be distinguished from conventional intra-articular injections of opiate and/or local anesthetics at the completion of arthroscopic or "open" joints (e.g., knee, shoulder, etc.) procedures. The solution of the present invention is used for continuous infusion throughout the surgical procedure in provide preemptive inhibition of pain and inflammation. In contrast, the high concentrations necessary to achieve therapeutic efficacy with a constant infusion of local anesthetics, such as bupivacaine (0.5-2% solutions), would result in profound systemic toxicity.

[0251] Upon completion of the procedure of the present invention, it may be desirable to inject or otherwise apply a higher concentration of the same pain and inflammation inhibitors as used in the irrigation solution at the operative site, as an alternative or supplement to systemic.

[0252] The solution of the present invention also has application in cardiovascular and general vascular therapeutic and therapeutic procedures to potentially decrease vessel wall spasm, platelet aggregation, vascular smooth muscle cell proliferation and receptor activation (prevented by vessel manipulation). Reference herein to arterial treatment is intended to encompass the treatment of venous grafts that

257
956

vested and placed in the arterial system. A suitable solution for such techniques is disclosed in Example II herein below. The cardiovascular and general vascular solution preferably includes any combination, and preferably all, of the following: a 5-HT₂ receptor antagonist (Saxena, P. R., et al., *Cardiovascular Effects of Serotonin Inhibitory Agonists and Antagonists*, J Cardiovasc Pharmacol 15 (Suppl. 7), pp. S17-S34 (1990); Douglas, 1985); a 5-HT₂ receptor antagonist to block activation of these receptors on sympathetic neurons and C-fiber nociceptive neurons in the vessel walls, which has been shown to produce brady- and tachycardia (Saxena et al. 1990); a bradykinin₁ receptor antagonist; and a cyclooxygenase inhibitor to prevent production of prostaglandins at tissue injury sites and thereby decreasing pain and inflammation. In addition, the cardiovascular and general vascular solution also preferably will contain a serotonin_{1A} (also known as serotonin_{5A}) antagonist because serotonin_{1A} has been shown to produce significant vascular spasm via activation of the serotonin_{1A} receptors in humans. Kannam, A. J., et al., *Variable Participation of 5-HT_{1A}-Like Receptors and 5-HT₂ Receptors in Serotonin-Induced Contraction of Human Isolated Coronary Arteries*, Circulation 90, pp. 1141-53 (1994). This excitatory action of serotonin_{1A} receptors in vessel walls, resulting in vasoconstriction, is in contrast to the previously-discussed inhibitory action of serotonin_{1A} receptors in neurons. The cardiovascular and general vascular solution of the present invention also may suitably include one or more of the anti-restenosis agents disclosed herein that reduce the incidence and severity of post-procedural restenosis resulting from, for example, angioplasty or rotational atherectomy.

[0253] The solution of the present invention also has utility for reducing pain and inflammation associated with urologic procedures, such as trans-urethral prostate resection and similar urologic procedures. References herein to application of solution to the urinary tract or to the urological structures is intended to include application to the urinary tract per se, bladder and prostate and associated structures. Studies have demonstrated that serotonin, histamine and bradykinin produce inflammation in lower urinary tract tissues. Schwartz, M. M., et al., *Vascular Leakage in the Kidney and Lower Urinary Tract: Effects of Histamine, Serotonin and Bradykinin*, Proc Soc Exp Biol Med 140, pp. 535-539 (1972). A suitable irrigation solution for urologic procedures is disclosed in Example III herein below. The solution preferably includes a combination, and preferably all, of the following: a histamine₁ receptor antagonist to

inhibit histamine-induced pain and inflammation; a 5-HT₂ receptor antagonist to block activation of these receptors on peripheral C-fiber nociceptive neurons; a bradykinin₁ antagonist; a bradykinin₂ antagonist; and a cyclooxygenase inhibitor to decrease pain/inflammation produced by prostaglandins at the tissue injury sites. Preferably an anti-spasm agent is also included to prevent spasm in the urethral canal and bladder wall.

[0254] Some of the solutions of the present invention may suitably also include a gelling agent to produce a dilute gel. This gellable solution may be applied, for example, within the urinary tract or an arterial vessel to deliver a continuous, dilute local predetermined concentration of agents.

[0255] The solution of the present invention may also be employed perioperatively for the inhibition of pain and inflammation in surgical wounds, as well as to reduce pain and inflammation associated with burns. Burns result in the release of a significant quantity of biogenic amines, which not only produce pain and inflammation, but also result in profound plasma extravasation (fluid loss), often a life-threatening component of severe burns. Holliman, C. J., et al., *The Effect of Ketanserin, a Specific Serotonin Antagonist, on Burn Shock Hemodynamic Parameters in a Porcine Burn Model*, J Trauma 23, pp. 867-871 (1983). The solution disclosed in Example I for arthroscopy may also be suitably applied to a wound or burn for pain and inflammation control, and for surgical procedures such as arthroscopy. The agents of the solution of Example I may alternately be included in a paste or salve base, for application to the burn or wound.

VI. EXAMPLES

[0256] The following are several formulations in accordance with the present invention suitable for certain operative procedures (followed by a summary of three clinical studies utilizing the agents of the present invention).

[0257] A. Example I

Irrigation Solution for Arthroscopy

[0258] The following composition is suitable for use in anatomic joint irrigation during arthroscopic procedures. Each drug is solubilized in a carrier fluid containing physiologic electrolytes, such as normal saline or lactated Ringer's solution, as are the remaining solutions described in subsequent examples.

Class of Agent	Drug	Concentration (Nascent as a Therapeutic)		
		Preferred	Most Preferred	
serotonin _{1A} antagonist	ketanserin	0.1-1,000	50-500	100
serotonin _{2A} antagonist	ketanserin	10-10,000	200-2,000	1,000
histamine ₁ antagonist	cimetidine	0.1-1,000	50-500	200
serotonin _{1A} antagonist	ketanserin	1-1,000	10-200	50
agonist				
bradykinin ₁ antagonist	[des-Arg ¹⁰] bradykinin or HOE 140	1-1,000	50-500	200
bradykinin ₂ antagonist	HOE 140	1-1,000	50-500	200

2/29/00

B. Example II

Irrigation Solution for Cardiovascular and General Vascular Therapeutic and Diagnostic Procedures

[0259] The following drugs and concentration ranges in solution in a physiologic carrier fluid are suitable for use in irrigating operative sites during cardiovascular and general vascular procedures.

Class of Agent	Drug	Concentration (Nanosolar) Therapeutic	Preferred	Most Preferred
serotonins, antagonist	metoclopramide	0.1-2,000	50-500	200
serotonins, antagonist	metoclopramide	10-10,000	200-2,000	1,000
serotonins, antagonist	tricyclics	0.1-1,000	50-500	200
tricyclics, antagonist	[des-Arg ¹⁰] derivative of BOC 140	1-1,000	50-500	200
cyclooxygenase inhibitors	ketorolac	100-10,000	500-5,000	3,000

C. Example III

Irrigation Solution for Urologic Procedures

[0260] The following drugs and concentration ranges in solution in a physiologic carrier fluid are suitable for use in irrigating operative sites during urologic procedures.

Class of Agent	Drug	Concentration (Nanosolar) Therapeutic	Preferred	Most Preferred
histamines, antagonist	serotonins	0.1-1,000	50-500	200
serotonins, antagonist	metoclopramide	10-10,000	200-2,000	1,000
tricyclics, antagonist	[des-Arg ¹⁰] derivative of BOC 140	1-1,000	50-500	200
tricyclics, antagonist	tricyclics	0.1-1,000	50-500	200
cyclooxygenase inhibitors	ketorolac	100-10,000	500-5,000	3,000

D. Example IV

Irrigation Solution for Arthroscopy, Burns, General Surgical Wounds and Oral/Dental Applications

[0261] The following composition is preferred for use in anatomic irrigation during arthroscopic and oral/dental pro-

cedures and the management of burns and general surgical wounds. While the solution set forth in Example I is suitable for use with the present invention, the following solution is even more preferred because of expected higher efficacy.

Class of Agent	Drug	Concentration (Nanosolar) Therapeutic	Preferred	Most Preferred
serotonins, antagonist	metoclopramide	0.1-1,000	50-500	200
serotonins, antagonist	metoclopramide	10-10,000	200-2,000	1,000
histamines, antagonist	tricyclics	0.1-1,000	50-500	200
serotonins, antagonist	tricyclics	1-1,000	50-500	200
tricyclics, antagonist	tricyclics	100-10,000	500-5,000	3,000

2/29/2009

-continued

Class of Agent	Drug	Concentration (Nanosolar) Therapeutic	Preferred	Most Preferred
neurakine, antagonist	GR 82334	1-1,000	10-500	200
neurakine, antagonist	(*) SR 47968	1-1,000	10-500	200
protein ₂ antagonist	PPADS	100-100,000	10,000-100,000	50,000
ATP-sensitive K ⁺ channel agonist	(-) picrotoxin	1-10,000	100-1,000	500
Ca ²⁺ channel antagonist	nifedipine	1-10,000	100-5,000	1,000
calcium channel antagonist	apocynin	0.1-1,000	50-500	200

E. Example V

Alternate Irrigation Solution for Cardiovascular and General Vascular Therapeutic and Diagnostic Procedures

[0262] The following drugs and concentration ranges in solution in a physiologic carrier fluid are preferred for use in irrigating operative sites during cardiovascular and general vascular procedures. Again, this solution is preferred relative to the solution set forth in Example II above for higher efficacy.

Class of Agent	Drug	Concentration (Nanosolar) Therapeutic	Preferred	Most Preferred
anesthetics, antagonist	propofol	0.1-2,000	50-500	200
cyclooxygenase inhibitor	ketorolac	100-10,000	500-5,000	3,000
endothelin antagonist	BQ 123	0.01-1,000	10-1,000	500
ATP-sensitive K ⁺ channel agonist	(-) picrotoxin	1-10,000	100-1,000	500

-continued

Class of Agent	Drug	Concentration (Nanosolar) Therapeutic	Preferred	Most Preferred
Ca ²⁺ channel antagonist	nifedipine	1-10,000	100-1,000	500
nitric oxide donor	SN-1	10-10,000	100-1,000	500

F. Example VI

Alternate Irrigation Solution for Urologic Procedures

[0263] The following drugs and concentration ranges in solution in a physiologic carrier fluid are preferred for use in irrigating operative sites during urologic procedures. The solution is believed to have even higher efficacy than the solution set forth in prior Example III.

Class of Agent	Drug	Concentration (Nanosolar) Therapeutic	Preferred	Most Preferred
anesthetics, antagonist	LY 53857	0.1-500	1-100	50
flavonoid, antagonist	terfenadine	0.1-1,000	50-500	200
cyclooxygenase inhibitor	ketorolac	100-10,000	500-5,000	3,000
neurakine, antagonist	SR 47968	1-1,000	10-500	200
protein ₂ antagonist	PPADS	100-100,000	10,000-100,000	50,000
ATP-sensitive K ⁺ channel agonist	(-) picrotoxin	1-10,000	100-1,000	500
Ca ²⁺ channel antagonist	nifedipine	1-10,000	100-5,000	1,000
calcium channel antagonist	apocynin	0.1-1,000	50-500	200
nitric oxide donor	SN-1	10-10,000	100-1,000	500

G. Example VII

Cardiovascular and General Vascular
Anti-Restenois Irrigation Solution

[0264] The following drugs and concentration ranges in solution in a physiologic carrier fluid are preferred for use in irrigation during cardiovascular and general vascular therapeutic and diagnostic procedures. The drugs in this preferred solution may also be added at the same concentration to the cardiovascular and general vascular irrigation solutions of Examples II and V described above or Example VIII described below for preferred anti-spasmodic, anti-restenosis, anti-pain/anti-inflammation solutions.

Class of Agent	Drug	Concentration (Nanomolar): Therapeutic	Preferred	Most Preferred
H ₁ antagonist	mepyramine	0.1-1,000	5-200	100
bradykinin ₁ antagonist	[Leu ⁵][des-Arg ¹⁰] kallidin	0.1-500	10-200	100
bradykinin ₂ antagonist	HOE 140	1-1,000	50-500	200
μ -opioid agonist	fentanyl	0.1-500	10-200	100

Class of Agent	Drug	Concentration (Nanomolar): Therapeutic	Preferred	Most Preferred
thrombin inhibitor	bivalirudin	0.2-20,000	2-2,000	200
glycoprotein IIb/IIIa receptor blocker	isegrelate	0.1-10,000 nM	1-1,000 nM	100 nM
PKC inhibitor	GF 109203X*	0.1-10,000	1-1,000	200
protein tyrosine kinase inhibitor	typhostin	10-100,000	200-20,000	10,000

*Also known as Go 6850 or Bisindolymaleimide 1 (available from Wako-Lambert)

H. Example VIII

Alternate Irrigation Solution for Cardiovascular and
General Vascular Therapeutic and Diagnostic
Procedures

[0265] An additional preferred solution for use in cardiovascular and general vascular therapeutic and diagnostic procedures is formulated the same as the previously described formulation of Example V, except that the nitric oxide (NO donor) SIN-1 is replaced by a combination of two agents, FK 409 (NOR-3) and FR 144420 (NOR-4), at the concentrations set forth below:

Class of Agent	Drug	Concentration (Nanomolar): Therapeutic	Preferred	Most Preferred
NO donor	FK 409 (NOR-3)	1-1,000	10-500	250
NO donor	FR 144420 (NOR-4)	10-10,000	100-5,000	1,000

I. Example IX

Alternate Irrigation Solution for Arthroscopy,
General Surgical Wounds, Burns and Oral/Dental
Applications

[0266] An alternate preferred solution for use in irrigation of arthroscopic, general surgical and oral/dental applications is formulated the same as in the previously described Example IV, with the following substitution, deletion and additions at the concentrations set forth below:

[0267] 1) amitriptyline is replaced by mepyramine as the H₁ antagonist;

[0268] 2) the kallikrein inhibitor, aprotinin, is deleted;

[0269] 3) a bradykinin₁ antagonist, [Leu⁵][des-Arg¹⁰] kallidin, is added;

[0270] 4) a bradykinin₂ antagonist, HOE 140, is added; and

[0271] 5) a μ -opioid agonist, fentanyl, is added.

J. Example X

Alternate Irrigation Solution for Urologic
Procedures

[0272] An alternate preferred solution for use in irrigation during urologic procedures is formulated the same as in the previously described Example VI with the following substitution, deletion and additions at the concentrations set forth below:

[0273] 1) SIN-1 is replaced as the NO donor by a combination of two agents:

[0274] a) FK 409 (NOR-3); and

[0275] b) FR 144420 (NOR-4);

[0276] 2) the kallikrein inhibitor, aprotinin, is deleted;

[0277] 3) a bradykinin₁ antagonist, [Leu⁵][des-Arg¹⁰] kallidin, is added; and

[0278] 4) a bradykinin₂ antagonist, HOE 150, is added.

2/3
62

[0283] The diameter measurements were then converted to area measurements by the formula:

$$\text{Area} = (\pi)(\text{Diameter})^2/4.$$

[0284] For calculation of vasoconstriction, baseline values were used to represent the maximum area of the artery and percent vasoconstriction was calculated as: % Vasoconstriction = $\{(\text{Baseline area} - \text{Later time point area}) / \text{Baseline area}\} \times 100$.

4. Statistical Methods

[0285] All values are expressed as mean $\pm$ standard error of the mean. The time course of vasomotor response in

diameters in each segment at the 5 minute, 15 minute and 30 minute time points were similar to the baseline diameters. The balloon dilated segment showed lesser changes in arterial dimension than the proximal and distal segments. The baseline diameter of this segment was 1.82 ± 0.05 mm; the nominal inflated diameter of the balloon used for angioplasty was 2.5 mm and the actual measured inflated diameter of the balloon was 2.20 ± 0.03 mm ($p < 0.0001$ vs. baseline diameter of the balloon treated segment). Thus, the inflated balloon caused circumferential stretch of the balloon dilated segment, but there was only slight increase in lumen diameter from baseline to the 30 minute time point (1.82 ± 0.05 mm to 1.94 ± 0.07 mm, $p = \text{NS}$ by post hoc testing).

TABLE 30

Angiographically Determined Lumen Diameters at the Specified Times Before and After Balloon Dilatation of Normal Iliac Arteries

Segment	Baseline	5 Minute	Immediate Post PTA	15 Minute	30 Minute
Proximal ¹	1.28 ± 0.7	1.03 ± 0.7	$1.81 \pm 0.08^*$	$2.00 \pm .08$	$2.23 \pm .08$
Balloon ²	$1.82 \pm .05$	$1.77 \pm .03$	$1.79 \pm .03$	$1.90 \pm .04$	$1.94 \pm .07$
Distal ³	$1.76 \pm .04$	$1.63 \pm .04^{**}$	$1.93 \pm .04^*$	$1.54 \pm .03$	$1.69 \pm .06$

All measurements in mm. Means $\pm$ SEM. PTA = percutaneous transluminal angioplasty.

¹ $p < 0.0002$ (ANOVA within group comparisons).

² $p = 0.03$ (ANOVA within group comparisons).

³ $p < 0.0011$ (ANOVA within group comparisons; $N = 16$ at all time points).

⁴ $p < 0.01$ versus baseline and 30 minute diameter measurements (Scheffe test for post hoc comparisons).

⁵ $p < 0.01$ versus immediate post PTA measurements (Scheffe test for post hoc comparisons). All other post hoc comparisons were not significant using the $p < 0.01$ threshold.

control arteries was assessed using one way analysis of variance with correction for repeated measures. Post hoc comparison of data between specific time points was performed using the Scheffe test. Once the time points at which significant vasoconstriction occurred had been determined in control arteries, the control and histamine/serotonin receptor antagonist treated arteries were compared at those time points where significant vasoconstriction occurred in control arteries using multiple analysis of variance with treatment group identified as an independent variable. To compensate for the absence of a single a priori stated hypothesis, a p value < 0.01 was considered significant. Statistics were performed using StatSoft for Windows, version 4.5, (StatSoft, Tulsa, Okla.).

5. Results

[0286] The time course of arterial dimension changes before and after balloon angioplasty in normal arteries receiving saline infusion was evaluated in 16 arteries from 8 animals (Table 30). Three segments of each artery were studied: the proximal segment immediately upstream from the balloon dilated segment, the balloon dilated segment and the distal segment immediately downstream from the balloon dilated segment. The proximal and distal segments demonstrated similar patterns of change in arterial dimension: in each, there was significant change in arterial diameter when all time points were compared (proximal segment, $p = 0.0002$ and distal segment, $p < 0.001$, ANOVA). Post hoc testing indicated that the diameters at the immediate post angioplasty time point were significantly less than the diameters at baseline or at the 30 minute time point in each of these segments. On the other hand, the arterial

[0287] Arterial lumen diameters were used to calculate lumen area then the area measurements were used to calculate percent vasoconstriction by comparison of the 5 minute, immediate post angioplasty, 15 and 30 minute data to the baseline measurements. The proximal and distal segment data expressed as percent vasoconstriction are shown in FIG. 9; the changes in the amount of vasoconstriction over time are significant (in the proximal segment, $p = 0.0005$; in the distal segment, $p = 0.0001$, ANOVA). Post hoc testing identifies the vasoconstriction at the immediate post angioplasty time point as significantly different from that present at the 30 minute time point ($P < 0.001$ in both segments). In the distal segment, the immediate post angioplasty vasoconstriction was also significantly less than that at 5 minutes ($p < 0.01$); no other differences in intra-time point comparisons were significant by post hoc testing.

[0288] The luminal changes in control arteries can be summarized as follows: 1) Vasoconstriction with loss of approximately 30% of baseline luminal area occurs in the segments of artery proximal and distal to the balloon dilated segment immediately after balloon dilatation. There are trends to smaller amounts of vasoconstriction in the proximal and distal segments before dilatation and at the 15 minute time point (approximately 7 minutes after dilatation) also but, by the 30 minute time point (approximately 22 minutes after dilatation), a trend towards vasodilatation has replaced the previous vasoconstriction; 2) In the balloon dilated segment, only minor changes in lumen dimensions are present, and, despite the use of a balloon with a signifi-

castly larger inflated diameter than was present in this segment at baseline, there was no significant increase in lumen diameter of the dilated segment. These findings lead to a conclusion that any effects of the putative histamine/serotonin treatment would only be detectable in the proximal and distal segments at the time points where vasoconstriction was present.

[0289] The histamine/serotonin receptor blockade solution was infused into 16 arteries (8 animals); angiographic data was available at all time points in 13 arteries. Heart rate and systolic blood pressure measurements were available in a subset of animals (Table 31). There were no differences in heart rate or systolic blood pressure when the two animal groups were compared within specific time points. Histamine/serotonin treated animals showed trends toward a decrease in the systolic blood pressure from baseline to 30 minutes (-14 ± 5 mm Hg, $p=0.04$) and a lower heart rate (-26 ± 10 , $p=0.05$). Within the control animals, there was no change in heart rate or systolic blood pressure over the duration of the experiment.

TABLE 31

Systolic Blood Pressure and Heart Rate Measurements
in Control and Histamine/Serotonin Treated Animals

Group	Baseline (N)	5 Minute (N)	15 Minute (N)	30 Minute (N)
Systolic Blood Pressure				
Control	83 ± 4 (8)	84 ± 4 (8)	87 ± 3 (8)	89 ± 4 (8)
Histamine/Serotonin	83 ± 5 (6)	87 ± 9 (4)	82 ± 9 (6)	80 ± 8 (6)*
Heart Rate				
Control	221 ± 18 (5)	224 ± 18 (4)	217 ± 23 (5)	227 ± 22 (5)
Histamine/Serotonin	232 ± 8 (5)	232 ± 8 (5)	209 ± 14 (5)	206 ± 12 (5)**

Systolic blood pressure in mm Hg and heart rate in beats per minute. Mean $\pm$ SEM.

* $p=0.04$ for decrease in systolic blood pressure from baseline to 30 minutes.

** $p=0.05$ for decrease in heart rate from baseline to 30 minutes within the histamine/serotonin treated animals.

[0290] The proximal and distal segments of histamine/serotonin treated arteries were compared to control arteries using the percent vasoconstriction measurement. FIG. 10A shows the effects of the histamine/serotonin infusion on proximal segment vasoconstriction relative to the vasoconstriction present in the control arteries. When the findings in the two treatment groups were compared at the baseline, immediate post angioplasty and 15 minute time points, histamine/serotonin infusion resulted in significantly less vasoconstriction compared to the control saline infusion ($p=0.003$, 2-way ANOVA). Comparison of the two treatment groups in the distal segment is illustrated in FIG. 10B. Despite observed differences in mean diameter measurements in the distal segment, saline treated vessels exhibited less vasoconstriction than saline treated control vessels at baseline, immediate post-angioplasty and 15 minute time points, this pattern did not achieve statistical significance ($p=0.32$, 2-way ANOVA). Lack of statistical significance may be attributed to smaller than expected vasoconstriction values in the control vessels.

1. Example XII

Amiripryline Inhibition of 5-Hydroxytryptamine-Induced Knee Joint Plasma Extravasation—Comparison of Intra-Articular Versus Intravenous Routes of Administration

[0291] The following study was undertaken in order to compare two routes of administration of the 5-HT₂ receptor antagonist, amiripryline: 1) continuous intra-articular infusion; versus 2) intravenous injection, in a rat knee synovial model of inflammation. The ability of amiripryline to inhibit 5-HT-induced joint plasma extravasation by comparing both the efficacy and total drug dose of amiripryline delivered via each route was determined.

1. Animals

[0292] Approval from the Institutional Animal Care Committee at the University of California, San Francisco was obtained for these studies. Male Sprague-Dawley rats (Bentley and Kiegan, Fremont, Calif.) weighing 300-450 g were used in these studies. Rats were housed under controlled

lighting conditions (lights on 6 A.M. to 6 P.M.), with food and water available ad libitum.

2. Plasma Extravasation

[0293] Rats were anesthetized with sodium pentobarbital (65 mg/kg) and then given a tail vein injection of Evans Blue dye (50 mg/kg in a volume of 2.5 ml/kg), which is used as a marker for plasma protein extravasation. The knee joint capsule was exposed by excising the overlying skin, and a 30-gauge needle was inserted into the joint and used for the infusion of fluid. The infusion rate (250 μ l/min) was controlled by a Sage Instruments Syringe pump (Model 341B, Orion Research Inc., Boston, Mass.). A 25-gauge needle was also inserted into the joint space and peritoneal fluid was extracted at 250 μ l/min, controlled by a Sage Instruments Syringe pump (Model 351).

[0294] The rats were randomly assigned to three groups: 1) those receiving only intra-articular (IA) 5-HT (1 μ M), 2) those receiving amiripryline intravenously (IV) (doses ranging from 0.01 to 1.0 mg/kg) followed by IA 5-HT (1 mM), and 3) those receiving amiripryline intra-articularly

(IA) (concentrations ranging from 1 to 100 μ M) followed by IA 5-HT (1 μ M) plus IA amitriptyline. In all groups, baseline plasma extravasation levels were obtained at the beginning of each experiment by perfusing 0.9% saline intra-articularly and collecting three perfusate samples over a 15 min period (one every 5 min). The first group was then administered 5-HT IA for a total of 25 min. Perfusate samples were collected every 5 min for a total of 25 min. Samples were then analyzed for Evans Blue dye concentration by spectrophotometric measurement of absorbance at 620 nm, which is linearly related to its concentration (Carr and Wilhelm, 1964). The IV amitriptyline group was administered the drug during the tail vein injection of the Evans Blue dye. The knee joints were then perfused for 15 min with saline (baseline), followed by 25 min perfusion with 5-HT (1 μ M). Perfusate samples were collected every 5 min for a total of 25 min. Samples were then analyzed using spectrophotometry. In the IA amitriptyline group, amitriptyline was perfused intra-articularly for 10 min after the 15 min saline perfusion, then amitriptyline was perfused in combination with 5-HT for an additional 25 min. Perfusate samples were collected every 5 min and analyzed as above.

[0295] Some rat knees were excluded from the study due to physical damage of knee joint or inflow and outflow mismatch (detectable by presence of blood in perfusate and high baseline plasma extravasation levels or knee joint swelling due to improper needle placement).

a. 5-HT-Induced Plasma Extravasation

[0296] Baseline plasma extravasation was measured in all knee joints tested (total $n=22$). Baseline plasma extravasation levels were low, averaging 0.022 ± 0.003 absorbance units at 620 nm (average standard error of the mean). This baseline extravasation level is shown in FIGS. 11 and 12 as a dashed line.

[0297] 5-HT (1 μ M) perfused into the rat knee joint produces a time-dependent increase in plasma extravasation above baseline levels. During the 25 min perfusion of 5-HT intra-articularly, maximum levels of plasma extravasation were achieved by 15 min and continued until the perfusion was terminated at 25 min (data not shown). Therefore, 5-HT-induced plasma extravasation levels reported are the average of the 15, 20 and 25 min time points during each experiment. 5-HT-induced plasma extravasation averaged 0.192 ± 0.011 , approximately an 8-fold stimulation above baseline. This data is graphed in FIGS. 11 and 12, corresponding to the "0" dose of IV amitriptyline and the "0" concentration of IA amitriptyline, respectively.

b. Effect of Intravenous Amitriptyline on 5-HT-Induced Plasma Extravasation

[0298] Amitriptyline administered via tail vein injection produced a dose-dependent decrease in 5-HT-induced plasma extravasation as shown in FIG. 11. The IC_{50} for IV amitriptyline inhibition of 5-HT-induced plasma extravasation is approximately 0.025 mg/kg. 5-HT-induced plasma extravasation is completely inhibited by an IV amitriptyline dose of 1 mg/kg, the plasma extravasation averaging 0.034 ± 0.010 .

c. Effect of Intra-Articular Amitriptyline on 5-HT-Induced Plasma Extravasation

[0299] Amitriptyline administered alone in increasing concentrations intra-articularly did not affect plasma

extravasation levels relative to baseline, with the plasma extravasation averaging 0.018 ± 0.002 (data not shown). Amitriptyline co-perfused in increasing concentrations with 5-HT produced a concentration-dependent decrease in 5-HT-induced plasma extravasation as shown in FIG. 12. 5-HT-induced plasma extravasation in the presence of 3 μ M IA amitriptyline was not significantly different from that produced by 5-HT alone, however, 30 μ M amitriptyline co-perfused with 5-HT produced a greater than 50% inhibition, while 100 μ M amitriptyline produced complete inhibition of 5-HT-induced plasma extravasation. The IC_{50} for IA amitriptyline inhibition of 5-HT-induced plasma extravasation is approximately 20 μ M.

[0300] The major finding of the present study is that 5-HT (1 μ M) perfused intra-articularly in the rat knee joint produces a stimulation of plasma extravasation that is approximately 8-fold above baseline levels and that either intravenous or intra-articular administration of the 5-HT₂ receptor antagonist, amitriptyline, can inhibit 5-HT-induced plasma extravasation. The total dosage of administered amitriptyline, however, differs dramatically between the two methods of drug delivery. The IC_{50} for IV amitriptyline inhibition of 5-HT-induced plasma extravasation is 0.025 mg/kg, or 7.5×10^{-5} mg in a 300 g adult rat. The IC_{50} for IA amitriptyline inhibition of 5-HT-induced plasma extravasation is approximately 20 μ M. Since 1 ml of this solution was delivered every five minutes for a total of 35 min during the experiment, the total dosage perfused into the knee was 7 ml, for a total dosage of 4.4×10^{-5} mg perfused into the knee. This IA amitriptyline dose is approximately 200-fold less than the IV amitriptyline dose. Furthermore, it is likely that only a small fraction of the IA perfused drug is systemically absorbed, resulting in an even greater difference in the total delivered dose of drug.

[0301] Since 5-HT may play an important role in surgical pain and inflammation, as discussed earlier, 5-HT antagonists such as amitriptyline may be beneficial if used during the perioperative period. A recent study attempted to determine the effects of oral amitriptyline on post-operative orthopedic pain (Kerrick et al., 1993). An oral dose as low as 50 mg produced undesirable central nervous system side-effects, such as a "decreased feeling of well-being". Their study, in addition, also showed that oral amitriptyline produced higher pain scale scores than placebo ($P<0.05$) in the post-operative patients. Whether this was due to the overall unpleasantness produced by oral amitriptyline is not known. In contrast, an intra-articular route of administration allows an extremely low concentration of drug to be delivered locally to the site of inflammation, possibly resulting in maximal benefit with minimal side-effects.

M. Example XII

Effects of Cardiovascular and General Vascular Solution on Rotational Atherectomy-Induced Vasospasm in Rabbit Arteries

1. Solution Tested

[0302] This study utilized an irrigation solution consisting of the agents set forth in Example V. above, with the following exceptions. Nitroprusside replaced SIN-1 as the nitric oxide donor and nicardipine replaced nisoldipine as the Ca^{2+} channel antagonist.

[0303] The concentration of nitroprusside was selected based on its previously-defined pharmacological activity (EC_{50}). The concentrations of the other agents in this test solution were determined based on the binding constants of the agents with their cognate receptors. Furthermore, all concentrations were adjusted based on a blood flow rate of 80 cc per minute in the distal aorta of the rabbit and a flow rate of 5 cc per minute in the solution delivery catheter. Three components were mixed in one or less DMSO, and then these components and the remaining three components were mixed to their final concentrations in normal saline. A control solution consisting of normal saline was utilized. The test solution or the control solution was infused at a rate of 5 cc per minute for 20 minutes. A brief pause in the infusion was necessary at the times blood pressure measurements were made, so each animal received about 95 cc of the solution in the 20 minute treatment period.

2. Animal Protocol

[0304] This protocol was approved by the Seattle Veterans Affairs Medical Center Committee on Animal Use, which is accredited by the American Association for Accreditation of Laboratory Animal Care. The iliac arteries of 3-4 kg male New Zealand white rabbits fed a 2% cholesterol rabbit chow for 3-4 weeks were studied. The animals were sedated using intravenous xylazine (5 mg/kg) and ketamine (35 mg/kg) dosed to effect and a cutdown was performed in the ventral midline of the neck to isolate a carotid artery. The artery was ligated distally, an arteriotomy performed and a 5 French sheath was introduced into the descending aorta and positioned at the level of the renal arteries. Baseline blood pressure and heart rate were recorded. An angiogram of the distal aorta and bilateral iliac arteries was recorded on 35 mm cine film (frame rate 15 per second) using hand injection of iopamidol 76% (Squibb Diagnostics, Princeton, N.J.) into the descending aorta.

[0305] For each angiogram, a calibration object was placed in the radiographic field of view to allow for correction for magnification when diameter measurements were made. Infusion of either the above described test solution or a saline control solution was started through the side arm of the 5 French sheath (and delivered to the distal aorta) at a rate of 5 cc per minute and continued for 20 minutes. At 5 minutes into the infusion, a second angiogram was performed using the previously described technique. Then a 1.25 mm or a 1.50 mm rotational atherectomy burr (Heart Technology/Boston Scientific Inc.) was advanced to the iliac arteries. The rotational atherectomy burr was advanced three times over a guide wire to each of the iliac arteries at a rotation rate of 150,000 to 200,000 RPM. In each iliac, the rotational atherectomy burr was advanced from the distal aorta to the mid portion of the iliac artery between the first and second deep femoral branches. The rotational atherectomy burr was rapidly removed and another angiogram was recorded on cine film at a mean of 8 minutes after the infusion was begun.

[0306] The infusion was continued until the 20 minute time point, and another angiogram (the fourth) was performed. Then the infusion was stopped. A total of about 95 cc of the control or test solution had been infused. At the 30 minute time point (15 minutes after the infusion was stopped), a final angiogram was recorded as before. Blood pressure and heart rate were recorded at the 15 and 30

minute time points immediately before the angiograms. After the final angiogram, the animal was euthanized with an overdose of the anesthetic agents administered intravenously.

3. Angiographic Analysis

[0307] The angiograms were recorded on 35 mm cine film at a frame rate of 15 per second. Angiograms were reviewed in random order without knowledge of treatment assignment. For analysis, the angiograms were projected from a Vanguard projector at a distance of 5.5 feet. The entire angiogram for each animal was reviewed to identify the anatomy of the iliac arteries and to identify the sites of greatest spasm in the iliac arteries. A map of the iliac anatomy was prepared to assist in consistently identifying sites for measurement. Measurements were made on the 15 minute post rotational atherectomy angiogram first, then in random order on the remaining angiograms from that animal. Measurements were made using an electronic hand-held caliper (Brown & Sharpe, Inc., N. Kingston, R.I.). Iliac artery diameters were measured at three locations: proximal to the first deep femoral branch of the iliac artery; at the site of most severe spasm (this occurred between the first and second deep femoral artery branches in all cases); and at a distal site (near or distal to the origin of the second deep femoral artery branch of the iliac artery). Measurements were made at baseline (before test solution infusion was begun), 5 minutes into the infusion, immediately post rotational atherectomy (a mean of 8 minutes after the test solution was begun), at 20 minutes just after the infusion was stopped (this was 15 minutes after the rotational atherectomy was begun) and at 15 minutes after the infusion was stopped (30 minutes after the rotational atherectomy was begun). The calibration object was measured in each angiogram.

[0308] The diameter measurements were then converted to area measurements by the formula:

$$\text{Area} = (D^2)(\pi)/4$$

[0309] For calculation of vasoconstriction, baseline values were used to represent the maximum area of the artery and percent vasoconstriction was calculated as:

$$\% \text{ Vasoconstriction} = ((\text{Baseline area} - \text{Last time point area}) / \text{Baseline area}) \times 100\%$$

4. Statistical Methods

[0310] All values are expressed as means $\pm$ standard error of the mean. The time course of vasomotor response in control arteries was assessed using one way analysis of variance with correction for repeated measures. Post hoc comparison of data between specific time points was performed using the Scheffé test. Test solution treated arteries were compared to saline treated arteries at specified locations in the iliac arteries and at specified time points using multiple analysis of variance (MANOVA). To compensate for the absence of a single a priori hypothesis, a p value <0.01 was considered significant. Statistics were performed using Statistica for Windows, version 4.5, (Statsoft, Tulsa, Okla.).

265
265

5. Results

[0311] Eight arteries in 4 animals received saline solution and 13 arteries in seven animals received test solution. In each artery, regardless of the solution used, rotational atherectomy was performed with the rotating burr passing from the distal aorta to the mid-portion of the iliac artery. Thus, the proximal iliac artery segment and the segment designated as the site of maximal vasoconstriction were subjected to the rotating burr. The guide wire for the rotational atherectomy catheter passed through the distal segment, but the rotating burr of the rotational atherectomy catheter itself did not enter the distal segment.

[0312] Iliac artery diameters in saline treated arteries at the three specified segments are summarized in Table 32. In the proximal segment, there was no significant change in the diameter of the artery over the time course of the experiment ($p=0.88$, ANOVA). In the mid-iliac artery at the site of maximal vasoconstriction, there was a significant reduction in diameter with the largest reduction occurring at the 15 minute post-rotational atherectomy time point ($p<0.0001$, ANOVA comparing measurements at all 5 time points). The distal segment diameter did not significantly change over the time course of the experiment ($p=0.19$, ANOVA comparing all time points) although there was a trend towards a smaller diameter at the immediate post- and 15 minute post-rotational atherectomy time points.

TABLE 32

Iliac Artery Lumen Diameter at Specified Time Points in Saline Treated Arteries					
Segment	5 Minutes				
	Baseline N = 8	Infusion N = 8	Immediate Post RA N = 8	15 Minute after RA N = 8	30 Minute after RA N = 8
Proximal ^a	2.40 ± .18	2.32 ± .14	2.32 ± 0.14	2.38 ± .13	2.44 ± .17*
Mid ^b	2.01 ± .08	1.84 ± .07	1.57 ± .18	1.24 ± .13	1.87 ± .06**
Distal ^c	2.01 ± .10	1.86 ± .08	1.79 ± .08	1.81 ± .07	1.92 ± .05***

RA = rotational atherectomy

^aProximal iliac artery measurement site, proximal to the first deep femoral branch

^bMid iliac artery at the site of maximal vasoconstriction

^cDistal iliac artery measurement site, near or distal to the second deep femoral branch

* $p = 0.08$ by ANOVA comparing diameters in the proximal segment at the five time points.

** $p = 0.000007$ by ANOVA comparing diameters at site of maximal vasoconstriction at the five time points.

*** $p = 0.19$ by ANOVA comparing diameters in the distal segment at the five time points.

[0313] The diameters of iliac arteries treated with the test solution are shown in Table 33. Angiograms were not recorded in three of these arteries at the 5 minute post-initiation of the infusion time point and angiographic data were excluded from two arteries (one animal) at the 30 minute post-rotational atherectomy time point because the animal received an air embolus at the 15 minute angiogram that resulted in hemodynamic instability. Because there is a variable number of observations at the five time points, no ANOVA statistic was applied to this data. Still it is apparent that the magnitude of change in the diameter measurements within segments in the test solution treated arteries over the time course of the experiment is less than was seen in the saline treated arteries.

TABLE 33

Iliac Artery Lumen Diameter at Specified Time Points in Test Solution Treated Arteries					
Segment	5 Minutes				
	Baseline N = 13	Infusion N = 10	Immediate Post RA N = 13	15 Minute after RA N = 13	30 Minute after RA N = 11
Proximal ^a	2.28 ± .06	2.07 ± .10	2.22 ± .08	2.42 ± .06	2.39 ± .08
Mid ^b	1.97 ± .06	1.79 ± .06	1.74 ± .04	1.94 ± .07	1.93 ± .08
Distal ^c	2.00 ± .06	1.92 ± .04	1.92 ± .04	2.00 ± .06	2.01 ± .07

RA = rotational atherectomy

^aProximal iliac artery measurement site, proximal to the first deep femoral branch

^bMid iliac artery at the site of maximal vasoconstriction

^cDistal iliac artery measurement site, near or distal to the second deep femoral branch. Because of the different number of observations at the various time points, ANOVA was not performed to determine the statistical significance difference in diameters within specific segments.

[0314] The primary endpoint for this study was the comparison of the amounts of vasoconstriction in saline treated and test solution treated arteries. Vasoconstriction was based on arterial lumen areas derived from artery diameter measurements. Area values at the 5 minute, immediate post-rotational atherectomy and later time points were compared to the baseline area values to calculate the relative change in

area. The results were termed "vasoconstriction" if the lumen area was smaller at the later time point than at baseline, and "vasodilatation" if the lumen area was larger at the later time point compared to the baseline area (Tables 27 and 28). To facilitate statistical analysis with the largest number of observations possible in both treatment groups, the test solution and saline treated artery data were compared at the immediate post- and at the 15 minute post-rotational atherectomy time points.

[0315] In the proximal segment (FIG. 13), there was essentially no change in lumen area with either treatment at the immediate post-rotational atherectomy time point, but there was some vasodilatation in this segment by the 15

minute postrotation) atherectomy time point. Test solution did not alter the results of rotational atherectomy compared to saline treatment in this segment. In the mid-vessel (FIG. 14) at the site of maximal vasoconstriction however, test solution significantly blunted the vasoconstriction, caused by rotational atherectomy in the saline treated arteries ($p=0.0004$, MANOVA corrected for repeated measures). In the distal segment (FIG. 15), there was little vasoconstriction in the saline treated arteries and test solution did not significantly alter the response to rotational atherectomy.

TABLE 34

Amount of Vasoconstriction (Negative Values) or Vasodilation (Positive Values) at Specified Time Points in Saline Treated Arteries				
Segment	5 Minutes into Infusion N = 8	Immediate Post RA N = 8	15 Minutes after RA N = 8	30 Minutes after RA N = 8
Proximal ¹	$-3\% \pm 3\%$	$-1\% \pm 30\%$	$3\% \pm 8\%$	$3\% \pm 13\%$
Mid ²	$-14\% \pm 7\%$	$-35\% \pm 10\%$	$-35\% \pm 7\%$	$-11\% \pm 9\%$
Distal ³	$-5\% \pm 10\%$	$-14\% \pm 14\%$	$-14\% \pm 10\%$	$2\% \pm 12\%$

¹Proximal iliac artery anastomosis site, proximal to the first deep femoral branch

²Mid iliac artery at the site of maximal vasoconstriction

³Distal iliac artery anastomosis site, near or distal to the second deep femoral branch

[0316]

TABLE 35

Amount of Vasoconstriction (Negative Values) or Vasodilation (Positive Values) at Specified Time Points in Test Solution Treated Arteries				
Segment	5 Minutes into Infusion N = 10	Immediate Post RA N = 13	15 Minutes after RA N = 13	30 Minutes after RA N = 11
Proximal ¹	$-17\% \pm 5\%$	$-4\% \pm 3\%$	$14\% \pm 8\%$	$7\% \pm 9\%$
Mid ²	$-14\% \pm 5\%$	$-27\% \pm 5\%$	$0.3\% \pm 7\%$	$-5\% \pm 5\%$
Distal ³	$-8\% \pm 3\%$	$-9\% \pm 4\%$	$1\% \pm 4\%$	$3\% \pm 1\%$

¹Proximal iliac artery anastomosis site, proximal to the first deep femoral branch

²Mid iliac artery at the site of maximal vasoconstriction

³Distal iliac artery anastomosis site, near or distal to the second deep femoral branch

[0317] The hemodynamic response in the saline and test solution treated arteries is summarized in Table 36. Compared to saline treated animals, test solution treated animals sustained substantial hypotension and significant tachycardia during the solution infusion. By 15 minutes after completion of the infusion (or at the 30 minute postrotational atherectomy time point), test solution treated animals showed some partial, but not complete, return of blood pressure towards baseline.

TABLE 36

Blood Pressure and Heart Rate During the Protocol				
Group	Baseline (N)	5 Minutes (N)	15 Minutes (N)	30 Minutes (N)
Systolic Blood Pressure				
Saline	83 ± 9 (4)	93 ± 6 (5)	92 ± 11 (4)	81 ± 30 (4)*

TABLE 36-continued

Blood Pressure and Heart Rate During the Protocol				
Group	Baseline (N)	5 Minutes (N)	15 Minutes (N)	30 Minutes (N)
Test Solution Heart Rate				
Saline	202 ± 16 (3)	204 ± 3 (3)	198 ± 22 (3)	193 ± 29 (3)*
Test Solution	187 ± 11 (7)	248 ± 11 (7)	240 ± 5 (7)	247 ± 18 (7)**

*There was no significant change in systolic blood pressure or heart rate in this group ($p = 0.37$ for systolic blood pressure and $p = 0.94$ for heart rate, ANOVA).

**There was a highly significant change in systolic blood pressure and heart rate in this group ($p = 0.0011$ for systolic blood pressure and $p = 0.002$ for heart rate, ANOVA).

6. Summary of Study

[0318] 1. Rotational atherectomy in hypercholesterolemic New Zealand white rabbits results in prominent vasospasm in the mid-portion of iliac arteries subjected to the rotating burr. The vasospasm is most apparent 15 minutes after rotational atherectomy treatment and has almost completely resolved without pharmacologic intervention by 30 minutes after rotational atherectomy.

[0319] 2. Under the conditions of rotational atherectomy treatment studied in this protocol, test solution treatment in accordance with the present invention almost completely abolishes the vasospasm seen after the mid-iliac artery is subjected to the rotating burr.

[0020] 3. Treatment with test solution of the present invention given the concentration of components used in this protocol results in profound hypotension during the infusion of the solution. The attenuation of vasospasm after rotational subarachnoid by test solution occurred in the presence of severe hypotension.

[0021] While the preferred embodiment of the invention has been illustrated and described, it will be appreciated that various changes to the disclosed solutions and methods can be made therein without departing from the spirit and scope of the invention. For example, alternative pain inhibitors and anti-inflammation and anti-spasm and anti-vasospasm agents may be discovered that may augment or replace the disclosed agents in accordance with the disclosure contained herein. It is therefore intended that the scope of claims patent granted herein be limited only by the definitions of the appended claims.

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. A solution for use in inhibiting tumor cell adhesion, pain and inflammation at a wound during a surgical procedure, comprising:

therapeutically effective amounts of at least one tumor-cell anti-adhesion agent and at least one pain/inflammation inhibitory agent in a dilute solution within a liquid irrigation carrier, the agents being selected to act on differing molecular targets, the at least one tumor-cell anti-adhesion agent being selected to be deliverable by irrigation of the wound to provide without metabolic transformation a therapeutic anti-adhesion effect.

2. The solution of claim 1, wherein said anti-adhesion agent is selected from the group consisting of (CD44 receptor antagonists, integrin receptor antagonists and selectin receptor antagonists.

3. The solution of claim 1, wherein said anti-adhesion agent comprises an inhibitor of matrix metalloproteinases.

4. The solution of claim 1, wherein the pain/inflammation inhibitory agents are selected from the group consisting of: serotonin receptor antagonists, serotonergic receptor agonists, histamine receptor antagonists, bradykinin receptor antagonists, kallikrein inhibitors, tachykinin receptor antagonists including ornithine, receptor subtype antagonists and non-related, receptor subtype antagonists, calcitonin gene-related peptide receptor antagonists, interleukin receptor antagonists, phospholipase inhibitors including PLA_2 isoform inhibitors and PLC_1 isoform inhibitors, cyclooxygenase inhibitors, prostaglandin receptor antagonists including cyclooxygenase EP-1 receptor subtype antagonists and cyclooxygenase EP-4 receptor subtype antagonists and thromboxane receptor subtype antagonists, leukotriene receptor antagonists including leukotriene B₂ receptor subtype antagonists and leukotriene D₄ receptor subtype antagonists, opioid receptor agonists including μ -opioid receptor subtype agonists, δ -opioid receptor subtype agonists, and κ -opioid receptor subtype agonists, peripheric agonists and antagonists including P_{2U} receptor agonists and P_{2U} receptor antagonists, and ATP-sensitive potassium channel openers.

5. The solution of claim 1, wherein the pain/inflammation inhibitory agents are selected from the group consisting of: serotonin receptor antagonists, serotonergic receptor agonists, histamine receptor antagonists, bradykinin receptor antagonists, kallikrein inhibitors, tachykinin receptor antagonists

including ornithine, receptor subtype antagonists and non-related, receptor subtype antagonists, calcitonin gene-related peptide receptor antagonists, phospholipase inhibitors including PLA_2 isoform inhibitors and PLC_1 isoform inhibitors, cyclooxygenase inhibitors, prostaglandin receptor antagonists including cyclooxygenase EP-1 receptor subtype antagonists and cyclooxygenase EP-4 receptor subtype antagonists and thromboxane receptor subtype antagonists, leukotriene receptor antagonists including leukotriene B₂ receptor subtype antagonists and leukotriene D₄ receptor subtype antagonists, opioid receptor agonists including μ -opioid receptor subtype agonists, δ -opioid receptor subtype agonists, and κ -opioid receptor subtype agonists, peripheric agonists and antagonists including P_{2U} receptor agonists and P_{2U} receptor antagonists, and ATP-sensitive potassium channel openers.

6. The solution of claim 1, further comprising a plurality of pain/inflammation inhibitory agents.

7. The solution of claim 1, wherein each of the agents in the solution applied is included at a concentration or dosage that is sufficient to provide a level of inhibitory effect at the wound when locally applied, and that results in a plasma concentration that is less than a plasma concentration which would be required to provide the same level of inhibitory effect at the wound if applied systemically.

8. The solution of claim 1, wherein each of the plurality of agents in the solution is delivered locally at a concentration of no greater than 100,000 nanomolar.

9. The solution of claim 8, wherein each of the plurality of agents in the solution is delivered locally at a concentration of no greater than 10,000 nanomolar.

10. A solution for use in the inhibition of tumor cell attachment and implantation during a surgical procedure within a body cavity of a patient in need of such treatment, comprising:

therapeutically effective amounts of at least one tumor-cell anti-adhesion agent and at least one pain/inflammation inhibitory agent in a dilute solution within a liquid irrigation carrier, the agents being selected to act on differing molecular targets, the at least one tumor-cell anti-adhesion agent being selected to be deliverable by irrigation in the body cavity to provide without metabolic transformation a therapeutic anti-tumor cell attachment and anti-tumor cell implantation effect.

11. A solution for use in inhibiting tumor cell adhesion, pain and inflammation at a wound during a surgical procedure, comprising:

therapeutically effective amounts of at least one tumor-cell anti-adhesion agent and at least one pain/inflammation inhibitory agent in a dilute solution within a liquid irrigation carrier, the agents being selected to act on differing molecular targets, the at least one tumor-cell anti-adhesion agent being selected from the group consisting of (CD44 receptor antagonists, integrin receptor antagonists, selectin receptor antagonists and inhibitors of matrix metalloproteinases and being selected to be deliverable by irrigation of the wound to provide without metabolic transformation a therapeutic anti-adhesion effect.

12. A solution for use in inhibiting tumor cell adhesion, pain and inflammation at a wound during a surgical procedure, comprising:

2/10
269

therapeutically effective amounts of at least one tumor-cell anti-adhesion agent and at least one pain/inflammation inhibitory agent in a dilute solution within a liquid carrier, the agents being selected to act on a plurality of differing molecular targets, the at least one tumor-cell anti-adhesion agent being selected from the group consisting of CD44 receptor antagonists, integrin receptor antagonists and selectin receptor antagonists, and being selected to be deliverable in the wound to provide without metabolic transformation a therapeutic anti-adhesion effect.

13. A solution for use in inhibiting tumor cell adhesion at a wound during a surgical procedure, comprising:

therapeutically effective amounts of a first tumor-cell anti-adhesion agent and a second tumor-cell anti-adhesion agent in a dilute solution within a liquid irrigation carrier, the agents being selected to act on differing molecular targets, at least one of the agents being selected to be deliverable by irrigation of the wound to provide without metabolic transformation a therapeutic anti-adhesion effect.

14. The solution of claim 13, wherein each of the agents in the solution applied is included at a concentration or dosage that is sufficient to provide a level of inhibitory effect at the wound when locally applied, and that results in a plasma concentration that is less than a plasma concentration which would be required to provide the same level of inhibitory effect at the wound if applied systemically.

15. The solution of claim 13, wherein each of the plurality of agents in the solution is delivered locally at a concentration of no greater than 100,000 nanomolar.

16. The solution of claim 13, wherein each of the plurality of agents in the solution is delivered locally at a concentration of no greater than 10,000 nanomolar.

17. The solution of claim 13, further comprising at least one pain/inflammation inhibitory agent.

18. The solution of claim 17, wherein each of the agents in the solution applied is included at a concentration or dosage that is sufficient to provide a level of inhibitory effect at the wound when locally applied, and that results in a plasma concentration that is less than a plasma concentration which would be required to provide the same level of inhibitory effect at the wound if applied systemically.

19. The solution of claim 17, wherein each of the plurality of agents in the solution is delivered locally at a concentration of no greater than 100,000 nanomolar.

20. The solution of claim 17, wherein each of the plurality of agents in the solution is delivered locally at a concentration of no greater than 10,000 nanomolar.

21. The solution of claim 13, wherein at least one of the agents is selected from the group consisting of CD44 receptor antagonists, integrin receptor antagonists, selectin receptor antagonists and inhibitors of matrix metalloproteinases.

22. A solution for use in inhibiting tumor cell adhesion, pain and inflammation at a wound during a surgical procedure, comprising:

therapeutically effective amounts of at least one tumor-cell anti-adhesion agent and at least one pain/inflammation inhibitory agent in a dilute solution within a sustained release carrier, the agents being selected to act on differing molecular targets, the at least one tumor-cell anti-adhesion agent being selected to provide without metabolic transformation a therapeutic anti-adhesion effect at the wound.

23. The solution of claim 22, wherein the sustained release carrier comprises a gel.

24. The solution of claim 22, wherein said anti-adhesion agent is selected from the group consisting of CD44 receptor antagonists, integrin receptor antagonists and selectin receptor antagonists.

25. A solution for use in inhibiting tumor cell adhesion at a wound during a surgical procedure, comprising:

therapeutically effective amounts of a first tumor-cell anti-adhesion agent and a second tumor-cell anti-adhesion agent in a dilute solution within a sustained release carrier, the agents being selected to act on differing molecular targets, at least one of the agents being selected to provide without metabolic transformation a therapeutic anti-adhesion effect.

26. The solution of claim 25, wherein the sustained release carrier comprises a gel.

27. The solution of claim 25, wherein said anti-adhesion agent is selected from the group consisting of CD44 receptor antagonists, integrin receptor antagonists and selectin receptor antagonists.

28. A solution for use in inhibition of tumor cell attachment and implantation during a surgical procedure within a body cavity of a patient in need of such treatment, comprising:


therapeutically effective amounts of at least one tumor-cell anti-adhesion agent and at least one pain/inflammation inhibitory agent in a dilute solution within a sustained release carrier, the agents being selected to act on differing molecular targets, the at least one tumor-cell anti-adhesion agent being selected to provide in the body cavity without metabolic transformation a therapeutic anti-tumor cell attachment and anti-tumor cell implantation effect.

29. A solution for use in inhibition of tumor cell attachment and implantation during a surgical procedure within a body cavity of a patient in need of such treatment, comprising:

therapeutically effective amounts of a first tumor-cell anti-adhesion agent and a second tumor-cell anti-adhesion agent in a dilute solution within a sustained release carrier, the agents being selected to act on differing molecular targets, at least one of the agents being selected to provide in the body cavity without metabolic transformation a therapeutic anti-tumor cell attachment and anti-tumor cell implantation effect.

* * * * *

COPPA
27/270



No. 06-051721-00012-0000

SECRETARÍA DE INDUSTRIA Y COMERCIO
DIVISIÓN DE NUEVAS CREACIONES
SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

Señora Jefe,

DIVISIÓN DE NUEVAS CREACIONES

Superintendencia de Industria y Comercio

E. S. D.

Referencia : Expediente N° 06 51721

Asunto : Remisión de información a la solicitud de patente de
Invención titulada "ENOXAPARINA PARA EL
TRATAMIENTO DEL CANCER"

Solicitante : AVENTIS PHARMA S.A.

Publicada en la Gaceta de la Propiedad Industrial

N° 607 del 31 de agosto de 2009

Yo, **CIELO ANGELA PEÑA RODRIGUEZ**, abogada en ejercicio, identificada como aparece al pie de su firma, con tarjeta profesional No. **82701** del Consejo Superior de la Judicatura, en mi condición de apoderada de la sociedad **GYNOPHARM S.A.** conformada bajo las leyes de la República de Colombia y domiciliada en la ciudad de Barranquilla, Colombia, atentamente manifiesto que estando dentro del término de ley y por orden expresa de mi representada, presento remisión de información a la concesión del registro de la Patente de Invención titulada "ENOXAPARINA PARA EL TRATAMIENTO DEL CANCER", cuyo titular es **AVENTIS PHARMA S.A.**, y pido a Usted declarar fundada esta remisión de información y en consecuencia negar el registro de la patente solicitada.

372
271

1. INTERÉS PARA ACTUAR

Conforme a lo dispuesto en el artículo 42 de la Decisión 486 de 2000 de la CAN, estando dentro del término estipulado por la ley, manifiesto el legítimo interés de nuestra representada para oponerse al registro de la patente de la referencia, atendiendo a que la solicitud pretendida no cumple con los requisitos dispuestos en la ley como se analizará más adelante y de ser concedida afectaría directamente la comercialización de algunos productos de mi representada, que contienen, en particular enoxaparina. Por lo tanto, solicito respetuosamente a ese Despacho se sirva tener en cuenta la presente remisión de información dentro del trámite administrativo que se surte en esta Superintendencia.

2. FUNDAMENTOS DE HECHOS

- 2.1. La solicitud objeto de la presente fue presentada el 30 de mayo de 2006 reivindicando prioridad bajo la solicitud EP20030293028 del 2003-12-04; y fue publicada en Colombia, en la Gaceta de la Propiedad Industrial N° 607 del 31 de agosto de 2009, cuya publicación internacional corresponde a la WO2005/053713 del 31/08/2009.
- 2.2. La solicitud colombiana 06 51721 objeto de la presente remisión de información, se refiere al uso de enoxaparina para tratar una enfermedad asociada a la modulación de la actividad de la heparanasa, excepto cuando dicha enfermedad es Liquefactive en el que la actividad de la heparanasa contribuye a la patología y/o síntomas de la enfermedad, excepto cuando dicha enfermedad es una enfermedad autoinmune.

273
272

2.3. En primera instancia, se debe advertir que algunas reivindicaciones también se refieren a un uso y a un método de tratamiento y no sólo a la composición farmacológica o a un método de fabricación mediante la cual se obtenga un producto tangible y según la legislación, decisión 486 de la Comunidad Andina de Naciones, Artículo 14.- *"Los Países Miembros otorgarán patentes para las invenciones, sean de producto o de procedimiento (...)"*, los usos no están contemplados como patentables; y, Artículo 20.- *"No serán patentables (...) d) los métodos terapéuticos o quirúrgicos para el tratamiento humano o animal, así como los métodos de diagnóstico aplicados a los seres humanos o a animales"*. Solo serán patentables los productos o procedimientos. Por lo tanto a luz de la norma, dicha materia referente al uso y a un método de tratamiento no sería patentable.

2.4. Ahora bien, con base en el artículo 14 de la Decisión 486 de la CAN consagra lo siguiente: *"Los países miembros otorgarán patentes para las invenciones, sean de producto o procedimiento, en todos los campos de la tecnología, siempre que sean nuevas, tengan nivel inventivo y sean susceptibles de aplicación industrial"*. Así las cosas, las invenciones objeto de patente deben ser nuevas y tener nivel inventivo. Bien, pues antes de la fecha de prioridad de esta solicitud se encuentran los siguientes documentos que afecta la patentabilidad de la presente solicitud:

- D1: US2003195461 publicada el 16 de octubre de 2003.

2.5. Ahora bien, además que la presente bajo la Norma colombiana pretende un objeto que no es patentable, además se refiere a una materia que no es novedosa. Particularmente el documento D1, revela con anterioridad un método para la inhibición de la adherencia de célula de un tumor y una variedad de dolor e inflamación que incluye al menos a un agente de adherencia de célula de antitumor y múltiple dolor e inflamación agentes inhibitorios en la concentración diluida en

274
23

un portador fisiológico. Particularmente en el párrafo 0107, D1 revela que el activo inhibición de la adherencia de célula de un tumor es la enoxaparina. Así las cosas, como lo evidencia dicho documento D1, además que la presente no comprende aplicación industrial por referirse a un uso, la presente solicitud tampoco es novedosa pues lo revelado ya se encontraba en el estado de la técnica.

2.6. En consecuencia y de acuerdo a lo descrito anteriormente, se deriva que la solicitud colombiana 06 51721 no puede pretender un monopolio por patente toda vez que lo que pretende no cumple con los dos de los tres requisitos necesarios para su protección.

2.7. Que por consiguiente, respecto a la solicitud pretendida se tiene que:

2.7.1. **CARECE DE NOVEDAD:** Según la decisión 486 de la Comunidad Andina de Naciones, Artículo 16. "Una invención se considerará nueva cuando no está comprendida en el estado de la técnica. El estado de la técnica comprenderá todo lo que haya sido accesible al público por una descripción escrita u oral, utilización, comercialización o cualquier otro medio antes de la fecha de presentación de la solicitud de patente o, en su caso, de la prioridad reconocida". A la fecha de prioridad, 4 de diciembre de 2003 ya era conocido, pues como se demostró, era parte del arte anterior con base en el documento D1, el uso de la enoxaparina como activo para la inhibición de la adherencia de célula de un tumor, sobre el cual busca protección en el capítulo reivindicatorio.

2.7.2. **CARENCIA DE APLICACIÓN INDUSTRIAL:** La Decisión 486 de la CAN consagra en su artículo 14 lo siguiente: "Los países miembros otorgarán patentes para las invenciones, sean de producto o procedimiento, en todos los campos de la tecnología, siempre que sean nuevas, tengan nivel inventivo y sean susceptibles de aplicación industrial". La presente solicitud carece de aplicación industrial ya que como se demostró anteriormente, algunas cláusulas reclaman el método terapéutico y estos no son aplicables industrialmente porque primero no se

23/5
274

obtiene un producto o proceso; y segundo no es reproducible o repetible a escala industrial. Por lo tanto, el objeto de la presente invención referido a los usos y métodos terapéuticos, no cumplen con el requisito de la aplicación industrial.

2.8. Dado lo anterior, es posible deducir que la solicitud y lo reivindicado no es objeto de patentabilidad pues es contrario a lo que dicta la Decisión 486 de la Comunidad Andina de Naciones, Artículo 14.- *"Los Países Miembros otorgan patentes para las invenciones, sean de producto o de procedimiento, en todos los campos de la tecnología, siempre que sean nuevas, tengan nivel inventivo y sean susceptibles de aplicación industrial"*. La solicitud pretendida no cumple con dos de los tres requisitos de patentabilidad.

2.9. Por todo lo anterior, atentamente solicito a usted que se sirva declarar fundada la presente remisión de información y en consecuencia negar el registro a la solicitud de patente titulada **"ENOXAPARINA PARA EL TRATAMIENTO DEL CANCER"**, cuyo titular es AVENTIS PHARMA S.A., solicitud Colombiana que apareció publicada en la Gaceta de la Propiedad Industrial N° 607 del 31 de agosto de 2009.

3. PRUEBAS

De conformidad con lo dispuesto por las normas vigentes, solicito a usted tener como prueba en este asunto los siguientes:

- D1: US2003195461 publicada el 16 de octubre de 2003.

27/95
275

4. FUNDAMENTO DE DERECHO

Fundamento esta observación en las normas legales siguientes:

- 4.1. Numeral 1 del artículo 586 del Código de Comercio.
- 4.2. Artículo 42 de la Decisión 486 de la Comisión del Acuerdo de Cartagena.
- 4.3. En las demás normas concordantes.

5. ANEXOS

Para los efectos correspondientes anexo al presente escrito los siguientes documentos:

1. Poder para actuar en el presente.
2. Documento que acredita al representante legal de GYNOPHARM S.A.
3. Recibo de caja del respectivo pago de tasa.
4. Copias de los documentos:

- DI: US2003195461 publicada el 16 de octubre de 2003.

2776
276

6. NOTIFICACIONES

Para efectos de notificaciones que por disposición del artículo 50 del Decreto 01 de 1984 debe hacer su Despacho, informo que mi representada y la suscrita recibiremos notificaciones en la Secretaría de su Despacho o en mis oficinas situadas en la Carrera 13 N° 119-95, Of. 104 de esta ciudad de Bogotá.

Señor Superintendente,

CIELO ANGELA PEÑA RODRIGUEZ
C.C. 51'940.252 de Bogotá
T.P.A. 82701 del C.S. de la J.

Ente Q8 Proceso 24/05/2012
278
277

Industria y Comercio
SUPERINTENDENCIA

2020
Bogotá, D.C.,

Doctor:
Emilio Ferrero
Apoderado

Oficio N°: - 2554


ASUNTO:

Radicación PCT N°	06-51721
Trámite	011
Evento	379
Actuación	440
Folios	058

Con fundamento en lo previsto por el artículo 43 de la Decisión 486 de la Comisión de la Comunidad Andina, se le comunica que la oposición presentada por el doctor José Luis Reyes Villamizar, en su calidad de apoderado de Tecnoquímicas S.A., reúne los requisitos formales exigidos por la ley al momento de su presentación.

En cumplimiento de lo dispuesto en la citada norma, se le concede el término de sesenta (60) días hábiles siguientes a la fecha de notificación del presente oficio, para que haga valer sus argumentaciones y presente pruebas.

Notifíquese el presente oficio conforme a lo dispuesto en el numeral 5.2, literal e), del capítulo quinto del título primero de la Circular Única N° 10 de 2001.


ALIX CARMENZA CÉSPEDES DE VERGEL
Directora de Nuevas Creaciones (C).

26 FEB. 2010

El anterior oficio fue notificado por fijación en lista de fecha _____.

200201

2020
Bogotá, D.C.,

Doctor:
Emilio Ferrero
Apoderado

Oficio N°: 2567


ASUNTO:

Radicación PCT N°	06-51721
Trámite	011
Evento	379
Actuación	440
Folios	007

Con fundamento, en lo previsto por el artículo 43 de la Decisión 488 de la Comisión de la Comunidad Andina, se le comunica que la oposición presentada por el doctor Tito Noe Parra Murillo, en su calidad de apoderado del Laboratorio Franco Colombiano Lafrancoi S.A., reúne los requisitos formales exigidos por la ley al momento de su presentación.

En cumplimiento de lo dispuesto en la citada norma, se le concede el término de sesenta (60) días hábiles siguientes a la fecha de notificación del presente oficio, para que haga valer sus argumentaciones y presente pruebas.

Notifíquese el presente oficio conforme a lo dispuesto en el numeral 5.2, literal e), del capítulo quinto del título primero de la Circular Única N° 10 de 2001.


ALIX CARMENZA CESPEDES DE VERGEL.
Directora de Nuevas Creaciones (C).

26 FEB. 2010

El anterior oficio fue notificado por fijación en lista de fecha _____.

202021